var title_f18_17_18704="Mirizzi syndrome with erosion into the common hepatic duct";
var content_f18_17_18704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Mirizzi syndrome with erosion of the stone into the common hepatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgery is the mainstay of therapy for Mirizzi syndrome, permitting removal of the causal factors: the inflamed gallbladder and the impacted stone. When the stone has eroded into the common bile duct or common hepatic duct, a bilioenteric anastomosis is typically required.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18704=[""].join("\n");
var outline_f18_17_18704=null;
var title_f18_17_18705="E-C technique";
var content_f18_17_18705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    E-C clamp technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is positioned so that the little, ring, and index fingers are spread over the mandible from the angle of the jaw forward towards the chin in the configuration of the letter \"E\". The jaw is then lifted, pulling the face into the mask. The thumb and forefinger are placed over the mask in the shape of the letter \"C\". The mask is squeezed onto the face and a seal is formed between the mask and the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18705=[""].join("\n");
var outline_f18_17_18705=null;
var title_f18_17_18706="Patient information: Chronic hives (The Basics)";
var content_f18_17_18706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86634\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/7/38001\">",
"          Angioedema of the lips",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/31/1523\">",
"         Patient information: Angioedema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/47/37617\">",
"         Patient information: Hives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/27/44466\">",
"         Patient information: Physical hives (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/45/2772\">",
"         Patient information: Hives (urticaria) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic hives (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H550744994\">",
"      <span class=\"h1\">",
"       What are chronic hives?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hives are raised, red patches of skin that are usually very itchy (",
"      <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"       picture 1",
"      </a>",
"      ). &ldquo;Chronic&rdquo; means long term. People who have chronic hives have them on most days of the week for 6 weeks or more. The medical term for hives is &ldquo;urticaria.&rdquo;",
"     </p>",
"     <p>",
"      Chronic hives are different from hives that happen suddenly and last only a short time. Sudden hives are usually caused by allergies or an infection. Sometimes, sudden hives means someone is having a life-threatening allergic reaction.",
"     </p>",
"     <p>",
"      Chronic hives are not caused by allergies or infections, and are not life-threatening. Chronic hives usually go away over time, but they can last a year or more. There is no cure for chronic hives, but medicines can help ease symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550745026\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic hives?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with chronic hives have raised, red areas on their skin. These areas are often round and can be pale in the middle. They are usually very itchy, especially at night. This can make it hard to sleep.",
"     </p>",
"     <p>",
"      The hives will come and go, but certain things can make symptoms worse. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heat, such as hot showers or hot, humid weather",
"       </li>",
"       <li>",
"        Tight clothes, waistbands, or clothing straps",
"       </li>",
"       <li>",
"        Medicines called nonsteroidal antiinflammatory drugs (NSAIDs) &ndash; Examples of NSAIDs are",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (brand name: Aleve).",
"       </li>",
"       <li>",
"        Alcohol",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"       <li>",
"        Certain foods, such as spicy foods",
"       </li>",
"       <li>",
"        Having a cold",
"       </li>",
"       <li>",
"        Not getting enough sleep",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Many people with chronic hives also get a condition called &ldquo;angioedema.&rdquo; Angioedema causes puffiness and swelling of the tissues under the skin. Parts of the body that are often affected include the lips, cheeks, eyelids, hands, feet, or genitals (",
"      <a class=\"graphic graphic_picture graphicRef86559 \" href=\"UTD.htm?37/7/38001\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550745059\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have chronic hives by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      He or she might order blood tests to make sure another condition isn&rsquo;t causing your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550745074\">",
"      <span class=\"h1\">",
"       How are chronic hives treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic hives usually go away over time. Many people get better within a year, but the condition can last a few years. To help with symptoms, doctors can prescribe different medicines. Most people need to take more than 1 medicine every day to control their symptoms. Medicines can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antihistamines &ndash; These are the same medicines people commonly take for allergies. They can help with itching and shrink the size of your hives.",
"       </li>",
"       <li>",
"        Steroid pills &ndash; Your doctor might prescribe steroids for a short time to help get your symptoms under control. These steroids are different from the ones athletes take to build muscle. These steroids help reduce itching and swelling.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these medicines don&rsquo;t help enough to ease your symptoms, let your doctor or nurse know. There are other medicines or treatments that might help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550745089\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can avoid the things that commonly make chronic hives worse. For example, don&rsquo;t take very hot showers or wear tight-fitting clothes. You can also avoid taking NSAIDs or drinking alcohol.",
"     </p>",
"     <p>",
"      Chronic hives are not caused by food allergies, but some people find that their chronic hives get worse after they eat certain foods. If your hives get worse when you eat certain foods, try to avoid those foods. But if you find that you are avoiding a lot of foods, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550745104\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=see_link\">",
"       Patient information: Hives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"       Patient information: Angioedema (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=see_link\">",
"       Patient information: Physical hives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"       Patient information: Hives (urticaria) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/17/18706?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86634 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18706=[""].join("\n");
var outline_f18_17_18706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550744994\">",
"      What are chronic hives?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550745026\">",
"      What are the symptoms of chronic hives?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550745059\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550745074\">",
"      How are chronic hives treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550745089\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550745104\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/7/38001\">",
"       Angioedema of the lips",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=related_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=related_link\">",
"      Patient information: Hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=related_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=related_link\">",
"      Patient information: Physical hives (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_17_18707="Patient information: Hormonal birth control (The Basics)";
var content_f18_17_18707=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16162\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/55/38783\">",
"         Ortho Evra",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/16/43278\">",
"          NuvaRing",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/5/19550\">",
"           Mirena IUD",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?43/39/44669\">",
"            Hormonal birth control",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/28/12738\">",
"         Patient information: Emergency contraception (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/17/37138\">",
"         Patient information: Intrauterine devices (IUD) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/22/1378\">",
"         Patient information: Long-acting methods of birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/25/36242\">",
"         Patient information: Vasectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/2/22563\">",
"         Patient information: Barrier methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/60/9157\">",
"         Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/32/24068\">",
"         Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/32/22021\">",
"         Patient information: Hormonal methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/16/4355\">",
"         Patient information: Long-term methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hormonal birth control (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10509204\">",
"      <span class=\"h1\">",
"       What is hormonal birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hormonal birth control is any pill, injection, device, or treatment that uses hormones to prevent pregnancy in women. There are a few different kinds of hormonal birth control. Some contain the hormones estrogen and progestin. Others contain only progestin.",
"     </p>",
"     <p>",
"      All hormonal birth control methods are very effective. The methods differ in how easy they are to use and their side effects (",
"      <a class=\"graphic graphic_table graphicRef75100 \" href=\"UTD.htm?43/39/44669\">",
"       table 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Pills",
"        </strong>",
"        &ndash; Women who take birth control pills need to take a pill every day. Skipping pills can increase the chance of getting pregnant. Birth control pill packets usually include 4 to 7 days of hormone-free pills each month. It is during these hormone-free days that women get their period. Women who prefer not to get a period can skip the hormone-free pills and take a hormone pill every day instead. This is called continuous dosing. It can be done with the patch and the vaginal ring as well. Most birth control pills contain estrogen and progestin but there is one that contains only progestin.",
"       </li>",
"       <li>",
"        <strong>",
"         Skin patches",
"        </strong>",
"        &ndash; Women can wear a hormone patch on their upper arm, shoulder, back, or hip (",
"        <a class=\"graphic graphic_picture graphicRef57796 \" href=\"UTD.htm?37/55/38783\">",
"         picture 1",
"        </a>",
"        ). The patch must be changed once a week. Normally women wear a new patch each week for 3 weeks and then leave the patch off during week 4. Week 4 is when women have their period. Skin patches for contraception contain both estrogen and progestin.",
"       </li>",
"       <li>",
"        <strong>",
"         Vaginal rings",
"        </strong>",
"        &ndash; A woman can put a bendable ring in her vagina that can stay in place for 3 weeks at a time (",
"        <a class=\"graphic graphic_picture graphicRef73663 \" href=\"UTD.htm?42/16/43278\">",
"         picture 2",
"        </a>",
"        ). This ring releases hormones in the vagina. It does not need to be removed when the woman has sex but can be removed for up to 3 hours. Normally women use the ring for 3 weeks and then go without a ring during week 4. Week 4 is when women have their period. Vaginal rings for contraception contain both estrogen and progestin.",
"       </li>",
"       <li>",
"        <strong>",
"         Injections",
"        </strong>",
"        &ndash; Women who use hormone injections get a shot in the arm or butt every 3 months. Injections for birth control contain only progestin. The medicine used in the shot is called Depo-Provera.",
"       </li>",
"       <li>",
"        <strong>",
"         Implants",
"        </strong>",
"        &ndash; A birth control implant is a tiny rod that releases hormones in the arm. It must be implanted by a doctor and can stay in the arm for up to 3 years. Implants for birth control contain only progestin.",
"       </li>",
"       <li>",
"        <strong>",
"         Hormone-releasing IUD",
"        </strong>",
"        &ndash; IUD stands for &ldquo;intrauterine device.&rdquo; This is a device that is placed inside the uterus to prevent pregnancy. Two IUDs work by releasing hormones into the body. One is called Skyla, and it can stay in place for up to 3 years. The other is called Mirena, and it can stay in place for up to 5 years (",
"        <a class=\"graphic graphic_picture graphicRef74378 \" href=\"UTD.htm?19/5/19550\">",
"         picture 3",
"        </a>",
"        ). The hormone-releasing IUDs contain only progestin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hormonal birth control is a safe and reliable way to prevent pregnancy for most women. But it does not protect women from infections that spread through sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10509332\">",
"      <span class=\"h1\">",
"       How do I choose the right hormonal birth control for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Work with your doctor or nurse to choose the best option for you. As you think about your decision, think about how likely you are to use each method the right way. Can you remember to take a pill every day? Can you remember to change a patch once a week? Long-acting methods (IUD, implant) are the most convenient because they work for 3 to 5 years, depending on the method. The injection, which works for 3 months, is more convenient than the pill, patch, or ring. Also, ask your doctor how the method you are thinking about will affect your period. See the Table for a list of side effects and risks for each of the different forms (",
"      <a class=\"graphic graphic_table graphicRef75100 \" href=\"UTD.htm?43/39/44669\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10509364\">",
"      <span class=\"h1\">",
"       Is hormonal birth control safe for all women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Some women should not use estrogen-containing hormonal birth control. This includes women who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are age 35 or older and smoke cigarettes &ndash; These women are at increased risk for heart attacks and strokes.",
"       </li>",
"       <li>",
"        Are pregnant",
"       </li>",
"       <li>",
"        Have had blood clots or a stroke in the past",
"       </li>",
"       <li>",
"        Have had breast cancer",
"       </li>",
"       <li>",
"        Have irregular or very heavy periods &ndash; Women with this problem should have it checked out before starting hormonal birth control.",
"       </li>",
"       <li>",
"        Have some types of liver disease &ndash; Hormonal birth control can make some types of liver disease worse.",
"       </li>",
"       <li>",
"        Have some types of heart disease",
"       </li>",
"       <li>",
"        Get the type of migraine headaches that cause vision problems (flashing or zigzag lights)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women who have high blood pressure can use hormonal birth control, but their blood pressure needs to be followed closely by a doctor.",
"     </p>",
"     <p>",
"      Many women who can&rsquo;t take estrogen-containing hormonal birth control can take hormonal birth control that contains only progestin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10509379\">",
"      <span class=\"h1\">",
"       What if I take medicines besides birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some medicines can affect how well hormonal birth control works. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Some medicines used to prevent seizures (called &ldquo;anticonvulsants&rdquo;)",
"       </li>",
"       <li>",
"        Some antibiotics",
"       </li>",
"       <li>",
"        St. John's Wort (an herbal medicine for depression)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you take any of these medicines, talk to your doctor about how to handle birth control. Also, if you already take hormonal birth control, mention it to any doctor or nurse who might be prescribing medicines for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10509394\">",
"      <span class=\"h1\">",
"       What if I forget to use my hormonal birth control?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have sex and have forgotten to use your birth control, you can take a \"morning after\" pill to reduce the risk of pregnancy. Do this as soon as possible after sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10509409\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=see_link\">",
"       Patient information: Emergency contraception (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36242?source=see_link\">",
"       Patient information: Vasectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=see_link\">",
"       Patient information: Long-acting methods of birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37138?source=see_link\">",
"       Patient information: Intrauterine devices (IUD) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"       Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"       Patient information: Hormonal methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       Patient information: Long-term methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"       Patient information: Barrier methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"       Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/17/18707?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16162 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18707=[""].join("\n");
var outline_f18_17_18707=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509204\">",
"      What is hormonal birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509332\">",
"      How do I choose the right hormonal birth control for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509364\">",
"      Is hormonal birth control safe for all women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509379\">",
"      What if I take medicines besides birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509394\">",
"      What if I forget to use my hormonal birth control?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10509409\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/55/38783\">",
"      Ortho Evra",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/16/43278\">",
"       NuvaRing",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/5/19550\">",
"        Mirena IUD",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?43/39/44669\">",
"         Hormonal birth control",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=related_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=related_link\">",
"      Patient information: Emergency contraception (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=related_link\">",
"      Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/17/37138?source=related_link\">",
"      Patient information: Intrauterine devices (IUD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=related_link\">",
"      Patient information: Long-acting methods of birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36242?source=related_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_17_18708="Necrotizing right lower lobe pneumonia";
var content_f18_17_18708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Necrotizing right lower lobe pneumonia due to anaerobes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 464px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHQAdEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0rxZ4jg8N2tpNPaXd211cfZ44rUJuLbHfJ3soxiNu/pXND4nWxOP+Ed13Pv8AZf8A4/Vv4nR+afDCeuqn/wBJLmsvV7Xw94a+Cvge70rwR4Z1bxVrNrp9raR3emxSefNJErO7nAJ4zklhywJNAEl58VrGzeNbnQNdQycJgWxB/ETVDJ8X9MibD6FrwP8Au2//AMepNUtfCviT9n+38UaX4W0DS9Xe4so5Xs7COFoJhexRyBSBuUHnjOdrc5rza4uo4J2SWzLlOGJfBoA9Fb40aOvXRNe/792//wAepy/GTSWTcuia6V/3bf8A+PV5fJc6e7fPayxj+8CGq3aWUFwu61kEg/ukYIoA9Ak+NejRn5tD8Q/hDAf5S1APjt4eJI/sjXwR2MMI/wDatci+h/IJPLG72qT+wLO8QLfWy7uzrwwoA6+P436FJ9zR9eP/AGzg/wDjtWI/jFpUgymh68R/uW//AMerhZPBz28e6wCzR+hGGH+NLZaJ5JxdBkb/AJ59/wAaAO/X4tae2MaBrxz/ALNt/wDHqtRfEmGUEx+GtfIHU4tR/wC165Ox08FsoiRoOpA5rWiQngMFRR3oA2/+Fhr/ANC1r352n/x+px44kPTwvrv/AH3Z/wDx+udE1uH25WTmti3VXjVowR7E5oAtjxtKSB/wi+u8/wC3Z/8AyRU3/CXXQ/5lXXP+/tl/8kVUJAPzKPoa0YAska7UwPY0AVJfGk0S5k8La4oP/TSz/wDkimJ46eQ4XwxrhPTHmWf/AMkUs6RR3kjBNzxqWUN0B+lQyLG1ypWJN5AJ2jHNAFxvF9yoyfCmu/8Afyz/APkioH8dPG5VvC+uhv8AftP/AI/VyV2SH5AAcckVkSpnLNge5oAsN4/2glvDOugf71p/8fqP/hYsf/Qt67+dp/8AH6yb26tLdTucFvX0rlr3xLpdsxE0+Sf7vP8AKgDum+Jdupw3h3XAfra//H6qz/FvToQTJoGv4HXCW7Y/KavPpdZ06cCWGYuPYGhfsmor+4mCzDvnGfrQB2TfHPQAcHR9ez/1yg/+O0x/jv4dT72k68P+2UP/AMdrz680WOVyZUVJOnmKOv1FZF7obROEkiwx6YGc/SgD1Q/H3w0BzpWvf9+Yf/jtIPj/AOGT00vXv+/MP/x2vL4vBEkqiS5YQR/3QMsa0rHQ7GzwLe0Vn7PINzUAem2vxm0m6GYNA8RMD3MEIH6y0+b4xaTCcSaJroP+7bH/ANrVwx0yd490z+VHjOD8orPkTToXI2vcuOuzp+dAHov/AAujRv8AoCa9/wB+7f8A+PUv/C59H/6Amvf98W//AMerzYzQsDiwCj/fyf5U+xsJLyTCWq+UPvMWxigD02D4uadPMkMOga+8j/dUJb//AB6rOofE+20+2luLzw7r8cMSGR2xbHCgZJ4mrjLOz+ytmzXyjjBkI5/OoPFNrOPCetSTTuf9CmO0sTn5D1oA9U+IHjPTvA2jQ6lq0N3NBLcLbqtsis24qzZIZlGMIe/pXn//AA0T4T/6B2u/9+If/jtL+1X/AMk80/8A7Ckf/omar97Bomg+FPhNBaeEvCs02v6fH9ru7rw8dQm3LbxPvEcRV3Yljnqe/rQBn/8ADRPhP/oHa7/34h/+O0f8NE+E/wDoHa7/AN+If/jtJ4vt9D1z9mjxDr//AAinhnS9btrlLZpNNsI4XjK3USnjBeJip5QnIB5618rUAfVX/DRPhP8A6B2u/wDfiH/47R/w0T4T/wCgdrv/AH4h/wDjtfKtFAH1V/w0T4T/AOgdrv8A34h/+O1c0347+HdSn8my0nXZZPTyoB/OWvkmu2+GFuZNUaQ8KvegD6lt/HpuQDD4Y11gf9q0H856up4pvX+74T10/wDbWy/+SK5nQWyq47V2tieBQBVHiPUcf8ihrv8A39sv/kinDxBqR6eENd/7/WX/AMkVtx8jPaplOfTFAHPf29qZ/wCZP13/AL/WX/yRS/29qn/Qn67/AN/rL/5Iro1bI4pSTQBzf9vap/0J+u/9/rH/AOSKDr2pj/mT9d/7/WX/AMkV0wIx1pCQRQBzP9v6mf8AmUNd/wC/1l/8kUh8QakvXwhrv/f6y/8AkiumYYGR0qN+SfagDmW8T3y/e8Ja6P8AtrZf/JFVpvGs0IPmeFtdH/A7P/5IrorlMiud1OPhqAMy6+KNpagmfw9rygdf+PU/ynrCu/j94ZtJNlxpevI3p5MJ/lLVHxHbAo5ArxPxvp+HZ1HQ5FAHuf8Aw0T4T/6B2u/9+If/AI7XZ/Dr4iaT4+/tD+x7e/h+w+X5n2pEXO/djG1m/uHOcdq+Iq+iP2Rv+Zr/AO3T/wBrUAfRFFFFAHD/ABTlMCeGpAM7dVPH/brcVT0afwFq+heAZvFw1u5udA0mK1/s2bRLqa080wqjl1+zkOQV4IbHyg81f+JqeYfDC+uqH/0kuaj0dAheJ/qooAztYPg/TvBet6J4LfXXOr6xaXy2U2lXMUFuRdQtIIy0CqiBUJwx4C8ViX3h6W9GViBlXo3HI9K7S7i4k74qC1IjCnqVOCPWgDhF8HM+7MsXmAcqvJFZ1xo7Wcg38Hsy8V6fPCYpfMijBjPOQKoXtktx5iso2sCfpQByNjqdxCBHjfjue/1rYgvrWZlE1q0TnjKciqNrbDJOK3tO0ssBIVwx74+6P8aALlnaIButiGf1B4X/AOvU01vC67blFkP970qGYJp0JfOwLycd65288Si4mCcQ5GAPWgC9qTfZom+xr5iL2xyPwrjNZ1lVJjbJY/eIOMe1bL3TBldZGD9iDXL6usd1du0j+XISTv25Un3FADYLyPaDHPIjZ43V0Wm6heQhWkcye4PauFnMtmy/aYQYs8SxHK10+k3ULIGSVWB/hPXNAHomkaktyNshBP8AtDmujtnQRYVQPQ15/p/8LISPWu30ifdCElwT60AZGvXxtrh3GSyjIxWDpusS3eqRkqw3NyM11mpWsEt9tkTOWwfSqttbwy30UyW8cTk87RgdcUAa9w58khR+lcvrl4tlb5bLSEdM11VyAUPJCivO/Gl7Dbl3lP8Aur3NAHA+L72e6RtzhEBzgHH+TXnt3JFydr7u3zGtTxP4iVmdAuSW6L2rj5NRmZ8rtX8M/wA6ANvTL+S2nDRx/KTz3zXYW9467JRGMYyCBXnlpb398wYO6Rnq7HatdvoNlb2tum9muJQDyxwo+goA77QJ2vgrSqYo+hd+h/Cu8s9Mtmt1CgOccS9SK8sstRmVQXkGwf3/ALoro/DXjW2S4+zK4xnBZvu/hQB0F9YRWrH7S5ZuwHJNYd7qMsalLO0S3P8Az0Ybm/DsK7LVdPFzEJYvmJw2fw6j2Nc+1sAWWRMHupoA5dvOuyftUzyf7xrQsdCmuFHlIAp6Fu9bFlplu17EdwC7hlG711VlYSwyySOmVHC4oA4iLw3cq58+LEY7qc5rYgtAiBIoiEUeldYV3RkumB0AHUmsm4fdKIVOTnLH39KAKFrayzTxxiMjccZPQVX8fW8cPg7XVDfdsJ+T3/dtXVadFsJkPXoK5P4mr5vhfWQvGLKZj+EbUAVf2q/+Sead/wBhSP8A9EzVb0/x58MNS8K/D3+1PGeo6TrfhqwiSNrKydjHKYERw2+3kVsbSOOPrxVT9qv/AJJ5p3/YUj/9EzV8q0AfT3xE8afDSH4LeJ/Dng/xBc6jq2q3SXsr3NtMJbqY3ETyOzGNUB2oeBgccDJ5+YaKKACiiigAr0f4aoYowe8hz9BXnI5NeoeB08qKMdyBmgD2zQXGxcdK7SwYFR1rg/D7YVfSu209+BQBvRNxzUinNVYWz06VLNKI48jrQBMZFjGWPNI8mRkCsO51AxtlsN6CoodV85W+ZRj0oA3Ul3NhfvVOSNhI69K5ddTEMox/Eea3IpwY8n0z1oAk80hio5HrUqvkVTEq5+U9T0pzzgcDFAEk/T1rC1BAQa2RMroR3rLvBnPFAHD63H8rcV5T4wtPMjfjoa9j1mLAbIrzjxLbblegDwi6j8qd09DX0F+yN/zNf/bp/wC1q8O8R23kXxPZq9x/ZG/5mv8A7dP/AGtQB9EUUUUAch8Qhm58Lf8AYUb/ANI7moYh5cgc/jVjx/gXfhXcQB/ajdf+vO5qMkSEAD5B1PrQBdngZotwU/NWV5TpPyCFbjnsa13uWkiVU/h4ouZkihIdFdz+lAFO3jm582QoPTOBRex2/kt5cgLsNuQelMZRcoGBy46ZPOPSmi2coVKnJ/WgCvYWFuJRtHC8k1oXMyW8bOcAKMgdqSCLyISuPmzz7n/CsfXTI8JRmwpPze9AHPaxfPqUzKhJReeK43UMteFWdUA9811N68dpCQWSNMEnPGf8a8+vtRgMrOuS2c5oA14b57QBTKZI+m1qmuIob6IzW0uSOGQjkVzx1CKVQRye+KdBeLHOdrSoTxnHSgDUFpcQMCkiFcZIPQ/hU8OmRtJ8hNpN12nlG+npVKz1NBceTcyDDDCnGM11ljGs0SMCrdvagB+npd2camQHbjhwcj8xXb+H71ZBycnGT7GsCyidQqLkEcY7Gum0qGJeDEgPdgMGgCO/vkFw7nOVPOKj027S4uhsLcHuKJrNZWkUOAc4ORnNXNJ06OC5dd5YgYxigCXWbvyLBmP14rwjxrPe6lduER9nYnjNe3eIgr2MqL8zHivJdbgKOy4BI7kUAeU6hoMu4NcTpGpONqjc36Ukelw2xXyUV5c/em7fgK7G+i2ocJv7gAcA1zupT29mEa4lUMf4F5Y/X0oAdFp8skg86UYUdB0zVya5t7JTGkollA+6Og+prnJ9eUowjeVS3XaMVT+3xLHzHLknruBoA6Ga6ubk/vZlKgcKOBU2nPKjKdhxntzXPw6nb7FULIGz7GtrTbqOZ/3M4cj+EcGgD3X4f655umw2lzIfl4jY9vb6V0+pWaOvnbcMOGx6eteU+H5l8uEj5HKjB9/evUNB1A3Vt5M5zKo4z3FAFQ6fFIVLylf+A5rctL2W1j2QyoyDr5oqvPCsfzYOw9B/Sqjs7r7egoA15NXtpv3cpCSEYMqAkD8KZDpMa4mWYSx9QU6GsQxj06VsaI5UND1jk4I9D60AagijFq5RgSM8VxHjld3g7xAz/e+wXB/8htXWyOYiUJxng4rmvHaAeCvEJH/QPuP/AEW1AGP+1X/yTzTv+wpH/wCipq+Va+qv2q/+Sead/wBhSP8A9EzV8q0AFFFFABRRRQAq8MPrXqvgzmOM9TgV5bAu+ZF9TXrPg+Ly4kYjk0Aep6IcKtdpp7jA7VxGkSABSTXT2s+cYPFAHSpNgYH41Fd3AVW3EAVh3OsJCdiHcw6kdqzL7VmZMhh60AVNX1kGZ0HQ5HHesyw1WQXBUFVB457/AIVyuvaoYriX5jjnHv8A/WrMsdaPmxGRxktxQB6rHfRu6sjdx1roYL0m2IjbJwfoMV5Pp2pv/aRjZtq78Aeprt9Ou90UYbKqzEfXigDdivSrHnPrVuO63jp+Nck15skIjJ646jJq3bXwLbd25vSgDqrV8Hd17VLcA4PHFUrSXhQce9X3YGPPB4oA5jWE3RtjmvPvEMWVbivRdTUENt61xOuoCjA5oA8P8YwclgOhr1v9kb/ma/8At0/9rV5v4yhGyTHvXpH7I3/M1/8Abp/7WoA+iKKKKAOS8fY+1+Fc/wDQUb/0juaYVJPHAp/j3/j88K/9hRv/AEjuaav3iKALFsp25Paq1wdzEk1Zd9kQ5qm7ZoAYV4BU4NXrOR1UksSBwB71SAzWnaRDgt91R+ZoAkuZTHb7idx+6vrmuP1q6CB04aU+vRf8TV3xDqf2e5McbZYcN7e31rktRZ3Y7MsOuc0Acvrly7mXzGLPjB57VxV4Seg6++K7LU7YzrhnAYnPyiubnt4ELho2Z84+Zu/4UAYTSyRbSAMYINXra8LIqMAcjkmnT7QCViQYHpTI9QQ4Dhd4HBx+lAGghWb5XHPb2NbekT3OwTRyE4x8oPU+tZ1lqcckSr5SAZ+b1xXTaMLcvBEgX5vlJHY0AdPp19IYIpM7h0YHqK7XSJBJE7soPyZrlLSwRFG/JBP0rrdKVI7YiEg8Y5oAitUJuz6nnFaVuhE2/uVFZuZEushSQe4rWst7lmII9M0AYXiaVLWDeRj5iSfQV5P4n1VbnIiT5i2M+teu+K7f7TBJGWABXI4zXjGsQR+a6gMpUkbV70AcN4n1S4t4Fhjb97nJI7CuMy8rs7kscklieprrdYt4pQzPJJu3Z5PUelZ6rbDK/ZkOegIoA55uOPzppJxjtV+9eNFaM23lyHvWfQAoJq3pqNJOoyAgOWJ7VWVc4LZC56irtvEPl8uTYM5+fvQB6NoOs+W4SYmSMYA/vL9DXp+g6gv7l43DoxG1x/n9K8At7iSFwWTC56jkV3ng7WWilAzujcjcmeCP8fegD6BlUTQpg/K6gj2PrWWyFGIIx2NWPDl0t3ZiMMWBAZGP06VNfIVfJGCetAFVYxjtTrcmOcbeMmhckUm07gR2NAGvebZAH/vDOa5Xxu3/ABRXiFRyP7OuOv8A1yauhMmbKPI5xXNeNDnwT4hJHH9n3H/otqAMz9qv/knmnf8AYUj/APRM1fKtfVX7Vf8AyT3Tv+wpH/6Kmr5VoAKKKKACiiigC9o8Xm3qe1et+Hkwqgdq818NQ/vN5HU8V6bpci28Id+vp60AdhbXUdvGGdsD1pLjxQiIUgO0f3j1NeUeKPGPlzNBZnzXHBYn5V/xrk11+8aQtPKzk++AKAPcX8QpIu5XOfTNR32qM0AZMhmHB9K830y+lkhDofl/IV01nM8sab8sO6g/rQBR8QTNNJBJneXUliTgDHFZkUgt5VZyG54x0FbuqWhe2Ic/Mh/SstEi2Lld2f7w4oA3kkZtTguBwjMHye44ru4pWSyt3Un/AFxXPpjvXEtB5v2MIxZwAvXqBXbXsEp0dhF0E+VA9O9AGG9+yXEqK+SHI4NdBosxcqVxnuRXOrZO1+7eUG3NuweOtb1s5t1ClxtHOVxg0AdpaPhBzk960oZMx9a47Tr8M4Ay3vmuqtmygJoAqXyAhic1xfiBAofHSu71HiJj3xXB6+xZSMflQB5P4tUAt79a7/8AZJGH8Wj3tf8A2tXA+L85au//AGTOJfF31tP/AGtQB9C0UUUAcl49/wCPzwp/2FW/9I7mmFv32BUnj3i98K/9hRv/AEjuaibiUUAPvASikduagTnk1bkw0ZHeqwXjA70ASQJvcAdWOK1GdYIHcDOxTj3NVLNcEv6cD61LqLbIFB/L1oA4LUI/MnZ5iSSc1malMFiC4GwJ+VdFqMMa7pZSd38KDq3+ArzrxZPPu/e52AcBOgoApajqMAlPl4LDgBTxWJeXnmhiqgn2rPmfBJB+U8+4NUJLkBsB1G7k0AWJ5Jxu2bfpt6VhzXFyJDkp6j5AK0vMYjkHjnPrVhrWOWPZJG2DyWHUGgCLT7qWSPzSqoFxzjB/+vXR6Hqo81BsYMr5BzjNRaN4ZmktQIom2KC5O6rOm6RJHfDzGUg8jFAHsGm3EVxaxuGILDPNdNp8Sm1kfdjJ/pXHeHLeT7LtxlOoJrt7dAliFHfBFADYA3mEgnFaEGdhyeSeKqW7ASFT1IOPrVx5AGIHIFAFDUUXLbyDxXkvi/SEglmuLWVyxzmPGfyr1HVAzs2CcmuR1m0JRgRlj6UAfO+s38a3MlvKHDhucjpVC81iL7KsVpAVl/jlc5z9B2rofiDobW8xuEUhwfXqPWuN+x3BwPLOW/OgCuWJOSST70bj/kU6SGSNyjowYdsU11KsQwII7GgBySbQBtBwc5pyODgE4J7ntUNFAG/p/mYyTlP7wPBrrNGjBkQRrtYnJxwK87tbiW3kDROUPf0P1Heu58L6lHezorBYZuAP7jf4GgD3PwHcNFEqzHaWwAD61216m+MPjkdfpXnmi7lgSNidyd8d69Ds286whY8kja1AGavyNTuCGJ7CnToUfB9cUbR5bZ+lAErj/RQB6Yrn/GcX/FC+Ij6adcf+i2ronGIAPSsDx05HgPxDjodPnH/kNqAMb9qv/knmnf8AYUj/APRM1fKtfVX7Vf8AyTzTv+wpH/6Jmr5VoAKKKKAClHWkqW3XMo44HNAHS6NIlvGhJAwO56VFrniKWdGt7ZsJ0Lg9R6Vhz3DNlVOF9qrUAKTk89ach2sD6etMooA6zSz5kEEgBGeCB0967DSZkBCIBn0z3rz/AEW8CzxRsSIh1J7+tddbqYbiFgWKdQT0NAHS6nKiQlsBnzjjpjFcvIx+0rHGD82MKK6CWNrmM/LwQCBnrSaVpiyXEUkzbVBLEgZyfQ0AbGgWxkmUkBim0YHb/OK9HSBpLSRWxndke3ANcL4emRLkgEDd0Ueteg2ysysuP4gfpxQBi6tbg4EQwdvzHpmsCeORnCAFQOQK7VrPznUOeOpOP0qCewj3lkhBOfvHpQBiaUjA4UdPTtXW2c+xFQswI6ZNYih4mx5iKAei1oQRGRgzZyO5NAGleP5kBye1cXrEbAN8prstgMRUmue1mMxhsEZ6igDxjxcuQxru/wBkv/WeLfraf+1q5DxsAskjDjPIrrv2Sv8AWeLfra/+1qAPoaiiigDkfH/F34V/7Cjf+kdzTCcyDpS/EM4uPCxP/QVb/wBI7mmg/vB9aALD4C/jVZASRViU/JjNRxdM4oA0bSPcqDt941R16cINzDIHQeprXt0wgUdcVy3iDzJtSIiYNGuFwD92gDKl3zZdmBkPqOK5rXNLmuE2vGBuyeeK7VYlUDABb1qrertfL4IA6mgDxfWtFFkpkkVpYycNg4x+FYl7aQhVa2Gz0BHNeyapBb3SGMoCWHpxXDat4YuVZjbSKsbdCBkj/CgDg5BOSpcE8gbsdMVNFK6MyojOcYJC5qxLZyxagy3Ehwvyjk81V1GBophGpIY/MMDr9aAOs0bVLiFYInZvJcFPTNdPp8cb3cbIwMe3nHrXmn9nSkIY3Yg84Hauj0xZ7a5tlPmJ5gJC5oA9s0NVWJfLGcjFddEipGAVGMdBXD+CXlZA0jExqMAEdTXd790dAFRox5pKnBJqwigAY5OKiIOcjpTopOCOh7UAVL7OThcVhX8RIJIJAFdBfsSpY/lXK6u7ENlmoA8o+J0lrb2bibGZD5a+ory+YI11av5yLx8xLDoK3PindtcaysSg+Wm4j3PrXIxII0kMoOdny/WgB17cb52MbcdM9zVQnJyetFJQAop8aFyQOcUypPOYrtIGPXHNADkt3d9qYY98Vv6UViK4xwcH1/KsuxlV87mUMOi9Ca17VtwzIvfHuKAPYfB2rJJAsE7fJ0jkY5K+x9v5V6r4ZdpLSaFxh0IIFfPnhp3jYNksg4xjpXtvgO8M9qyscvGBhu5X0/CgDavo90mfXBqJ8BAK0NQT5lcdDWXMSGxQBZkB8kZrm/iFgeA9ex/z4zf+gGujmP7pB7VzHxBbPgnXh/04Tf8AoBoAzv2q/wDknmnf9hSP/wBEzV8q19VftV/8k807/sKR/wDomavlWgAooooAKtwrstZHI5I4qvEm+RV9etT3cysqxx/cXr7mgCrRRRQAUoGSB0pKcoy3AJPYCgDotIsYjMsW8sTzuHAA+tegaLYxNFt3Fzj5cnNcN4csrt5FeZD5XZmPNejaDo0rJvSVlXsQDgUAW7izlhEQQKzsABjrST200U7RBDGzDKnpurt9MsFJh3hj8uCxHWtK90yzWNZLmJjxgY4agDyvRYLmPxLawSockFzg9q9l02SMxScjO7GfTiuQ0XRojrMjhRlgSrEcgeldO0S6fY/OeN/XuaAGXF0iNjdk7ulV7qfI+U5C846Vg3U08kyEkxoXOCPSt23jhlU+Wxc4BPHSgCKNBI4dh83rV9HKqdvXrUsMChP9WcdakMeFPyqtADbSZmVt44+lYPiFsDrxit0MFAXI5rG1uFtrF/mU9MUAeP8AjM7t3oOK7L9kr/WeLfra/wDtauZ8Y2REEsiHcF5IPUD1rqP2TRtm8XD3tf8A2tQB9CUUUUAcZ8SjiTwuf+oqf/SS5qKNslT3p/xOOD4YP/UVP/pJc1XtjlR7UAXpWO0A96nt0BKccZyaqt95Qav2oyGx1AwKANBSfLlYehFcZqCO12doOc8Ed66++Yw2HHU/zri9Zu2ZmigwAwwZAevqKAIpNQSFwkYDuOG54WqNzfwyhj5h39MVUSKSRSY0Y49F6VVurCZUczRtGDzycUAQXE80jN5IU45wTk1SkuzJIkEhZXboMYzQLmG2bcwZ5FPHHX8a2rRYb6JHSIr3YcZFAHEXmni8upCqndH0Rh941L/wid1dGGcqhZcdQc49Diu9OjQSqzrOATyRkVsabHCsKK0gDcDpnNAHncfhK6gcSbkTHIUHdmtrSNOV5reNoldwDhj6V2d8lvBGSQ5ODjavSqmgMr3YURsAqn5sUAbOmWK28CqgACiti3R/KGeDURA8sBPxq7bqWQYxx0oAjCYjcnr2qpE+ZcDmteQDyyMZzWXgK5G0LzQAy9jZ42CjORxWBf2Y8k7/AJmNdHLgLycccVj3jqgJc9KAPDPHHhtb3UCfLGAK51fCEFzeJA1xtOMAY/TNekeJrmNL9nGTjqB3rnbyZYbtXWCRdwB4wcZoA5TXvD1pp9g1tbvAZP4mY4OfrXFXFjPASCu71K8iu98SzRPC5mDEKpJ3DG78RXGXqym3hnBjXzPlVEOAFH1oAyyCOD1opSSOD9aWQ7nJwB7CgBvAxgmtbSL0xyBbhXkQ8Bs8r/n0rKKMOqkVNZsyzLtGc8Y9aAPWfDWHjSa2KuhPVR39COxr1bw/IbMRMgwRyw+teK+DJTZXCzEbW7p/CR6EV69pFxHcQpPA2V7r3Q+hoA9ImxLEu3o65FZFwOhq9pkom0uCQdVJQ/hVW6XErL/tHFADbg4UAVy3j98+D9c/68J//RbV0c78LXK+O33eEtcz/wA+M/8A6LagCP8Aar/5J5p3/YUj/wDRM1fKtfVX7Vf/ACT3T/8AsKR/+iZq+VaACiiprWB7iUIo47n0oAap2Rk924qOrmpRGGdUxhQowKp0AFFFFADlGTgnFdLoVlCkqO6l887iOBWVpcSO24LvYdQ3QV2OhwSTYjijXaSMNnpQB1/h2zM+GO0p6bfu12FlMIJ/Jj+Y9M46VlacBZW4iZSSo6joas283753CMMDOQM0Addp53ACTBPXjtWlqMpMHGeBke9clZaltlXZgqRkHNblzM7WRwwJdSAcdM0ALo0+3UFLKpZuK2tSsDcwct3zz2rH8ORAFSw+de+K6iOXehUDhfWgDjrqxnKKjqHjVuD6Cr8ETKFDn5QPujpWlqF5aqrxNgv3welcb4h15LIqkLoV/iYSD5fagDoJbtFO3nPSo3usKS3YZrkU1iNcSSz+aT/AhzirpvoLuHMEpDE8rySKAFm1ZheBChYueimtXUZAbRj1QrkA9qxGVImHykHucdfxrQmfzLLH8BGM0Aed+K5wEnG3AaMqfyre/ZR/4+PF31tP/a1c34yjdYpBg45+aul/ZSGLnxeMd7X/ANrUAfQNFFFAHE/FDp4Z/wCwof8A0kuapWr9BVz4onC+Gf8AsKn/ANJLms62OOvWgDUXLMCT2rS0zmFnPTdgVmIfkU9617NAkUcfTBy31oATXVMtgbdWIdh1HYVh6XoB3BpWZl9K6J4zLO0j/dx8vvToXKqdq5xQBQeOK3OxIxkdcVg6nqNuWZJhGFPB3mtDUtSWN3bY5yeT2rlr3T7fUrnzFmKn/aXNAGLqo0yRGkt1UOTsxnAqvpOi61HcTtbk/YGUFV9/bua1JPD1raPHPcN5uCT8tdLo+v2VygtYVIaMfxCgDn7SF4ZCsjjA42EY5rpNOGYWZwplHHHSoZIhLeGR1AU8Zx+VaFs8ZUoy4ZTz6H3oABbebHmTBY9RU+j2iRyOQMHOKhkm2geV83qBVvSiEhdurdeaANGVBnFWrRMR8VQMjPhgOa1LUsYxkc46UADjnHeqUke58jOcVfI+Y5FVWyZQBjrQBUuIcp83BFYl3yhDrn0711MyF1PTJFYV7btg5AAoA8s8VbYXlk2qzbsr7e9cVdapNcSDzGBzwCBiu+8X2JWK4lkGVGcDGa81sXW6nXfzsONrL/KgCSbToptDfz2G9wdx9BmvPNY3LciLnyoxtQH0r0PXVCqkNpJhFGMdQfrXI6naSSSHzk8wsOCjfcxQBzdFSvBKr7TGwJ6AioyCDgjBoAsReW2OX3Y9a3bOILt3ENxjlcCucQsjBlyD2Nb2l3irtW4Q46B88/lQB1OmQbHXaTj0NdpoGpGzu1UDMZ+Vwe4rjLGWOQK8Mm9Ccb1ORn/Guos4VYIy9QOvr9aAPcPDDBrCSMHKMQyH1GKdeqRcNnjgVifDy7eSwaGQ/OjcZ9K6HVB++V/UbTQBi3BwxBNct45f/ij9cPrZTf8AoBrp9Q4fHqK5Tx6Qvg7WV9bOX/0A0AT/ALVf/JPNO/7Ckf8A6Jmr5Ur6q/ar/wCSead/2FI//RM1fKtABXS+HrQ+UXKnJ9qw7G2a5lwBwOtdVMx07S3ZTgKML7t60Ac7rsqSajIIzlU+XPuOtZ1KTkknk0lABSqpYgKMk06ONpDhFJPtXV6H4flDB7iIAHGGJ4+lAD/Deg72YuxDlfyrp7KxkS4VFB8tBuzj7xrb0ewjRd0Khtwxj0q1a2UskzxYKrgjaP50AY8+tmDczNuYHGB1rQ0/VZ7y3laDIyOAO/tWJe+GriS8O7cIf49prbint7Gzt4LNQhQfO2c7zQBs6VCWt/MnHK/wjgA+lbq66Y3SKRQU4BUdqw7W7C2nnTOsZzjHbFXtKtFvpC6MoDN1oA7rTCjRCaPAVxxmrc9yIraQBxuIODWZ9neC0jSE8pySeKzr0ahJbkRW7s3TI6YoA4/xZq09gUZ5RGXbO0feYe3tXPwRTXz+dJYrtwTkscn681s6zo93JqjXFyqO4+6p/hFadmI9h3qVfBIxzQBlLFEkSEQJHjqOtGmXktpcMWCLGechRmp70uFJQHOPvY6/SsOZ7qS6A+UQ9TnvQBvSaqJbkASMwYj5QCcV1Fg8d1ZuoUfLzg9/rXnEwm8omEOhPfpx9a6rw2LmO0JmdidmAW60AUvElqqvKoAZe6+xrS/Zttxa6x4xjX7v+iEfQ+dWX4im8yEsvUDBrY/Z0bdrPi72WzH/AKPoA9uooooA4j4o/d8M/wDYUP8A6SXNZ8H3eK0PihyPDP8A2FT/AOklzVG3TG2gDVgjy0YPrk1qWQ3rKx9efxqhadHPovFatpHsiRe7Nk0ALdSpDDkkDjGT0rn5tTufKnLYiiUfias6zcGS5NqE3Rjv2J9aZe2S3mntAhxIADQByk2qPdq0RKAjoegan6dE8yMIshsY+hqhLpbxTlJsnnoK2NGV4JIwVIVj6dKAMjUkurO6QSF5It3IHYUJcW5uligjMcjDOU6Gus1QxhS8nAYVxDlYLtpAD97CnPIFAHWXMbpawZcIpAJb8elLYzxO7ndvJ6Vla7fJHpMSk4kYDAX36GqmmXqpGTnazevrQB09uwSQs6GtEERwqyDqPSsSO8V8ANgMcY/un0rZiiaXTVYAjace9AE1tIxY5HA9BW1aMGxjoRWDZFwNpP51swHCqBQBebaDz0qudokzj9KmI71Ey4NABJwuR0xWFqFwY88DA9a3tuVwa5/WISQ3pQBwuvapGbacXEMbo2QE7/WvE9b1CfR9bEfkxeWT5uQeMH+te0ahpmXLAZ7nvivKviJpyXMbmMESx5K8cse4oAT7Xb3io8UUqb+PlIYD8KxPEdg0KvdW7rkAICzbTms3w5dz2fzEyBgcpnp+VdDq841TTQLlFcoD90YJPrQBy1hqclpJvu0Eka8bWGcn2qXxEYJ7lbqzjVDIoYr97t/Os65spIVDAOUyTtPpSWFztkzNnyycHFAFQh2XJzt9e1IqMQDyFJ4Patq5jidlMYfb/CF+6Kjjt04LfM2f4eMfUUAXPD90bCUMgGDwyHkNXqXhySC/jLW4YMMbkJyV9x6ivMbW2YMSkQwP4l6AfSu48Iyz2c8cynDqeAO496APXvDObW5hK9iFb3HeuyvlDNMvpyPwrjdNdJY47iHAVuT/ALJ9K7a5XcYJP76An8RQBzWoL0bHSuQ8fkf8Ipq4/wCnSb/0A12tymVOfyrivHgz4Y1o46Wc3/oDUAWP2q/+Sead/wBhSP8A9EzV8rV9U/tV/wDJPdP/AOwpH/6Jmr5f06LzbuNewOaAOk8N6eQgLDk81Y8ZRmHT4UUDG7JzW7oVvtjTjnFZfxMYRR2kY4L5P4CgDgKfDGZJAq9TTa2/D2nvcP5inDdFoAfokTwOskkasjclSORXf6SsV3CQgPmLgjPaqGn6LKJcJED7np0rsPDOiCC9LyNvJxlQMLmgC3okTOrIFw3HIHWujt9L33MMiZGDhgO9a9lpsS4CovvgVr29qkK5CjmgDhvEjgMbeKAhXOC2MZrh7q3jtbsyy7SBxsXoD65r3Z7fevKqF9COtVHsomADwxMmemwUAfPGu3ksr4jRhHjCopOTXpvw8t5106PzfMZlUH5h0rupbCEHd5ESn/rmP8KsWsaRA+XheMsaAK+lpNMhE2TkntW1bD7OTG6DBptrdRJndgt2xVS+ud8oKNhu49RQA7VDa7TlYwx6ZUVz0wYfcMaH/cA/pV3USXhbaOf5VlQKzKfn+bscUARXPmMAFlUeuVqp9nVJMkxc9fk6fmK0m8tARJuB9RVS4ZFJYDcuOtACixtZJAcQuQP7ozWhHDEkfEajtwKx2uNoBiVE9TWvpNw7kCU70I64FAHKeJrXh1AC55FXv2eYHt9Y8WJIpVtlof1nqbxU8aRkSAkBsZXtVn4ILt1/xNzkG3siD6jdcUAeuUUUUAcR8UThfDJHbVT/AOklzVezUM2ewqz8UOnhn/sKn/0kuai0z/VgUAa2nqGkZf8AZya0zxBvzg8gfWqFguDI3TIC1oPHvgRD90cn8aAMq4UBW2kE+vvU1gI/LXLYcc1N/Z6tJlXYD0xwKkTTNrZWYZPtQBTvI7d5ThACO+OaqRRhX5RQueD61qx6aF3F5c574pHsVICh/wAcUAZ8sUVwCrYKmse98NQXBBEzRnPOFrpW0okAeYFp/wBgeNMeZuPuKAMVvB9jeWUMNzI7iMcMvBFVbnwfaRSBw87BeMcdK6mItEu0/jSyS+bwD8vTNAHP2XhzTbRHaFZirHcRI+ea2bZoiFgAAQ8fWoLmRQScHHQ9qhsmzdoAAeaANX7JCjEhT+dTwKqt8q/nSucnkCpYiMfLQArdRx70yTPHy1K4yAaQjkZoAj5AHFYesZ2SZ/Kuhxge1YWsMBGxAHJoA53yVaNiw5xxXFeK9DW6UZTLdivGa715H2kBUz9Kz3cTShJIlyvPWgDw3xH4YNmsc9sSQxAZW4+tV9UtDbaAk8MeHAz8vzc9MV634gs7a6t3jZWXr+P0ritRs5beBRarujbmRTyfc0AeVjUzPJ5VwXz0yTwDWTMjW85WRSMHI4xmutubBnunMiRrHklCQM5zVJ9KhnJ3yySS9gTigDNkuRPtdJTG68EbeP8A69aOnyFziZVDeoGKrGBBH5HklAjD5u5qSFREGTO7GMMfT60AdVp0ByJN2dvQKeM+9dXYQeZtcFY5e+On1ridG1AwHEkYeM9fpXaaTJHqCBrVsFRyh6/h60Adh4UvClyYJf8AVvgH0B9a9TjQtYQg/ejWvJ9Ij+dVcfN0zXq+mTCSzU/xRgK2fYUAYt4MbsdzXE+PEx4V1s+tlOf/ACG1d7fRgSsO2ciuK+IK/wDFJa2f+nGf/wBFtQBD+1X/AMk807/sKR/+iZq+a/Dqj7aD36V9KftV/wDJPNO/7Ckf/omavnXwlCZLvOO+KAPRtGiIRSPwri/iZl9ZjAJJVNmK9K0a22xKWzjFUNW8Ore3ZmZSC4wfwoA8es7KaeaNRG20sATivU/Ceh7AhKkdsYxxVqx8PR2z5AyRXVaZD5ToGHHSgC3DpwRQu3CfSr8duwkDQqePatyxtAyrxxWzb2yqM0AULZZFt1LKc46CtO3ZSBuBGB3q1HCGHzc1MttHtxjGaAK/lCVRtPFL5A2YbnFXUjWNcKKgkJBO3kUAUbwYUdjWdPIQCiZrQuWC5aTO1ecVjyXeUZRgyE0APsdxlZnBAPbPQVZnRHUSJkqD361WtImBDMflb7xq5K6qu0D5TQBVuF/d8jANUpBBEMmXHoMd6murkxgg4YKMkVUuJ45Ey8akY646UAUb2eEnJnGfpVLzYmyiSoc+pxzVieNJACqq34dKZBZ2+/Lx9e+4/wAqAKNzDJIqonI/vV0WjWptrYAkkkU6GCFDwFHpzWpHCwCOvzL3xzQBx3iVWmU7+Bkkir/wPOdf8UY6CCyA9huuKZ4jtjhgp69KX4GgjxB4pBBBENnx/wACuKAPX6KKKAOK+JoyfDI/6ih/9JLmiwTaqg9MU74lf6zwv/2FT/6SXNPgXCj6UAaluuI0x3Y1pYAcqOnSqNmnyRk/wmrbHaT13E/pQApbB2gdO9OQkkYzQqjblulPSRM8gigB2zcrbutRbce1WQB1zVe5bDDAAHrQAkp29evWk3grk4zVCS62SBGY4J61PCpfBDcfzoAjnBZTjiltodkbAnqOtTSKQcDoKi5yeTQBnXqkDA6d/enaPBi43kZxVox5GTjAPNWoIwF+UYFAEpIJI71KpKAAdaYF6Z6CrUeMfdoAOopCvPOKCxLHijPcD2oAP4cVga18iFSuTmuhz8uSKytYTzE6AGgDly5GduQR3pEtlIckAsR1FXWtlHzYogh3sQDt5oAwbuy+0ZDJyDjArndQ0b7RHJsZkKnaMH9a7Rg0Vyy+h/Co57RZInlUqATyB/OgD5q8V6Vc6XqbmViqs+R12/X2pllJucL83zHJJ5zXtHjDw/DqVi6Txhv4Q2Op968R1LT7nR7p4hJiNX4Ge386ANK7tBLEjR888kdQapiyaE7fmV2HQjg+4NO03UPkaMk5c1oFnEgt3JzwELDIP40AZMW+NgrptzwBjGfxrptHMkc8bRsQ46FeKZZwxyHy5F+Yf3hxmtuy0KUMJImC5GSpPI+lAHd+H5Euz5hGJU6jH3vcV32gMGEyd2Tj6ivLtNk+zqnlEq69PavQPDV8s8sUi/KQ2HX0NAGjfJ8iMB0ypriviEv/ABR+ue1jP/6LavQdRj2rKvb7wrg/iCufBmvdx9gn/wDRbUAZv7Vf/JPNO/7Ckf8A6JmrwvwJalnViOvIr3b9qhS3w/01R31WMf8AkKavJvCluIEjC9dvWgDvLFR5YUdq01h3bSq7j0wBWXpx9OldHpi8kj2oAzYNIuZixK7cnvW7pug+XgyEE981pW69O9advGxwe/0oAW1tVijUE5NX44s4GOKWKMAAmpwwAwKAHIoUY4p2QPpSLHI4+UY+tPW2PBd6AImOTycLUEhVThTgGrzWqsMBqhawJyVYfjQBiaodsB2k5c96x41CqWPc962dYt7gvjqingVg30pRwjAoAO/f6UAXWkAjQLwBSTTiGIOxz24qgkxaM44wRg00kN8pJ29v8aAEulWaRH5OT29KsNGocrgbCM/WorHeLl0UAgc/MKvOzmM5iAZf9mgDOdUXgKQe2KYVz2BP0qzJMgyGhPI/vYqm1zCcqCyN6MP6igAkCKyiR8E9AK3tLQxRsMnYR2rmQklzdDy/mTP3h0rqoVEVnjJzgDmgDnPEknQNwecGnfBc/wDFR+J8jn7PZf8AoVxVHxMGnZkXqBj6Vf8AgyQ3ibxSR0+z2X/oVxQB6vRRRQBxvxHGZvCw/wCoqf8A0kuangwAOlRfEQZuPC3/AGFW/wDSS5qWHG0CgDYsxiFB6nNSlS05c9Ow9KZbcLIT/DhVFWNvyg+n60ATqFKYYU0xRjoOajU7sZOBUoP1NADwnpxUUiq2Qy5FTA4WmEEnI4oAptZwM2WTPtmrEcIRdqqABUigg9KRix4A47UARFPmOTxTCqjO0deKe0bE9cA0qxn7ozigBY4AUIPIahIjGSvapQMKBjpSqexHFADdo/H1qdPu1HsGKlUAJg5oARj+lIRkClalB4A4oAY3PGaytVOGKlvwrX4xk1j6qo84ntjNAGcZIyuMMKfCqlDtIqtKhAyTj0pUOEOO1ADHQLOwIBz6Cs+5tQJgUJQnsOn5VoRPtJJ+6PWkuQrgHv3xQBj3trP5LY+YdQBXmHxB0AalpzuibLiI7wV6nHY17PEAYyM5K1zmq6fFKshJx8p7fe9qAPl5bN1lV7SQrk4w38JroNMnuLqJVKlnUgHuPzq54i0r7FqjSKhCOckVXt7hoHD7VjTOCAMAj3oA2NNZWm2+cBnP3un4Gut0+WLaFU5ZRgDPNcLI3kjfbBSnBx6fSrdpqjKV2HCHndj5l+hoA9AWYSqAeH6bvStvw3dNZ3yBs7TjcPUeorktPvy3l/aguXHySqeH+vvXV6aPNljWTnacg+goA9PvkDox65GfwIrz7x8v/FF6/wD9g+4/9FtXc6bKZtLjLn5kzG39K4n4hrs8HeIVPUWFwP8AyG1AFH9pZd/gzSF651aP/wBEzV5d4diG4bupFesftEru8K6MP+oqn/oievN/D9oZWQrnA60AdDZ25UjaeK6ewtynU1HpdqqRqMZNb1vACM4oAntYht561djzxtGajhiAHHWr9tE2RxxQA+GB3AyQB7VaCJEATyTSswiXtmqzSl2y34UAT+YT2qQgmNSaqhvrU4Y7AaAJFGB61IzLDE0jkAD19ar+bgVmapM8yBRkqD0oAsrcxXLMoJyO/rUF3ptvdxlJEDDr9PpWL5jrLsXjHet+1JCKxOcigDnJ/DMsbboJN0f9xutZdzDJbbhNGUPTkV6Gku5tj9T0qK8tUnVlkQMD6igDz63fepIPTnd/SrXnkDcpKuP1Fbdz4aRFLWjFc87eo/8ArVzt1bz28hW4jaNs8ehoAfcOz/xH1ANMto1mbDIuQeu0c0+OIs4Yq2x+3pUyKYh8pG0d/SgC3BEkZ+VAPwqV43US7s7Se/aqdu0zzfKdy4+ua3nAazViByKAOI1tQisRyTUvwXOfEfij/r3sv/Qriq3idtiOVz7j0o+BLbtf8UnOf3Nn/wChXFAHsNFFFAHH/EP/AI+PC3/YVb/0jualtAZJY0Hcj8qi+In/AB8eFv8AsKt/6R3NWtJXLq3cnAoA2AQqlicAtUiHf9Kpzvv2hR8qtj8asQE4ANAE4XByKlA4yeKWNRj1NP2454FACgLijaBTd350pPb1oAd0GKbgUZoHTnpQAvYUmOaOetH0IoAD0pvTBPSngc0Fcj0oAaMFgeamBBHXNR4AxUygA9BQA3gA+vpRxSt9OKcF+X2NAETY7ZrJ1hg2FAP1rYO0LggZNZOpqM/KME0AYgGXwQTil4VSSOD2HepFChiW+nFNlysa5GR6igCvksCOgzSTPgkDrQq/NkDgcmqzrJKxKg80AWIZEXcScNjp61i6xL5SkgfKa1l0+R8uxIGMVBLpEEsJjny47ZJoA8q8QQJdDa0kSE5w7H+lcfcRph4FjlkTd/rAhIB9ele16npVpbQNsghRky27ZXPxqUVmmGYickY/SgDyO6+3W8Q3wSeWjff2HgH1pttcszjY+7HRCOlevmCOS23IsXlsed3pWfP4S0zUpA1sqpcf3UOD+FAHK2cr/ZYUfDxKSRjgoT616F4XugESKXl8Da2f0Ncuvhu80acylfPhBwSByo/2h3+tXIrjywDGyrjnI7UAeyeHZxLZXUefnAzj6VzXxM/5FDXWHRtOnP8A5DapPh/qX224EhI3fckGMZ44P40fFNPL8Ga4Mf8ALlcY+nltQBW+P6l/DmhqO+qr/wCk89cfoFuEjjC/jXbfHMbtF0Ef9RUf+k09cjogIYA0Addpyjauelbluv8AdrG09flH0rateBQBfhGB071cVtiZqrF0GKthC456UAVm3OevNOjTmp1jA4pdu08dTQA0gAe9PVTJEeOlN25YdfWrttHszno1AGddN5FsZD948AVkozE8g5PWtjU/mk27flXoKpxQhnxtOT2FAFJLJmlDIOCa10QIqgDpU6Q+UMMBmmuwxxQAQqomGcZzV90BbtWdbgtKS3rxWjySKAIXtyQcYqneWZmiZJFDr7jNaZphP6mgDhtTEtixDQh4OxXIx9f8azbueIRMYW/1n8LdRXoN1bpMpDqrA9QRnNctrWixRxF4lCooyVTigDI0RjHcKeuOM1vSkiFgP72BWTAqwhAq4bIrSunC2uRigDjtecMsh68kGm/AI/8AE+8WDOcJaD/x64pmsHbC+7+Js/kKX9n8g674tI/uWZ/WegD2eiiigDjPiS22TwufTVW/9JLmtCxYRIrH+BR+Z/8A11nfEsZk8Lj/AKip/wDSS5q4OY3A7sKANKJNyEehzVqPAx7VDaEFPcVIzbTgHrQBbWTHFPJJA71TTnrVhDigCSlAP4Ug6U7tQAg4paAM9P1p4A70AN5z604D/JpcDOMUE9aAFC8UcY5OaaSTg0Ec/wAqAFYg/wCNO6KMUxBlh3HWpTj8KAG9Rg9KQHIxTyOM03pnNADX4FZeqSKGGV5xmtcgHgVlaxFkbgPmAoAwWmj39wSasiNpSCoyvY44pLew3MGY1ZuZhawhUPzH0oAjNutsNxG5iM4psbwsQB8hPbNZ011Iw+RuTxk1BIhPLEhvUUAbjJmNwCKpiMl+fWiykdIAX57VdCq+11HBoAxNZs1mgVW4Bbk+1cJqMXnXIjTO0cKMYBr0nU4i8RReAK5C7tHEhxEGXPpQBx+oCSO48gJiJAOnOa0tJ6hNpV16NWveWkDQBim2X0/xqnYWzxzY7dMj0oA6e3h8+FPMAZsfePevOvHWlS6bN9rtF/0JjiUD+A5/ka9EsrgoVjwOO9aupaXDeWTRyorxyKVdGHUEdKAPO/hve/Z9SyxIjwN2fQ12HxaXPgfWT3Wynz9DGa4q00ibw3dSWzMzwysTA5H8P90+4rr/AB/KLn4eaxIDkPpMhz9Iz/hQAvxwONH8P/8AYVH/AKTT1y+krnaR6V03xz/5Augf9hVf/SeeuV0aQ7VBoA67T8gDP51u2y5FYWnyAAVu2rDAwaANGEAdKuIcYqlCTxxVpCS3I4oAlYZxt70CPPX86WJuD608bj0oAVUC8nrUgNNA4pcUADIsg5Az60kcEcY4HPrS9KG+7QA0xIx56UvkRAfdz9aYv3qmoAakcaElVxT84HNNyM0pwe1AB1pCOOaXB7c00uV6igBj9PpVW4iEqkEZBq1K42nGc1VViGyT1oAwbqyFthTyDyKoXgJjCntzXR6momTYw6cg1g6qQsRUYyBxQBwPiy7EMD+oyBUn7N7+Zq3i5j122n856wPGM5ZHyf8A61a37ML79R8YH0+yD/0dQB7zRRRQBxfxL+/4Y/7Cp/8ASS5rSs/3kBcdGUH8qd4y0C41+304Wd7FZXFldfaVeW3Myt+6kjKlQ6npITnPaqFvoXieCJUTXtGKqMDOkS//ACTQBrRyBSAO9WlAYVz39g+J85/t7R//AAUS/wDyTU6aV4qQYGu6Lj/sES//ACTQBuqcEZGDU69K546b4qI/5Deh/wDgnl/+SqVdP8Vr01vQ/wDwTy//ACVQB0QJ75qUAnGcVzf2TxZ/0G9C/wDBPN/8lUv2Xxb/ANBvQv8AwTzf/JVAHS4pehrmfsvi3/oN6F/4J5v/AJKo+y+Lf+g3oX/gnm/+SqAOmNGPX1rmvs3i3/oN6F/4J5v/AJKo+zeLf+g3oX/gnm/+SqAOmHJo57VzX2fxbx/xOtB4/wCoPN/8lUG38Xf9BvQf/BPN/wDJVAHSAcgd6kXtmuWFt4tB/wCQ3oOf+wPN/wDJVOEHi4Z/4nWg/wDgnm/+SqAOoIxzzTcDjrzXMmHxcf8AmN6D/wCCeb/5Ko8jxd/0GtB/8E83/wAlUAdOq56Vm3+7zGB+7WWIfFwHGtaD/wCCeb/5KqCWx8VyNltb0P8ADR5f/kqgDTAKRMw4PQZrGukdgQD15qR9O8Vsmw65oePbR5f/AJJqu2h+Jyedc0X/AMFEv/yTQA1YRsGRyDUzBcAN096g/sDxN/0HdG/8FEv/AMk0x/DfiVmydf0j/wAFEn/yTQBowpiI45UmtGGPMQBFYceieJ41AXXdFx76RL/8k1OumeKlUKNc0TH/AGB5f/kmgC9cqAGbG6ubulmeQ4Py+mOlah0rxSR/yHNE/wDBPL/8k1CdB8TEHOuaL/4J5f8A5JoAwJxkhJCue1VNUf7JGmE+YjNbz+EfELsS2vaT9P7Ik/8Akii48I6/cKiya5o5CjA/4lEn/wAk0AcvpmqSRt5lz/qy2AO5PtXeR3wZQm05bHJrnpPh/rUk6SNr+mfJ0T+yZNv/AKUVpt4a8SnP/E+0j/wUSf8AyTQBF4otU1HSLmNMLOgzGeuG7f4VheJ90fwu1JJOHTR5EI9/LNb3/CLeJMYPiDSj9dJk/wDkmq2s+Cdf1bSLvTrjxBpaQXMTQuY9JkDBSMcZuCM80AV/jqcaJoJ/6io/9J564/SGXgN6dq9R+IXhWTxbpllawX6WMlrdC6EjwGYNiN02lQy/385z2rlrf4ZavBjZ4jsDj10p/wD4/QBNYN90DmuhtAeO1ZUHgvxBARt8Q6Wceukyf/JFX4vD/iaIALr2jn66RL/8k0AbUGcCrS8kZrCXSfFK9Nc0T/wTy/8AyTUg07xUP+Y5of8A4J5f/kqgDoFHGRThz7Vz4sfFg/5jehf+CeX/AOSqX7F4sx/yG9C/8E8v/wAlUAdBkBeajaTj2rCax8WEY/tvQ/8AwTy//JVNOneK8/8AIb0P/wAE8v8A8lUAbyyEHHapwciubGneKgRjW9D4/wCoPL/8lU8Wfiz/AKDehf8Agnm/+SqAOgAAJNLnniud+xeLP+g3oX/gnm/+SqUWfiz/AKDehf8Agnm/+SqAOg7/AEpxPYVzv2PxZ/0G9C/8E83/AMlUfY/Fn/Qb0L/wTy//ACVQB0WcUgbNc8bPxZ/0G9C/8E83/wAlUhsvFhx/xO9CH/cHm/8AkqgDoJF3jjg1B5YP3jWN9i8Wf9BvQv8AwTy//JVNbT/Fbddb0MfTR5f/AJKoA0rpAFJrkdUl3bx9cVqy6P4pkDBte0b5vTSJf/kms2Xwd4hlzu8QaXz6aTJ/8kUAeR+PJArTEHqSTWx+yk++58Xt72v/ALWrodY+D+paqXNx4mtF3dfL0th/Oc1vfCT4bf8ACvTqx/tb+0ft/lf8u3k+Xs3/AO22c7/bpQB6HRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j8XLnWJviVp2k6Tqd9atd29nBDHFfzW8XmzXMse5vLP8Au5OCcCjW/AfjDQZUj1zx/ommu43Kl54tu4SwOcEBkGeh/I1N8QP+S7eFf+uukf8Ape9enPDc+GvjX4o1zW9K1O+0nVtOt4bO4srGW8EYQYkhZI1ZhuI3ZIx70AeJeNtB8YeC7jS49a8Q3MqajHLJA9hrt3KMRmPOdwXr5q4xnoa506rrHP8AxPtd/wDBpcf/ABdet/tLrHv8ArbWLWUZs7wR2ZRVMIza4j2rkAjpgcelN+Hvwi8yOLU/GiyQxEgxaapw8g9ZD/CPbrQBxPg3QfGXi2426XqmvLaqcSXkuqXCxR+vO/k+wr2zSPh5p2n2Sx32r+ItWu2A3Tya1dxIG/2VSQHH1Jrr41itrSK1sYY7ayiAEcUQCqo57etOXqcH0IH4UAcz/wAILpBY4m10AHn/AInt90/7/UDwLo+1v3+vE84/4nt9/wDHq62NGlIEaZye3Aq/a2Ku25gWHGD2/wDr0AcOvgHSZCRHLrzY7/27fY/H99WjB8MdHKAy3WvbvQa7fYx/3+ruo4kjXCDp0FU7rWtNtNwub63jK9QZBkUAc0vw08Pgcya6T6/2/f8A/wAepf8AhWvh4D7+u/8Ag/v/AP49WwPFeiPceRHqVqZs4CmQDJqxJqOQxR4to6/ODx+dAHOyfDjw4inMuuL7nX7/AP8Aj1Vv+EA8OB1Uy61yP+hgv8H8fOrpBc2s3BnVmJxhWHX8KjmWMJhfMB7fIeaAMlPht4eI5bXc/wDYfv8A/wCPU7/hWvh3+9rv/g/v/wD49WzYXP7zDM2Qc57Y6VqGcIjNLwFBJIoA4+X4a+HuNr68Oe2v3/8A8ep//CtfDv8Ae13/AMH9/wD/AB6uoe6jZ4QjBix7GrMm7YfLxu7ZoA4w/DTw9twH13Pr/b9//wDHqZF8NNBBPmSa6R2P9v3/AD/5Grtk3+WN+N/t0qPzlVm3nCjnd2+lAHJf8K18O/3td/8AB/f/APx6kPw28Oj+LXf/AAoL/wD+PV1VxdrEu7KhfVmAz7VzWqeOvD9jK0V1rumxSDqu/eR+AzQBS/4V74dD7fM1sgdT/wAJBf8AH/kapv8AhXHhwgbX1zkZH/E/v/8A49WLd/E/wdHndq89yc/dhgY5/QVnX/xm0K2VTpttqF0xGfmAjCduc0AdW/w08PlSEk10Hsf7fv8A/wCPVDJ8MNFJO2619QP+o7fH/wBrVw6fHNg5B0YiEdT5vNath8b9KdlW+s54AeMgZoA15fhxpsSktJruP9nXr44/8jVVPgTSBkmbXQew/t2/x/6OrrtF8a6BrCRm01GHc5wEc7Tn8a2bizSQZAB77exP17UAecf8INo3BM+ugeh1y+z9T++4pjeBtIU4afXceo12+5/8jV3M9g2dybT6716H0FU3Vo32MFUjqCMcUAcPrnw5sdS04x6VrXiDSNQX7kg1m7ljc+jB5CR+BrwjxPZeLPDGotZa1qmv20vVH/tS4KSD1Vt+CK+rSvHJPPGPSqWu6Tp/iHTTpuvW32m1blW/5aRt/eQ9qAPkj+1tXyP+J/rv/g0uP/i6u6Hq+sJ4k0QNresuj6laRskmpTurK06BgVLYIIJGDW58RPAOoeD7oPlrvRpWxDeqO/8Adcdm/nXLaGP+Ki0HOM/2rZf+lEdAH1VRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4L8Z5Zrf4mWlzaztb3NtY2dxDKoUlHjuJnU4YEHDKOoIqGH4pfEOeeKGDxTeSSSMERFsbQsSegA8mn/G0/8AFxEUAsW0u3AAGcnzrivV/hP4BXwnZJqurokuu3CBo0Iz9lQjr/vH9KAL/hfwzrDXGn618QdWfWtetIpFtLZ4IFisvMKEsfLjUtJ+7UdSBz9a6+XMjGSRi0nXJpmd2WZiSR8xPUn1qVRuBGOCM5NACIoBUE+pzj/ParMEGVDupCkfKB1b2FLBECzN8rnGQvrWh8tvCbm4dU2qSzHoooAdBbKvBVR6L6D696xvF3jbRPCkOL+4DXBB2W0XLsR2x2rx/wCIPxdvb6eWy8NO1laKSr3IH7x+3y+grzSNZ9QnDyzNLKxwZpXyTk8Ek0Adl42+Lmtaxa3KRFtM08oZE8gkyMq5JBPfPtXiOoeP4w5Not5cE8kzvtBP5kn9K7G/WNL+SCSIJHG+xgDn5Qea8PvIfs13PATny3ZM+uDigD2Oyvft+nWt6pPmyoHPU7T9frxW/Zatu065S5nuF8xgUCOcbu+a858H6paroEMFzPGs0czRJGW+ZgTkYHXGWIrqR+7C5BKbiD29qALM4mjkRlnchjgOrEfjVvTPEut6Y6tp+r30O05G2Ziv/fJ4qCB2huPJlTzIJDtx1wPUUmo2gtLhbcSAxthvMPAY0Aeh+GPjDqtqwj8QW0epwf8APaMCOZP/AGU/j+dexeH9e07xLYpe6TciaMLl4c4lj9mXqP5V8oOiByI5N46cKcGrFhNeWt/DNpks8N9nETxEhiew46j2oA+uxKIZwyHgEbQBkZq3PqcyOFAiPHvz6fSsvQre8udMs31MKt8Y1Fxs6bwMH6ZPNbqWqKSxwTgAHGcUAVPt904O0HAA6LXkvxK8c6vYTtZaKBG4b97dOu/B9FB4GPU17SIuMFsKDnA9K5nWvDFpeSSPJbq5c5PHGT60AfLuq3eqXsr3GpXtzdsGwZJJGIJPt2qlAkTzbnbg53Hvn2NfR8fgfTo5G3RloJAVZdvDAiuE134UTRSN/Zsu+MkkDHb3oA8v8sttEJicqvUOOKW5CrDFwARuDgNkfXNdPqPgbVbZS8kWN3+xxgVz9/p95p37u4VQHAJAGeh4HtQA2xhu7qJXtVWd4CW8vHJXvwetQlNkCSup2uW8v0I/+t6VAGKyBlJ3dSRxj/Cnm4aSyS3ddyRs0iMeo3YyPfoKAEjdkxtchu5U4+nNdZonj3xJoRRYNSmkhQf6mc7x9BnmuQYvEuCgDdAGGa09YEK6sGjwYCI8hfXA3D2xzQB7l4P+MVlqMqWmvwrZSkACcHMZPv6V6m8cVyoI2urAMpHOfQ59K+MvLx9rwAXRgADwOSecfSvSPhb8SZ/D0iaZrjyT6UeI2+81ufb1X27UAe5XNo0BwBv759PrVZx067ieAOorchmgvbaOeCRJbeRdyupyrA1n3EQjLJyqnowXmgDMuYLa6sbmyvoEubGdSssL8hgfT0PvXz3418AT+D/GWgXNmWn0G51ez+zTdTGftCHy39x696+jQgCHsCuM+tcr8R22+GYkBUqdV0w464P26DnPY9enrQBepKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOX0/QLHUPi7eazqCiU6TpNmYIWGQ0jzXWGP+7sP4kV37OWYmRSX6789c85+nNcjoYJ+IWvcZH9l6f3x/wAtryuuJATIxg8HjketACpgMAB8qjPSp7SEysqr0GMDP51HGrSSqq/ePHsa3be3EMYUfeJyxoAS2tRGA+SXPGfSqmt6VFrFhLZzySJFKpBZGwemK0wcDjgnr9aY7JuZdyg43HnHHrigD5J8UeHLzwtqkum6jBlQS8U5X5ZU/vA/oRWHbRNsZvOWGTGQrZ6V9OfEaTwneaTHF4lvoIFk3rBPnLRtjBIx2/SvBvFvhm/0SeEvIt1ZXCh4NQiGYpUx69jwOKAOU16J7iKX7PcGC5ZA6ToA6se4IP0ryDXdPv7K8dtRQl5DnzRyrn2NexGIyQQt0beVJ+vIpRZrfpLZXECzhyF2SY+92/GgDz34faEbv7TqkwPl2wHlDH3myMn8Af19q7v5d8Zj+fB4VuhNacej22i28NlA+3YDHJBnlc9RnvyetV7y0axvZre4IDwkZIPQ+lAEUibJ0KPlixJPp/8AWro/7Dv9T8HG/tbd5ls5dpZVySO+PpWf4Yuo7XXtOa2iW9LzoklvPFkOhOGHvxX1emmWkelpa6bHFBZgfuxEMAc+1AHx9pOn32q3sdrptrNPcscbVUnHuT2r6H+GXw7h8NR/a9S2T6pIAxOMiHPYe/uK7fStPgskdbVEUsdzyBQC2fU1pJGN5wOg57UAMt0PAB4Xqc8Z44q0AoycjPTHpRtBXHAxThweOaAFUADGB9KRl3E/3aM5PTKmjhhgH60AQtAnJUYwRSGBWXay5J7jtUxzwAOn8qPQkcetAFGfTYnVsrkd9xzXGeK/BdtrPzrb7JAu0bB1x3r0HAPHRR2Bzmo5Iw5HzEf3cdqAPl3xj4Fu9JIdI2K7shAOD9a4qMKJ0Eg5VsE5xnnpX2BrWni6sZYpMMWUhWIzg18r+KtIk0rVJoZFIBYkk9R7ZoAoTrGmo3KXKsxYttIbBz/Dz+VU2DqcYwRyQa0Sf7QtmnAAvLdfmAON6DAB+orOG5ADtwO2R3oAtBHleFmDZcEMG5LEd/yx+VQSApnON567jj9K14rrZ4XBZgl3JKY09RH3P58VjylzgscnHU80AekfCfx9J4YvV06/ZpNGuGGGY5+zse49vUV9F7I7qEFGDnbuR+oIPTHtXxix321su1VUbmzntmvd/gF4vN5A/h+/nDXEC77Uk8tH3X8P5UAeiTRlGKsPmz0HQ1yPxJz/AMIzEDj/AJCumdP+v6CvRdQt/OjJHLDnHr7V558S1x4Zh6k/2ppnTp/x/QUAWqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjQc/8LF1w+ml2HUf9Nb2uxXJJ7YyMYrj9BP8AxcPXhnrpWn/+jbyu406282XJGEQjI7HigC/p1qI0DEHfJhuewxV48N6446/nTkHJP4Cgnk898detADT09T2NcR8QdQu9He31CGCaaxEUkF2YU3MFYfKfXAPNdseQB0PaszxHq0GhaBfancxvJBbRGQxxgFmA7frQB8i+L9R+33UJjnadUQqgPQZNbvgDxrFZ2/8AwjviiNbzwvdMA4cndbHs6kdADgms/wCIFnAdRXW9Og8vTNS/eIAMBWPJGO3WubaymjKC5Q2ySAkPICAR9O9AHpXjfwX/AMI4fPhlM2lMVazuQdwZTyMkdxn8RiuLvIJoIIrlWYPIxDNnkMP/ANYNekeC9Uh8RfDXU/DzSs91pyme280cSRDkp/PH1FY1pCNU8FatEYVa7sJVuIwAAzJxlT9KAK1toGmJ4eN5c3Nz9qkiEmXiOEbJ49+3NcZeJIbso7l5GwxwSck9jnvXongnyWEX9smWZo9zRQF8qxI5X2P6Guc1U28/iAvp0TQOzgRo4z5JHc+pFAGcsp0hjFuH2hQcvHglGPUBvTtgV7J8BvEd1fW99ol3IzpEolgYnkAnDL+ua8al/wCJfLcRXhjmuFYqFxk5z94n+ley/AvSpI7a41aRFTzvkUKuOM9aAPXfliUIoA4qeFMqCQDzn6VVcEr8pGRnr16VJZzAMyk8DoemKALI5+8AD3peAw6AD0pp6jAyc4/qaD6/wn+VAC8gEqec85pc5OTnHv0FAAbBC8deaUZx0GD2oAYTjpg45pSTkbsYNKvPIxk98UcAjjnPANABgAAKABQw5zkAdKM457ep7UnCnvzQAyQHaSflPr6fSvBvjrp9tBPb3GMSzHhf6174+MEnke9eG/H4FWsy3DbuO/FAHjqusO5/m3EFcg4z9faq5ik2qX6HnHb86sSL8g+Qc9DnioopGikJV+CpDZ7g9RigCNz5qjLEMDwOwHtUoEUlqsZQeYH3bgDnHp6VH5f7zrjIzk84oV08zDglevHWgCeaSFokCxyhgcAbgSAB1/Gr3hrVZtC8RadqkJ2tbShnXplejA/gTWQQchl4XqOcmpQhEe4qxLDJ46c9TQB9s208V5axTwMHhlUOjjoQRkGuB+LcPlaBG4wEfVNM/P7dBxR8C9Y/tLwJDbuxaawka3bPXb1X9Dj8Kv8AxdAPg5PX+1dMI/8AA+3oAo0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFLQBk6CcfELXztYn+y9Oxt6/668r02wh8i2A/i7mvPfBsSy/ErXty5xpennOOn769r0gkb0Cnljzz6UATHgVCnIDL35qST7rcZHTrUecbR6D6UADHGfQenrVTUGtzA0N6iPFKNjI6gq46EGrSjJZhg56c8H3qKW2jlI3jO3pyeCKAKc2mWYsYrNbO2+wxqFSAxAogHTaMcdq8L+Kfw+1O48Um9tWjTS5kUeZz+7I6gL/APqr6Al3NG6ByjdmOOPf6VnQWd09i9vqksU2/I49Owx60AeKfCHwreNrs64IsbdGDXAGN7HjHvRNpU/h3xxLazKZYdXiMO4/LjJIJr2ayEeistiyKkT5ZSD1PvWL8RdBXWrC2vI9yz2j5GO4JH8jQB4JbabcrqRimVi8MgG4ZU5B4/yak+JMDad4tMMQVVaJJU3jDEsMn3AzXrd/qVk9+8moW8n9obkjlEeF3EDhwa8/+OdtE/iLTdStw7x3toBycnchIP6YoA4bSYBe6rbwSo5dmw21sk889a+tdHsrexsbWC0iMcMcfyjvn/GvB/g/4c/tbWl1GcLsjYFkVSAD/wDXr6LSFdoGO3bIoAhx5ed46j7oGSeaYI8TsVPytyMdhVsQoAMrn8KR4VKnaAM9iODQAgbOC3Q45HenffGDwDnkio1VicAMMZOTyPwqTAAwR3FABwFXb3Io6ZPJ6U4EZPJPf/61ITk5zx7UAL2Ayc5oPA4/yKaSSOM88884pB3JJHOSCelADgVwST36kU48Ak8etJn5sqMk96PU56989aAE4Y55HpxXg/xznkutRt7WMBQoLYyMV7tKxWN3LDAUnrXzH8UL1r3XZHYZXdjI9B70AcheTqsgXy22qu0A56f/AF66BdN0HTvCC31/d/adXugfJtk6QjOOfU+9cw7MuWIOM8E9CfpV7w9o97rerRW9nbyTKuPOkKkpGnck9uOlAFvxAlumkadPFbLbG4jH7tSTwBgtz61jCylW2W4uCsUTHCFz8zY9F9Peux8dXem2OqRQW0H2i5tYliXfzFEB7d2riZ5Jby4kmlcvIwyWHOPagB6SRpBILUDzT1kk5JH+zUKElsbjnOCcnIpjAq46bs/UGpkDKyKEX5lwV3ZH4+9AHqfwE1VtP8Yvpzunk30JGFbI3ryD+WRXq/xe/wCRQTk86ppnH/b/AG9fNvhfUDpeuadeKUBgnDE45xnB/Svor4pXS3PgWzlTpNqWlvx0x9utzQBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAzwPx8Q/EjAZYaXpoHOP+W17XeqSbqMf7BY8/QV5/wCCzj4h+JAM5/srTsEf9db2u8t5ALmQlvlUBAT69aALch6DGcn1qHJzt6HrjOTT3fJ4Ixjqelcz468TW/hjSBdTbWuHbbFG+fm9enoKANLVtcsNFXfqVykKnoNpPP061gRfEXw99jnubm9ghjRtsa+YC8h/3a8X+Lfi638QG0lsJ3xJEPMiP8DDqAfSvL95OSzdMe9AH1XoXxO0XWNZj08Ry24kO2OZzwSegPpmrfinStWRvO05pHjXnCn5l/CvlCK6mhYPDIysOjZ6V7N8JfiFqFuLi11m5lvIXGYGlbLRsO2TzigD1CVrjVvCLt8zajbgnHRmI5x+Iqr4D8Q23iSzubCddl3DyU3Ebh64PQjvWtpF9Jqdkb+G3VLgZCgH5Xx615d4n0+fwt40tte0nMcdxISbc/fVv4lI7q3b60AdvrWgXdrq76lYSvO1wDFJbuqkYHOUB5De4rifH0UV/YxrdRSQTW8vmRgDayDA3YHcHAr0u2kuPEE1yL6waCzMMc1pMGIY5GefRge1ZfiCzuobG6n1ONLryrfZbuQrNu9ScZ96AM/4LxFbO7PluATlGc8kf4V6b07fN3r5s8B+Lrvw74ytoJ55DYXkgguYm5Ck8K4z0wa+kc4bGRQA4fdPBP1PWmMw34HUU4Nkcn26cZpjthgeceg70AKqhOmcGlbvzwP1odyMEf8A6qbwB+7wOPpzQAc5+YcHnFOxwQAAemAKZgqRjAxwT70DIPHGTyf8BQApyvr+falwevr/ABdcCg/N0wR37gGjOST1+vagBQOuDkepNGfTtR0H0/SopZI44zLMwCKMk/1oAw/GOpLZaTIisBLICAPbvXy94guvtWpTyM3zBtoCnPFeq/E3xE0ltcSRMSX/AHcWPSvEppHB3PkE8svTn1oA0NH019Tu4bW1liW5lkEcYkbCsT0+Y+/FdMviO+8J6TfaFDEtteSOVnyclW6HJ7muOgJiaOVmIkJyjE4K+hH+NJJ5krtJKzO7E7nc5J9yaAFa8n8zeJD5w5O45JPqc9abJK00u6VVJPXZwPyHFP8A3aW6sx3TBsAd9vue9MLOBxwjnbjHFAEanDEmMHtg9PyFLtByOBjtihdv3JMrzgkdse1WmsngvY02sylBJu+6MH+LntQAxAuwkY4XOK9z1S+bUPhNotw3X+0NMXn2v4B/SvDn8pUUQlnA+UuVIye/Br2DTm3/AAT0wk/d1ewUc5/5iEFAHZ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAR+CAT8Q/EuP8AoFadkf8Aba9rsTlPPcHc28exx6e+K43wUQPiF4kBI50rTu2f+W17XcKokkuUGSA/Xrg46/8A1/agCZgB1GRgnGfrxXlPx4ls7nSI7Iv/AKXAfMjOeRnHH1r1V2wQSwBwct2r5u+OGi3beOGu7VpJ/tKKQgydp6YFAHljkh23ZJ9cU05LAnHA5J/nXT3vhHVbbT1uLm2mSVucba5pw0TbZAquucg54+tADe3t6dMV3nw18P3viG+8qAFIUYb5Oyisv4eeDb/xlqjxWxaOztsPcTleB/sj39q+lPBvh2z8LWDCJdmwFn47KM/060AbNlHY6Dp0Vq11BCkScmWQLz6nJ4rK8R6TYeKtP+0abPb3MsZwHhcOD7ZHevlfxNqN1qWv6hdX0rGaeRnYOT93PA+gHavQ/wBnTUhb+NLmw81lS8tW2oD8u9SDnHrjNAHu/hhLmHSltrwENGMAk8ke1atzbRXVuYbhMpIuGz0o43kqzAYHGMYqhY6LbWuqahqMck7T3m3duclVUDgIOw70AeReMPhlenXre6sSJYDKpYjgrg969mWYIo3NhehbqM+uat4IHAyceufwrMaB2WWMnc27cpPSgDSR1YLhgVx1zSMQFJYkH+HIqtHA8Z5O1enUf06VOIgHJIUdeCc/jQA4ZYDGR0zn60EHngYHt0pwODgfdpFzwoHy+o6UAJkAYJJwfbrQW55AAHIwaHwx5OQOpNMzgEjJJ6D0FADjyByevUc//qp24EnkbunGahkl8tdxJGOSBzj2pkFzHMMqQM88npQBac8jvnjFch42163srWaA3AjSIbppMdB/d+tT+NPFdjoWnNJNcKrYIAQ5Yn0QdSf0FfN/i/xTceILwmRGTTRyLdWOWPqx9aAKnizxEdX1F2VnW1U/uww+8OxNYu0ocuCD+oqxNJGmHsYTG7cGQndj/dzVu0tr2IF44HYSEfO0eee3P60AVreEzyRo5VFAI3nk4pLgo+PJz5CEjcwxmrZtVtji6n8rg5H3nb8O341VlfcFRVjCjOzH6/WgCONJPM3qQG25BAzn/PpTS5MDIy5GQenT/wCtT1U8FRyBn5eo96mby5pyDtijwMfNnbQBFLcSPBFCqIAv91QCx9z1NX03y6RDC9wFKM24YLMwPRQAOQPeqEiI7MYgFjT7oJyzc/zqdBG2xVeWOTAyQc7j6UARbUTgySHJIIKFfpxXsunoV+BmkknG/V7Bvr/xMYP8K8dDSHLMzE+jk5r33VrBtO+DGi20i7XS80ksMY5N/bsf50AatFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEfgnP8AwsPxJ1x/Zem5x/12va7y1GL674+9tPt0rhfA2D8Q/Eucf8grTv8A0be13kYIv2PQPEP0J/xoAkkQKQRgHBGa868W+ItK0nx5omm3NtvmuVHnEdI9xwpPryK9GnA+Ukc5xWVfaRp11qUN7c2VvPdQgrFMyZdPp68/lQB5p4g+LnhpdSlsHtbiTYxjaQqAvB61p2/gfwp4uRdSa2dw3Tb8gb2zjnrWrdfDjwreag13caOhuCdzfMcZz/d6V19jaxWVulvaRrFCowqoAAKAK2h6Rp+iafHZaVbR29qnOxRjn1Pqfep722S5tZIH4SVCjYPY+9WCQPmwPUg/z+tGPmBB5I64yfwoA841/wCEmgatb7ZXnhugNqTxYzj3HQ1D8PvhNaeE9dXVP7TmvJ40ZYwyBAuRjJ554r0ogeYcA/jwD/8AXpThxgHcOvPWgAA68nnnnsaeOvPPGcj+VISo3BjgDrTVG1wSNoJx9TQAu4BcqBg88/rTIgQQCTkfMcVLnjrk9P8A9dKvyhgCATzyMUAJuwcD65oGAB045GewoVsZJXHPUHrxTWIGQcKOv170ASHGMr39e9KOSOefemYGSCfwoHyjPZfXtQA9lySQBn1qpO6RDzZ5FjiHUuwGPxp7ysWVEyGY43EV8wfEfxBea34mvop5Zms7edooot2B8pxkjpzigD36+8WaDbTGO41SxDdNokDH9K888WfEqazmmtdMtlBI+SRssMdM8da8ehkjSQZ2gE7T610Gh69baNFibThLdZJEjvvH4p70AYep3Fzf3qXF7PNc3Ezbcvnjnjae30qOaxlgn/eEZ6jd6Hua7rWvGVh4h8OfYotJtbPVROrpJEuFZQDnHoa4pJgqyGRw5GEEbD+eaANTQrSC4kRNSkjkt5iViWGHneMHAI7n0roviD4jeHS7DR7Kw+wRwA+YZRiRj6cdBUHw0svEL6njQ0iY7m3m5UNGnGAR789RWl8TtFu470XeuXy3FztCgIgUD6D+poA8oZWcF1VsHh39T9afGN+AMbCepbFWZI5zIQQyQ5HLsBkfSpbS1a8kMdvGZZR91FG44+goAZdRLF80c0ciH+6T8vtjrUEQJbBCgMDzXQxeG7oSL/aFxbWKMPuzyBTx0PHSsq4gghdUjnMxAx9zGffFAFdJBG0LCMZXqoz85z3q/qsNolzDLp6yqkke9kc5Cv3Ax6e9UFEiyMEznuQM1ctgs6GFiiPFl4y3AJ7j+tAFzwtpp1fxJpVgScXFwqsSOi5yevsDX0X8WlCeCkVRgDVNLAA/6/7evLPgXpRvPGZvWH7qwgZh3G9vlH6ZNep/Fw/8UYn/AGFdL/8AS+3oAz6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI/BDBfiH4kJwB/ZenDJ/67Xtd87MtzbNzhgyn06Z/pXAeCePiJ4kPXGladwTx/rb2uyvm2sm8ZZCHAXqO/AoA0rnIiJHVSD1xVMRFXkJdnLnfnPbGOP8A61Xid8WR/EvFV0B2KSQBjBGKABQG2qxyCPxz3p4YrnI79DTSQEIPIHXJ6cU/73GCQefrQAjN8y4xk8eo/D3oY5QEEe3Gc/8A16aec8+hGRnijBJJ5DH1/Q/rQAxioIj+XPT/AD71ICMccZP3un40mD3G7IOeOv1pAQB6NnGOuKAJNu0YwcjpkcUgICfpn+tIoyRnPI4B/lSsDuUrjJ4NACIe7fKfQU4Dpj73uaav3dx259TgHGfWkOCFI/I9qAJB3BPbOB2pjLwSwGT60pOcBcAY9Mc0KgVgwAUnAyPQUARBlEoGBkdumM+lKoLHbuLHHBPSiVFYHLFARjcOp/zipIQEhGDn0OOvNAEc0TOMh1DA8HHSvnT40eGJ9E15tWhGdP1Fsk/3JsfMD6Z6j8a+kHbO7gHGc1zXxA0mHWfBmrWk6qw8kyIf7rryCKAPlRYxtYuMDHPtT7pjJOxjfCt6dcEUNKYgCvEhGCAMDHuO9WtMtk1GUwGVI7tjmLecK3H3c9vagCmq+RPEqnDlhgrxjpzXvWm+BNKksI77XbFDkB5JC5TtkscGvGrjR7q2tNIYwP8Ab5Z32wYH3UII5z3/AJV7p8SdXa9+GkktpIoe4eKKfYwIjBOSpP4Y4oA4zxR8RRYSnTvBccNtYRYTz1ix5n09vfvXCzavcX1y9xqcqXUjcnzZirZ9AfSqGo20tjd+RMihpFEispyGQ8hgfSqqyFz+6zvYgjofXNAHr3gS98KLtXU7TT4pWQEm5PmcfUn+lP8AHOt6La2/2bwrNp8E0gO6a22rx6A44ryLYyxSb+WJ6lsHH1pjvG0ecL1JyvcUAPu0uJpvOmPmv/E7vvz/AD/pUJwABhslhggc470qbkZzBMVyvLj5c00AmTJ29euOD+FAErSKZyGCmJmycjqPp2NSQookQxKQAeeenP8AhUVriNmLjdGRjp/nFXYQmSw3FgOTu+8Me1AHvPwGslh8MXd1tw9xckE46hQB/Mmtb4vEf8Iggz/zFNM7/wDT/b1N8JoxH4GsOMM25iMY5Jql8U28zwlJJu4Or6Yqj2F/b/8A16AIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK3hF0Tx94lMhAT+y9NyScf8tr2ul+0+ZOxGfLJJwR0HocdPrXGaGxHxB18BmUNpWn52nH/LW8711Y3ZO07sc8tk/mP/AK1AHRWUw+zIp3blwuTzn8e496k4RtpAViOABgfh71nWsha2wrANnG1xz+fWr4OcMo68GgBJw/2aQQsscxQhHIyoOOCfaqHh6DVINOEet3MM97vZi8SkKFPQVqD5Scj5c8c5zSKOevX8hQAgwq4GSR6mhhkgKMZGBxx9aj8wi5XlgoByOw/+vTtwJYbPvDODzn/69AClnGeQCOOlCkHsMEYxnFRuXLJ5SoCDyGyTj2/+vT1BzywOR1OMf/X60AVLu3lmvbWZbyeGGDPmQxjCyE9Mmpp445Y2STcI5FKFQcZBHNPbdvOQA+OMdx+H/wBenA5B2spx3Hr+FAGT4Z8Paf4csXtdNjl8p3MjedIZDuPua2I2KNtX7vYE9vX3poA6AEAf3Rjaf85pYyGznBHfPf0oAUZD8kEHjOen1pXmCKpbGCdo54puMOMHnngdKf5CzFWlAIHIFACq4Kb8YUdu9NjcOhAyOehHNWNi4+6PypHRXGGAIoAhP3eRnIxg1xPxY8QronhSaKIj7XfYgiA4wP4j+Arsr63kkhbyZGDdQM9favn342XUsvi+K0lJCQWqlVJ43OSSfrxQBwheHcqvB5qJwck4NaHhU6V/wlOmS6wsUenrKDIgORgdM+2cZrGdJATGo64yM9f8aC6FFUZA/iyASaAPXviz4k0R7eGw0WG3nmwHluYAAIo/7qt6nvjsKoeHbvzLTSvDVzAgtNVyjWcbYKIeRLnrv4zz6VwelRW8avqVx89tbniPOPNk7Lz+tS6LqtwniODWdwW6gnWcgj5SOm0fhxigDuvif4EXw7oNte21zJc2Ns4iMMgw0YY9VP17e9eeahbGCyt57Uf6G4yzKed/cNxxXe+NfH//AAlWgPaw26WyCVf3LnJdhkgbh+dcHomqyaU7LLEZbOY7Zon5H1A9aAKEhDr1+Vf9WW9KYrMJsj74GOD0rT1GO3sNQkihtUKg7laQ7gAfb0qn55kTEzRyRknGwYKn1oArEkt8xyw64H+f5U5gQwxtQE5IAz/n8aURs2FGWUHOSP6VKqtMVCxKNilmKjqPXnv0oAkhG6Zt5GOpfOAO4OP6Vat0+0vb20MZPmyhASSNxJ7Cq0JDZQsHMZyoc5XHpXe/CTQzqniE6nOCbXTyDucE7nxwo+nWgD2zRohpWkQ2UYUCKPGT24/xrB+J6keCIhtwP7U0wnH/AF/29dESwj+ZmLOwyBzj86w/iwuPBkYyT/xNdM6nP/L/AG9AFOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCl4WtjP8QfERVsOul6cB75mvc/yro5YnRysuN4IyGOTjjsT/I1heDJUj+IviJXbG7StO7/APTa9ru7q2S5U7+WPKEDOOKAMqwl2vtIPPPAx+YzxWrCylCrkkEA8DpxWK8T28nzKR82RtbGfpWpYSByI3xtYEANkfgB0NAFxdzLnoT6GkIOSAMZ6en/ANanmLy13Dkj164HQUhIVhkDaTxntQA0fKcsec9Qe/p9OlCfdYjHqSB+lDKSdw2hcDaR79aw9Y8U6Zomq2NhqUzxXV82y3CRlw3QckDA5oA2yTk7h3wPbj9KYeA2/aFI4DE4z/SnfMSQTs3DGwg/p2pFyqgMD8oPQ5/OgADEDG4k+5pdmdvyvgcdcED29qAFWMKo2gjhcZUUHkguue3+fUUAIcjB47ggfLx3/XvSjbgKcZxuweOPak3tkCMrv6MDkY98U75lIXZwOeDxkd6AJYkG4ggkNz7Gp6rwuqBFzwxIUAdParFABRRSHpQAtfOXx5i8vx8rPwk1pHjn0JHpX0bXgv7REAXXNJu1bh4Xhb6qQR/M0AeVK5gfKEdD8xGeoxUlraO7IjyJEZDjPcjrnHUVSdz5nPzc/LwD9KfC6whivMrqQW/u57/U0AXNSvEuNttgpaWxIiQdST1Y/Wq5ZQnkh8Ko38LklvzquGJfh5DjGB3NWLdPmZ3UlU4ww69u3vQArs3lQKp2oo3Z4+9nr9elE2XlkOBtb5uozyOaY25Rh33qRyQT26ZBokkwwkwynsCD+lAGlue9solJZruIEAA8un+NUJs+WqkL8vJY/Kc980QtslVvnWRT8pztOasOBO7MwAQEk5ACketAAuPsfywLn+JlyTj88Y96S23u0i2zndsyVHDMB1x61NFPLb3ML2ZIwTxgNn1Ug8EY9qWP5z5y8FM7o1GAPdfT6UASWlveatd2lpbI8t3KQiJjgk9/8TX0r4T8NQeF/D0Vlb43J80j93cjk/4e1YPwj8FjQbL+09RjC6pdLlU/55Rnt9TwTXZ6lcbm8tSQF6n3oApTSMeAh2DgAjHuTn1rnvihch/BdupK7zqmmAgHni+g/wAK2ioY5deDznr0/QfWsH4kQqvguKR8F21PSwuOcD7fAaAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZOgtt+IevnIA/svT+T/ANdryu2tb9V+VyGTjgHp781xOgru+IevYYBv7L0/AIzn97eV1rB1UK6ljx94Y79//wBdAG46x3UGQd6hsDIyR/n1qh5b2ciENmMgkOTyD/nPaq0EhgcsAyMPcYrYhuYbpSpB3Y5BXn68UAXIJRPCHA68EHsfSonjO/afT5TyePT0zVRT/Z0m5zI0J46ZH1PpWkds0YIJKsMgg4oA89ufDHiVfiMNZtdbWLRiR5tozMcqB93b0/Gu2ktraSaJ5LeN3T5kLICVz3GeR+FSEFCFIJOOCehFL5QBHJAxjGelADW4zkEg9QRkD3oI7mNuOQV5zSFWQk4D9xyKQ/Kctlc8nOcfmKABCc4O7AYg98+/rQG3KFcggjrjv9KFyWILNyOOccevFDNh1XcpycAH9TmgBE2E5wmw9GXjA/8A104A8KwGCcnI79qC2Vyucg9N3PX9aC6qhlLFuMZyTk+lAEkSq74PG35gAf1/SrNV7YfK0z8F+eey9uvSkiuluJSkIZ4wDmQdAfQUAWcUdqqBydwYuSM5Uj/DtUck3lAksxTB/i56/wCeKALzZxx1rzn43aCdU8ITXEKPJcWUguVCDkr0cfkc/hXoUX+qQ4ySAaS4hS5gZHCsp9RkUAfF/lyFcru24z0HT9KeYyUd93zrjIbIIz3Fdr8SPA9x4W1GSa3XdpE0hMTAEeST/A39DXJ+S0xWOMDYqknHAAxkmgCsiKEbqr/wEYwTWhYwLNo+p+ZJsuYWXbk4LjuBnuKpLCptg7zN5oIWNAmQw7n27U/DeVBEuQeXYA9STgZ49BQBXWMtliMEnALnHapY/NkYLtLYOAp6LV/TDZwfaxdp5uyFmiKHAEnAx79c/hVWGV44T5rkq4KE/wBPpQA1vKEjAOZG3feC8fhSE52Ajtkgjv7U9oI1eMtMxR13DZk/T9eKfbQszA718vdyS2Nv50ATJ80aW8uPLXcwIHzB++T6dK9W+EfgY3TR61q9uptR81tHIOZD/eYeg7etM+Gvw9/tIxanrVuE08fNFC3Bm9CR2H1617S7xWsCgBURQFRRgD2AoAZe3CwR5yA2OD6ViPISB94/TnH61YlkeWTghmPUAA4q5b2uz5mX5uDtPQUAQWNqykPOTycgHqcdK5r4ssi+EIUBGTq2m8dc/wCnW9dTcXqQMQdzyH+EDOD6HtXA/E6V5fD1u77ctqmm/wAXI/06A4oAu0UtJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm+HYHm+IPiBkTeE0vTs4zu5lveldasbAH5HG09ckbcA9eOteNeIvG174L+KkktqqS21zpdqJ4X6OFmucc9iNxr2PQdY0nxhpgvtHkjabGZIi2GRsdGH170AK+SoMjuwP3cDge2Keco+UJBzkY4P8A+rmldJEby3Qgt1VjkH/6/FDbsZJP+7j7v+NAF611AMDHOPlPy5znP4dqmiLWRJBkltT6/MV+nqKy23OGI2b/AEwealguJLZyGB8snpnj+X0oA3xh1BGCpFQvHt6DKkYNUoMp+8tJB8xy8Ltnt0B7dqvw3CyNtIKuOqmgCFSDkHdleSRwD+NN35I3E7SMHjj86ddIGYMsgU9SM8moyZlC4LSDucgZoAYQynIPBOcEHA+h/p2qQM2/kNjpkjcCPXr/AEpGe4GB5RGey9qQpI53PhWYDgEcH+v60ALJKkeS5O/kgdCcUy1glmmEs+1YsfKitnnPpinW9nCsiPOS0idN3r61LqE5SBhC4EnT05+poAhv3NzIbVD+7JAkbnn/AGf8avQrHEoijwAo4XNZmnRSpGySRGNT82QenvVnYwGASWHIKgBufrQBLLAwDmMs245ILfyNRRWvmr+/VlXOdhbvnPJH8qfaXLNIYJwBKuTnj5h/nFLcyuZPIhDbiMs4x8g/xoAmlmjizvcDHX2rMjWazlLREvCxJaP1zzladbxQCTcvmSPnBdmJ/nUs0ZeMBcsO+eMUAS3VvbanZPFMiSxOMFXUEfQivGfF3wne2D3Ph9+fvG1c5H0Rz0+hr1u0O1T5JfcDyCMD8M/41opIGyrYyOoNAHx9fWN5Z3LLfWk0Eg6q4IBP8qYSA7lQcqTtbIJwex7V9XaxotlqHMsKOTwQwz+hrmbv4faJK5D6bbYJzuVtvP50AfO9uoRfkVyXGNgIGB6/Wl8zZCItq7dxO3Bx6Z96+gIfht4eyG/soOf7rStn65zW5pfhrTNNINjo1rBjjcqq/wCpoA8C0LwnruuSxxWFhI1tkETTLtjTPXtz9BXsPg/4XWWmTRXmtSjULuMho0CbYk/4D/EfrXfRQ+WA8zDC8gdAtLLOzEC2Xef72flH19aAJLiZIIi79B0UdT7Cs/ypbly83mKp52AjgdsVLIsaN5lw+6Xt7fQVWuNRzwi4HcsdpoAuN5NouMY/D5jWdcXclwpCLIijqOh/PpVdz5jbupxjcen8+aaysAfO3MfUf5+tACD77Ll84xk5P6/lXL/EdCvhiHAcL/ammj5h1P26CumJB+VUQL2JbB6VyvxFjRfDkJWIAjU9MyQOR/p8HWgDRooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSigDwj4zf8lEBOP8AkFW/X/rrcVzmg61qXh/UFvdIu2tblVwXXHzD0I6EfWvZ/F3w+0/xPrK6nc6hqVrOLdLcrbNFtKqzsCd8bHOXbv6VjH4O6Ueuua6f+BW//wAZoA6fwR8YrDV/sun+LIFtrx2CLcoP3LH1bnK/y57V6lLY7gJbYrMjYIO4fMPXPevBf+FO6T31zXT9Wt//AIzXR+HvCd94diaLSPGPiSCE/wDLNjayIPorwED8KAPSZEUArJ8r9gwGCfb1prfKjYQ7c5Izx06Z/wD1VxstnrswIl8Z62w6c21h/wDI1RjTNaDZHjLXAenFvYfX/n2oA7BSB86hVbgn5TkH61chu3BBnikcDq7KAVH9a4A6RrJOT4z1/J/6ZWX/AMj0g0bVwuB4x10Dr/qbH/5HoA9NS7QjaGB4wQy4P6UsbQK7mLILctsBJ/IV5k2kawxyfGev5xjiKyH/ALb0HSdZPXxpr/8A36sv/kegD06QI0YZPMQDHytkZ/SrCopRcAlcccYxXlQ0nWV6eNNfH0isv/kep0tPECfd8b6/+MFif/bagD1HP7w/eOBnp0qECOJdoGVYk5YdTXm32fxDnP8Awm2u/wDgNYf/ACNSfZfEH/Q6676f8e1h/wDI1AHpZn2FFwVPbjIPtmmtIj4VpHQ9SCcECvM5LHXZHVn8a68SpyP3Fjj8vs1L9i13Kn/hNNcBXoRbWAx/5LUAej3CbLiCYbmZDhuxYcjNEMTJC0gJeZ33O+Md/TtgcV52LbxAOnjbXeP+naw/+RqQ2uvk5PjXXT9bew/+RqAPR4yGX5W3Z5BY5/px9KijvQX5TCtwQx46156trr6ghfGuuAHsLaw/+RqZ9g1zdn/hMtaz/wBeun//ACNQB6akkcowGRmznHBxxS4DOdiBW4JPAOfSvLm03WyQf+Ez10EDAxb2A/8AbapEsteQYHjXXfxt7A/+21AHpsksSLiVsHsOD/Kmlo8hy4XIwMjnH1rzNrLXWBz401wgjH/HtYf/ACNQljrqfc8Z62O3FtYf/I1AHo8skbDYGctx91T/APqpI/PD/uUO1hyztkfz6V50LLXh08a66Ppb2H/yNSSWGuyDDeNdeI/64WI/9tqAPRGaNSftV0JSefKyMfTbUc16yfIieUvQeuPy/lXnH9jat/0OGudc/wDHvY9f/AanLpWsoPk8Za6v0gsR/wC21AHeMTIxIYlu+ZScfh2pSzBiGwTg5X5jxXCf2ZrWP+Rz10/WCxOf/Jam/wBk6xyP+Ey10Z64gsf/AJGoA7p5H27mHlr0Jzx19afBbzTYMakgnOSfl61wkema1G5dPGeuhic5MFif/baotU0bWNTsntLvxt4jMDjDCJbOIsPQlLcH9aAOt13xB4Z8OrKda1W286IZa2RvMkz2+QZP514940+KsniXU9M0bSLOO20aTVbDc8qfvpNt1Ew6HCjIHqalb4OaSzFm1zXix6kvb5P/AJBqaw+Eek2eoWd2NW1mVrW4iuVjkaDazRuHUHEQOMqOhFAHo9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postanterior (A) and lateral (B) chest radiographs show areas of consolidation and several air-fluid levels within the right lower lobe. Less extensive consolidation is evident in the right middle lobe. Computed tomography (CT) image (C) confirms the radiographic findings and also demonstrates a few centrilobular nodules in the right middle lobe (arrow). The patient was a 50-year-old man with pneumonia due to anaerobic organisms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: M&uuml;ller NL, Franquet T, Lee KS, Silva CIS. Bacterial pneumonia. In: Imaging of pulmonary infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18708=[""].join("\n");
var outline_f18_17_18708=null;
var title_f18_17_18709="Levodopa-benserazide: Patient drug information";
var content_f18_17_18709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levodopa-benserazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/30/486?source=see_link\">",
"     see \"Levodopa-benserazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prolopa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benserazide, levodopa, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, glaucoma, heart disease, kidney disease, liver disease, lung disease, or mental illness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have melanoma or skin spots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid a high protein diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11816 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18709=[""].join("\n");
var outline_f18_17_18709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012142\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012141\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012146\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012147\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012149\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012144\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012145\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012150\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012151\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/486?source=related_link\">",
"      Levodopa-benserazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_17_18710="Moraxella catarrhalis Gram stain";
var content_f18_17_18710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Moraxella catarrhalis on Gram stain of a sputum specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sputum sample shows several intact neutrophils and gram-negative diplococci with flattened internal edges resembling",
"    <em>",
"     Moraxella",
"    </em>",
"    species or",
"    <em>",
"     Neisseria",
"    </em>",
"    species. By culture, the organism was identified as",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marler LM, Siders JA, Allen SD. Direct Smear Atlas: A Monograph of Gram-Stained Preparations of Clinical Specimens. Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18710=[""].join("\n");
var outline_f18_17_18710=null;
var title_f18_17_18711="Conivaptan: Drug information";
var content_f18_17_18711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conivaptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/18/26915?source=see_link\">",
"    see \"Conivaptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2473286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vaprisol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2473289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasopressin Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2473342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Euvolemic or hypervolemic hyponatremia:",
"     </b>",
"     I.V.: 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of  40 mg over 24 hours (1.7 mg/hour) if serum sodium not rising sufficiently; total duration of therapy not to exceed 4 days.",
"     <b>",
"      Note:",
"     </b>",
"     If patient requires 40 mg/24 hours, may administer two consecutive 20 mg/100 mL premixed solutions over 24 hours (ie, 20 mg over 12 hours followed by 20 mg over 12 hours).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2473343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10499724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use not recommended; clinical response reduced; contraindicated in anuria (no benefit expected).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10499725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate impairment: 10 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 10 mg over 24 hours (0.42 mg/hour) for 2-4 days; may increase to a maximum dose of 20 mg over 24 hours (0.83 mg/hour) if serum sodium not rising sufficiently; total duration of therapy not to exceed 4 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment: Use not recommended (not studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2473349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaprisol&reg;: 20 mg (100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2839764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2473344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intravenous use only; infuse into large veins and change infusion site every 24 hours to minimize vascular irritation. Do not administer with any other product in the same intravenous line or container.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20 mg in 100 mL (concentration: 0.2 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2473333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible",
"     </b>",
"     with NS.",
"     <b>",
"      Incompatible",
"     </b>",
"     with LR.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2473290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2473300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Orthostatic hypotension (6% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (10% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions including pain, erythema, phlebitis, swelling  (63% to 73%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (6% to 8%), hypotension (5% to 8%), peripheral edema (3% to 8%), phlebitis (5%), atrial fibrillation (2% to 5%), ECG abnormality (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (8% to 10%), insomnia (4% to 5%), confusion (&le;5%), pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (1% to 5%), erythema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyponatremia (6% to 8%), hypomagnesemia (2% to 5%), hyper-/hypoglycemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (6% to 8%), vomiting (5% to 7%), diarrhea (&le;7%), nausea (3% to 5%), dry mouth (4%), dehydration (2%), oral candidiasis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Polyuria (5% to 6%), hematuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonia (2% to 5%), pharyngolaryngeal pain (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Thirst (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Atrial arrhythmias, sepsis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2473295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to conivaptan, corn or corn products, or any component of the formulation; use in hypovolemic hyponatremia; concurrent use with strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, and clarithromycin); anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2473296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Discontinue if hypotension occur; may correct and reinitiate if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Discontinue if hypovolemia occurs; may correct and reinitiate if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection-site reactions: May cause injection-site reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Safety and efficacy have not been established in patients with hypervolemic hyponatremia associated with heart failure. Consider alternative treatment options due to limited data in this population. Use in 79 hypervolemic, hyponatremic heart failure patients led to increased adverse events, atrial arrhythmias, and sepsis when compared to 10 similar heart failure patients treated with placebo. In other heart failure studies, conivaptan did not show significant improvements in outcomes over placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: No dosage adjustment necessary in mild hepatic impairment; no clinically relevant increase in systemic exposure was observed. Use caution in patients with moderate hepatic impairment; systemic exposure is approximately doubled; dosage adjustment required. Systemic exposure has not been studied in the setting of severe hepatic impairment; avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Coadministration of conivaptan and digoxin may increase the serum concentration of digoxin; monitor digoxin concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use contraindicated in patients taking strong CYP3A4 inhibitors; use caution in patients taking moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions). Consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Monitor closely for rate of serum sodium increase and neurological status; rapid serum sodium correction (&gt;12 mEq/L/24 hours) can lead to seizures, permanent neurological damage, coma, or death. Discontinue use if rate of serum sodium increase is undesirable; may reinitiate infusion (at reduced dose) if hyponatremia persists in the absence of neurological symptoms typically associated with rapid sodium rise. Of note, raising serum sodium concentrations with conivaptan has not demonstrated symptomatic benefit.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2473326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2473325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Conivaptan may increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Conivaptan may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4423878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of conivaptan.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2473291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2473292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies indicate that conivaptan accumulates in the placenta (2.2-fold relative to maternal plasma); systemic exposure to fetus is likely. No teratogenic effects have been observed in animal studies; however, these studies have shown decreased neonatal viability and delayed growth and development at doses lower than those required for therapeutic efficacy. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2473294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vaprisol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/100 mL 5% (100 mL): $687.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2473347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate of serum sodium increase, blood pressure, volume status, urine output",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2473334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V",
"     <sub>",
"      1A",
"     </sub>",
"     and V",
"     <sub>",
"      2",
"     </sub>",
"     . The antidiuretic action of AVP is mediated through activation of the V",
"     <sub>",
"      2",
"     </sub>",
"     receptor, which functions to regulate water and electrolyte balance at the level of the collecting ducts in the kidney. Serum levels of AVP are commonly elevated in euvolemic or hypervolemic hyponatremia, which results in the dilution of serum sodium and the relative hyponatremic state. Antagonism of the V",
"     <sub>",
"      2",
"     </sub>",
"     receptor by conivaptan promotes the excretion of free water (without loss of serum electrolytes) resulting in net fluid loss, increased urine output, decreased urine osmolality, and subsequent restoration of normal serum sodium concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2473336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4 to four minimally-active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (83%); urine (12%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8843 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18711=[""].join("\n");
var outline_f18_17_18711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473286\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473289\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473342\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473343\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10499724\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10499725\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473349\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2839764\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473344\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471301\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473333\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473290\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473300\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473295\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473296\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473326\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473325\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4423878\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473291\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473292\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473294\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322933\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473347\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473334\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473336\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/18/26915?source=related_link\">",
"      Conivaptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_17_18712="Transection of round ligaments during peripartum hysterectomy";
var content_f18_17_18712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Completion of cesarean section and transection of round ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mann, WJ Jr, Stovall, TG. Gynecologic Surgery, Churchill Livingstone, New York, 1996. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 1996 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18712=[""].join("\n");
var outline_f18_17_18712=null;
var title_f18_17_18713="Advanced case 6 with answer";
var content_f18_17_18713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 319px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE/AhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2DSdO099Hsneys2dra2LM1iSSSeST3Pqe9Jf6dp62UJWyslJa0BIsTnmUA8+46+vSjSby2XSLJTC5ItrYEjTZW788gYP179qS/vLZ7KECF87rQ86bL/z1Gecf/tdBT93lPrf3vtXrL4v1XkWzpenedF/oFj/rG/5cT/z1Hbv9PwqlJp1h/aCqLKz2/ZJmx9iPXzVAP1x37dKuNfW3nRfuZf8AWN/zDJv+evpjn6fhVOW8t/7QV/JkwLSYf8g6XOfNX2/Xt0pvlJp+2vvLr38/Iuy6Xp3nXGLCxxhsf6CR3Tt2/wA+tVbHTtPZ7zdZWR23U6jNieAFGB/9btVmW+tvPuP3MnG7/mGTDunbHH+fWqtjeWyveZhfm6uCMabL02j24+nah8t0KPtuR6y/H/IkudN09bCZhZWQYRykH7Ecj5OP89utJBpunnTY2NjZliiEn7Ec/wCq9fr+vNFxe2zWMoEMmTHMOdNl/ueuP/1daSC9tl02MGGTIRBxp0v/ADx9cf560e7cr99y7y/H/Ide6dp63diFsrIBrxFIFgeR5THGPTPbv1qe30vTvNtc2FlygzmxJ7N1Hf6/4VXvby2a7scQvgXkZOdMl6eU3bHP079ant762821zDJzGOumTHPDe3P1/wAKFy6ky9tyLWW3n5+RWt9O086hIpsrIqLa1IBsSRku+T9TgZPfpVuPS9N8yT/QLH/WJ/y4H/nq35fTv07VTt7y2/tCRjC+DbWg/wCQbKT9989v1/i6Crcd9beZL+5k/wBYn/MMmP8Ay1b24+nfp2oXKFT2195dO/ZeRT0zTrB9N3PZWbNifk2RzxMQOfp37dKNZ06wj0e7dLKzVxBKQy2RBB38c/17dKTTLy3TTcGF84nPGnSn/lse+P17dKNZvLd9Hu1WGQE28vJ06Vf4/Ujj69ulL3eU1/e+23lbm8+/oXLrS9ODyYsbIfvG6WJHZf8AOP8AGq15p2nrqdqq2VkFZrjIFiQDhBjj2/SrF1fW2+TEMo/eN002Udl9v0/xqteXlsdTtWEL4Vrj/mGyj+AdBj/9VN8tjOl7bS7ls+/Z+RYfTNO3N/oNl/qv+fL/AGP88/jUdnp2ntql6rWVkVW4iABsCQAYQTx6Z5x36097623N+5l/1X/QNl/ufT9fxqOzvLYapekwvhriLA/syU/8sR1GP079aHy6CXtuWWstvPuvIntNL04iLNjZH94nWxLfwfr9O/Wqmi6dYSaNaPJZWbO0MJJaxJJO855/r36Vas762IizDKf3iddNlb+D6c/Tv1qrot5bpo1orQuSIYeRp0rfxnuBz9e/Sh8txv23K9Zbx7+fkOv9O09bKErZWSktaAkWJzzKAefcdfXpVp9L07zYP9Ascea+f9BP/PQfn9O3Sql/eWz2UIEL53Wh502X/nqM84//AGugq099a+bB+5k/1r/8wyX/AJ6D25+nbpR7txP23KtZbvv2XkU5NOsP7QVRZWe37JM2PsR6+aoB+uO/bpVyfS9O8y6xYWXCvjFiR/d6en9PxqnLeW/9oK/kyYFpMP8AkHS5z5q+369ulW5762827/cy8K//ADDZRj7vtx/T8aFyjl7bTWX49/Qr2Onaez3m6ysjtup1GbE8AKMD/wCt2p9zpunrYTMLKyDCOUg/YjkfJx/nt1qOxvLZXvMwvzdXBGNNl6bR7cfTtT7i9tmsZQIZMmOYc6bL/c9cf/q60LlsU/a8+8vx/wAhIdN082ETGxsyxijJP2Ig58o9/r/jTr3TtPW7sQtlZANeIpAsDyPKY4x6Z7d+tMhvbZbCIeTJkRRjjTpf+eR74/8A19ade3ls13Y4hfAvIyc6ZL08pu2Ofp360PlsL97zvWWz7/5E8Ol6d5lrmxsuVXObEn+919f8+lVrfTtPOoSKbKyKi2tSAbEkZLvk/U4GT36VYhvrbzLX9zLyq5/4lspz9725/wA+lVre8tv7QkYwvg21oP8AkGyk/ffPb9f4ugofLoJe297WXTv39C2ml6dul/0Cx/1i/wDLgf8Anq35fT8O1VLDTtPa0nLWVmSHuQCbE9piB9MDp6dKtJfW2+X9zJ/rE/5hk3/PVvbj6fh2qpYXlulnODC/37k8abL/AM9jjnHH9OlHu3Evbcr1luu/Z+Qazp1hHo926WVmriCUhlsiCDv45/r26Vbu9L04F8WFkP3xHFiV42j/ADiqes3lu+j3arDICbeXk6dKv8fqRx9e3Srd5fWw34hlH749NNlX+Ee36ULluNe25VrLd9/LyK95p2nrqdqq2VkFZrjIFiQDhBjj2/SrP9l6d5v/AB42WPL/AOfE/wBz/PP41VvLy2Op2rCF8K1x/wAw2UfwDoMf/qqx9utvN/1Mv+r/AOgbL/c+n6/jQuXUJe25Y6y28+78iHT9O09tQu1aysiqzxAA2JIAMIJ4+vbueasWml6cRFmxsj+8TrYlv4P1+nfrVbT7y2GoXRMLkNPD/wAw2U/8sR1GP079asWd9bERZhlP7xOumyt/B9Ofp360LlsKr7bXWWy79vQq6Lp1hJpFk8llZs5hiJLWRJJ385Pf69+lOv8ATtPWyhK2VkpLWgJFic8ygHn3HX16UzRby3TR7JWhkJEMWcadK38fqBz9e/SnX95bPZQgQvndaHnTZf8AnqM84/8A2ugpe7ymj9r7Z6y+L9fQtvpenb4v9Asf9Y3/AC4H/nqv5/T8O9U5dOsP7RVBZWe37JM2PsR6+aoB+uO/bpVx7623xfuZP9Y3/MMm/wCeq+3P0/DvVKW8t/7QV/JkwLSYf8g6XOfNX2/Xt0pvlIpe27y69/PyLk+l6d5l1iwsuFfGLEj+709P6fjVe107T2utQDWVkQtzKqj7CeB5SYAHbvx261PPfW3m3f7mXhX/AOYbKMfd9uP6fjVe0vLZbrUcwvzcykY02X/nknbHH07de9D5boUPbcr1lt5+XkPudN09bCZhZWQYRykH7Ecj5OP89utJBpunnTkY2VmWMURz9iOc+X6/5z1ouL22axlAhkyY5hzpsv8Ac9cf/q60kF7bLpyDyZMiKIcadL/zz9cf/r60e7cr99y7y38/8h+o6dpovbLyrGzRGvI1INiTkeU2QfUZ7fjUsGl6d5lrmwsuVTObEn+919f6/hUF7eWzXdjiF8C8jJzpkvTym7Y5+nfrU0F9bebafuZeVT/mGynP3vbn+v4ULl1IftlBay28/PyK1tp1gdQlU2VmVFvbEA2JPJkfJ/HAye/SraaXp26X/QLH/WL/AMuB/wCerfl9Pw7VUtry3+3yuYXwbe1H/INlJ/1j57fr36DpVpL623y/uZP9Yn/MMm/56t7cfT8O1C5R1PbX0cunfsvIrWGnae9jMWsrIsJLoAmxOeJiBz7DgenSm6zp1hHo926WVmriCUhlsiCDv45/r26UtheWyWMwML58y6PGmy/89jjnHH9Ohpus3lu+j3arDICbeXk6dKv8fqRx9e3Sl7vKaR9r7Zay+Lz7+hcu9L04CXFjZD94/SxK/wAH6fTt1qteadp66naqtlZBWa4yBYkA4QY4/l6VYvL62AlxDKP3j9NNlX+D6cfTt1qteXludTtSIXwrXH/MNlH8A6DH/wCqm+WxFL22l3LZ9+z8i1/Zeneb/wAeNljy/wDnxP8Ac/zz+NVrLTtPbVrlGsrIorQYBsSQMxnPH+c9an+3W3m/6mX/AFf/AEDZf7n0/X8ar2N5bDVrljC+GaDj+zZT/wAsz1GP/wBfWh8ugL23LLWW3n3XkWrTS9OIizY2R/eJ1sS38H6/Tv1qromnWEmkWbyWVmzm3jJLWJJJ3nv/AF79Ks2d9bERZhlP7xOumyt/B9Ofp361V0S8t00izVoXJFvF002Vv4z3A5+vfpR7twftuV6y3Xfz8h1/p2nrZQlbKyUlrQEixOeZQDz7jr69KtPpenbov9Asf9Y3/Lgf+eq/n9Pw71Q1LU7EQWkLjZNK1qUR9PlBfEoLYyOTjr69BV57623xfuZP9Y//ADDJv+eq+3P0/DvR7txP23KtZbvv2XkVJ9OsBqewWVnt+yztj7EQMiVQD9cd+3Src+l6d5l1iwsuFfGLEj+709P6fjVSe8t/7S3eTJgWs4/5B0oP+tX2/Xt0q1PfW3m3f7mXhX/5hsox9324/p+NC5Rv23u6y/Hv6ENnp2ntNqQaysiFupFXNgeB5S8D0Ge3brS3Om6ethMwsrIMI5SD9iOR8nH+e3WktLy2WbUswvzdSEY0yX/nkvtx9D060lzf2pspU8p9zRzYB06X+59P/wBXWhcthv2vMtZdO/b0HW2m6e1hCxsrIsY4iT9iOT8nP+e/Wm3Wnaes+ngWVkA13GrD7CeR5TcH1Ge3frS297bLYxAwyZEcI402X+564/8A19abc3ls1xp+IX4u4yc6bL08lvbn6d+tD5bAva8z1l179vQswaXp3mWubCy5VM5sSf73X1/r+Fcp4rtbaC6tFgggjU2ykhLcpk7m5PqfeuqgvrbzbT9zLyqf8w2U5+97c/1/CuU8VzxS3VmyRsB9mUHdaPGc7m9ev1qanLbQ6cB7X2/vX/q512jb/wCxbD91N/x6238cmOv079v0o1Hf9hh/cz/fs/45f+ew9u/b9Kp6TJdf2RZbF04r9ntsbrqUHr3AXr6jt2pL+S6+xw+YunAbrTpdS5z5o/2fz9B0qr+6cns37Z/4u/mvMzPDfiO91Tx14r0ieAC30e4t0gKNLvIlAdt3J5zwMAfia3ZS/wDaa/upv+POf+OT/nqv+f51RtNNWy1a8v7Wz0mK8v5Va6lW7mzKUcKpPHZeBjtz1pZJLv8AtBfl07f9kmwPtUuMeYv+z19B3ptkUaUlv59fXzNqUv59x+6m/i/jk45T2/n/AIVU08vvvv3U3/H3cfxyf3R7f570yWS886f5dN6N/wAvcp/u/wCzz/n0qrYyXW+82Lpx/wBJnzm6l64HT5en86G9UONJ8j/z/wCCaN0X/s+b91N/q5v45P7lNti/9mQ/upvuR/xSf88f8/8A6qp3Ml59hm3Lp2PLlzi6lzjZ/u0lvJef2dFtXTiNiYzdS5x5Xpt/yeOlO+o1TfL/AMH/AIJe1Av9ssP3M/8Ax+x/xy/88W9v8/SrNuX861/dTn92Ojyc8N0wP5f41k30l19rsty6d/x+JjF3LjPlN1+Xp7+vFT28l55ttldMxsHW7mHZuvy8Uk9yZUnyL07+vmPtt/8AaUv7mf8A49bT+OX/AJ6P7d+36Vdj375f3U/+sT+OT/nq3t/k+9Y1vJdfb5MLp2/7Na5BupcY3v8A7PX19O1Wo5LzfJ8umf6xMf6XL/z1b/Z/yOetCYVabv8Ad18l5hpJf+y/9VN0uP45P+ex/wA/zo1wv/Yl7+6m/wCPeX+OT+//AJ/rVLTJLr+zvkXTiMT9bqXP+tPbb+Xr1NGsyXR0i73rpwXyJc7bqUn7/YFf/wBdK/umvs37e/8Ae7+fqbN0X3yfuph+8bq8novrVW9L/wBq2f7qf71z/HJ/cHt/nvWD4+1jUtF8L6tqVsumedbguv7+WT+4OhAz19RV2Sa7ku7CRhp+9hMw/wBJlAOYx144/Wm3oYUo+9y+T6+T8zH+JHjqDwZBHJLA1xM0Jka282YOYgoBZcKR3/iIHbNck3ifxMPiVJ4TtXuxf3upw6nFdBSY49O8oExMMbt2Pl346969F1WwTVEWPU9O0O9jRNyLcSPKFbZ1AZDz/wDqpLO1H/CQXV4tpo32xJI4hOZpN6p5QO0Ptzt9vWhsylhpyu+ayt39PM8p+EHjbxL4g8Xaba3d/dyRGS5e4jutiRTRqSqfZwihy64IYkkAV7PoW/8AsOy/dTf6mD+OT++fb/PaqGn6bFD9j8rTdBjNvNvi2yOvlsyfMy4T5Se5HNO0V7oaPabF04r5MON11KD989QF/P07UX1NKdCUabUnfWPX18y/qO/7DD+5n+/Z/wAcv/PYe3ft+lW3L+bB+6n/ANa/8cnP7we38v51j38l19jh8xdOA3WnS6lznzR/s/n6DpVl5LzzIPk0z/WP/wAvcv8Az0H+zx/k0X1LdN8q9X18l5iyl/7TX91N/wAec/8AHJ/z1X/P86uzl/Mu/wB1N91+rycfd6//AF/8KxZJLv8AtBfl07f9kmwPtUuMeYv+z19B3q5NJeeZdYXTfut0upT/AHeny800xypv3f8APz9R+nl999+6m/4+7j+OT+6Pb/PepLov/Z837qb/AFc38cn9ys6xkut95sXTj/pM+c3UvXA6fL0/nT7mS8+wzbl07Hly5xdS5xs/3aSehTpvn/4P/BLluX/s6H91N/qo/wCOT/nkf8//AFqXUC/2yw/cz/8AH7H/ABy/88W9v8/SqMD3n2CLaunEeVHj/Spc/wCqP+z/AJ6Ut9Jdfa7Lcunf8fiYxdy4z5Tdfl6e/rxQ3oL2b536Pr/wTVgL+Za4imPyr0eTn73T/wCt/jVS23/2lL+5n/49bT+OX/no/t37fpUcMl55ltldN+6vW6lH97/Z4qvbyXX2+TC6dv8As1rkG6lxje/+z19fTtQ3sJU373y6+a8zYTfvl/cz/wCsT+OT/nq3t+H196padv8AsU/7qcfvLr+OT/nufb/PfmkSS83S/Lpn+sX/AJe5v+erf7P+Rz1qpYSXX2Sby104jfc9bqXr5x/2fy9RyeaL6gqb5X6rr5PzLeuF/wCxbzMU2Ps8v8cn9/8Az/WvMrTxN4pk+Ix8H3TXjXVtqcmo3F0UPlPpxT5IgMZByQu/HUda77XnvToOo7RpqsLScgi5lPIORxjnp071T0KWbUtK0/XJLLRl1K9tomknWWQSFWjVtudpO3J6ZPNF9TKVPm5YJ2abe/p5+RjeC9Y1fUfGniW01ad7ldO1GaGAIrxiNDCDjHJ/Ekn8K9A+fzP9VN/q/wC/J/c/z/8Aqrk9Xv7bRtf0wSw6XBdapdTRI0Ukv76Qx8FyF9BwTW95l75n3dN/1f8Az9S/3P8AdoT3HGn7qje7SfXzb7kuml/7Svf3U/8Ax8Q/xy/88B7f5+lWrQviLEUx/eJ0eT+57f5/CsjT5Lr+0LvC6dnz4t2bqUAfuR/s/wCTxVm1kvMRfJpv+sXrdSj+D/doT0Lq0n+C6+XqLoRf+xbH91N/qIf45P7/APn+nNP1Hf8AYYf3M/37P+OX/nsPbv2/Ss/RpLr+yLPYunFfJixuupQfv9xt/wD1dqpX2uRnUo9Fkl00aiIbO78r7TNkx+ftz93HUcjtnIpX900lC1Z3/m7+fqdS5ffF+6n/ANY/8cn/AD1X2/D6+9UJS/8Aaa/upv8Ajzn/AI5P+eq/5/nQ8l5vi+XTP9Y3/L3N/wA9V/2f8jnrVKWS6/tFfl07f9kmwPtUuMeav+z19B3702yKVJ/n19fM2py/mXf7qb7r9Xk4+71/+v8A4VVsi/2vUv3U/wDx9S/xy/8APJPb/P0qOaS88y6wum/dbpdSn+70+Xmq9k1013fhF03JuZM7ruXGfLTodvT3ob1QoU3yP07+nmX7ov8A2fN+6m/1c38cn9ykty/9mR/upv8AUxfxyf8APOsaw1ZtY0A3tkdPe1kScBjcTKeAVPBX1B+tW4JLz+zk2rp2PKjx/pUuf9X6baL6jjC8Lp9e/wDwS9qBf7ZYfuZ/+P2P+OX/AJ4t7f5+lWIC/mWn7qb7qdHk5+90/wDrf41lX0l19rsty6d/x+JjF3LjPlN1+Xp7+vFTwyXnmWuV037q9bqUf3uvy8UJ7ilSfIvTv6+Y+13/ANpTfup/+Pa16PJ/z0k9v89uauJv3y/uZ/8AWJ/HJ/z1b2/D6+9YsM1wl7Mz/wBmKRb2xYtdygAeY/PT8/TqKtxTXbeYyjS2UuhBF3LgjzDyDt5GO/pz1oTCrTd/u6+S8yTTi/2Cb9zOP3l3/HL/AM9j7f5715h8XvFGu+GNSaFFvJdO1uxksNPSIHFve+Z99iw+YEH7vP3eldVr/iM+GPC11qdzDZSwJPNHsjupdxZ7jaMZGOp/Ecnmr3iO2N3pcjX1po8/2dJJYmeaR2jfdwyZXhvSlf3RToupV5FKz5u+u78zz/xt4y8W6N4k8O6XNa3kFmuoW9pe3vkSP/aMjRjzPLyMBeDwPmOeMAV0nxJ1O6tPG/gSzt5bqHz9VnEqJJIBKnl4Kk9SPauo1OCS6INza6PO0M5liLzyOUcJwy5Xg+/WvK/ibc3J+NPw+hcWYYTSyKEnkZDzjliMj8BTucVWlOnC7le7X9bntHz+Z/qpv9X/AH5P7n+f/wBVVbAv/bF3+6n+9b/xy/8APJvao/MvfM+7pv8Aq/8An6l/uf7tV7KS6/ta5wunbt0G7N1KAP3Z77f/ANVDex3xpPll6d/NeZr2hfEWIpj+8To8n9z2/wA/hVPQC/8AYtl+6mP+jxfxyf3z7f57U21kvMRfJpv+sXrdSj+D/dqpocl0NJs9i6dt8iLG66lB+93AX9KG9QdN8kvVdfXzOE+Jssg+Knwsi2SANLI2Cz5bAXGO/ft+Feqvv3xfuZ/9Y/8AHJ/z1X2/D6+9eUeNopLn4wfDFLoWoCpdOvlTuRuWMMAxIyvIHSvSWkvN0Xy6Z99v+Xqb/nqv+z/kc9aE9TGKu3Dqn37peYtwX/tX/VTf8elx/HJ/z2X2/wA9+auTl/Mu/wB1N91+rycfd6//AF/8Kxp5Lr+0/u6dv+zT4AupSMeav+z19PXqatzSXnmXWF037rdLqU/3eny800zaVN+7/n5+pNYl/P1T9zP/AMfcn8cv/PJPb/P0rgPErv8A8Le0BPLm40XUDjc/oK7KzkuvO1LYunH/AEp85u5evlL0+XkV53r11JJ8Z9IiItPOi0S83ATybMEZ4OM5x2xU390xxELSj6x6/wDBPUrUv/Z8P7qb/Vw/xyf3KZeF/tGm/up/+PyP+OX/AJ4t7f5+lVLaS8+ww7V07HlxYzdS5xs/3abdSXXn2G5dOH+lx4xdS9fKbr8vT39eKbeh0Km+Z/Pr5eprwF/MtP3U33U6PJz97p/9b/GuO8Y7vttnlJB/oq9Wfn5m9f6cV0cMl55lrldN+6vW6lH97r8vFcp4raY3dp5wtQ32Zf8AVzOw+83XI4PtU1HodOX02q9/19fM67Rpn/sWwH2tB/o1sMeZ0wen3e36e9JqUz/YYcXiD57PjzOmJhx93t19veoNJtGbSLFvtt8uba2OFvVAHPQDHH07Ul9astnCftt8fmsxg3q/89R7du3p1p3fLsc3LD2z1+1+qNNpn82P/S0/1jHPmdP3oOfu/j/nFUZZX/tRR9rQ/wChz8eZ/wBNV4+73qU2L+ZGftuo4Dtz9tXj96Pb/PWqUto39oKv22+/49Jzn7auf9avHTp7d6bb7E0owvv3/U1pZXM1wftaHO7nzOv3P9n/ADiqmnzPvvv9LT/j7uP+WnsP9nvXNvIJvijc6cuoalvttIeaQfbQQd80IXnGP4TW3Y2jM95/pt8MXM44vV54HJ46/wA6L6rQzpckoS8i5dSv/Z8/+lJ/q5v+Wn+x/u0ltK/9mQ/6Uh+ROPM/6Y/7v4f5zUFzZsLGY/bb84jl4N6uPufSmwWbHToj9tvxlEOBerj/AFPpj/PSnd32NVGHJuWb+Z/tlgftif8AH6hz5v8A0ybn7v4VZt5nEtsRdouEHPmfd4b/AGf85rPvrVhd2X+m35zeIOb5Tj903IOOvv8AhXKG9v0+MWj6ImqX4099Ee6eIXa8yCTaDuxxwTx70k99DGryRhHzX+Z2FtM/9pSj7Yg/0W048zpiR/8AZ7fp71cjmffJ/pacyJ/y06/vWOfu/j+P4Vl29q/2+Rftt9xbWhz9tUH/AFj8dP07c1aSybfL/p2of6xP+X5f+ere3+etCb7F1Ywvv2/JEWkyv/Zf/H2nS448z/psePu96Nclf+xb3/S0P7iXjzP9vp93vUGmWrPppP2y+Xi44W9XH+tPt/8ArpNZtGTR7xvtt82IJeGvVIPz9xj/APXS15djblh7ff7X6mT8X5Wb4e+Ig10jgxnI8zOeU/2RW35r/adLxdp92b/lp/0yH+zXmPxU1y5/tjxL4b+03T2sOjrenzLoNukaVBzxgjA6f4V6O9q32vTx9svfmEx/4/F4/djpxQ35HFh/ZyrOz2i/yZqvK+W/0pD+6x/rP9jp938KhsZn/tW/P2xP+PiI583/AKYjn7v4Ux7Nst/p2of6r/n9X+59Kis7Vjql6Ptt+MXEfIvlyf3I6nH6/hTd9NDoUYcsten6o0LSVwIsXaLiRf8AlpjHydfu/hVLRLgx6HZb72JB5MA+aXH8ZwPu9v8AOaktLNsRf6dqH+sX/l+UfwfT/PSvJPjTdzaV8O9AuI57x1e9tC6eeHUKnmSZCgdtn4UNu+xFVwhSlLezX6nrWozP9hhxeIPns/8Alp0xMOPu9uvt71beZ/Ng/wBLQ4lc/wCs6fvBz938f84rLu7Zhp9uwvb45Nnwb1e8o7Y7dvTrVt7JvMg/07UP9Y//AC/L/wA9B7cf5NF3fYtxhyrXq/yRFLK/9qKPtaH/AEOfjzP+mq8fd71dmlcyXWbtDlX58zr93/Z/zisqW0b+0FX7bff8ek5z9tXP+tXjp09u9XJrNvMuv9O1D7r/APL8p/u+3P8An0oTfYcow93X+riafK+++P2tP+Pu458z2H+z3p91K/8AZ8/+lp/q5v8Alp/sf7tec+Lr+Wy8ceELKG/vVa51i7SQC7GWQxYzkcdfWu9urI/YZCb2/O1JSAb1cfc+lJPTYhOEqrXZ/oWLeV/7Oh/0pD+6j48z/pkf9n8KfePI93ZEX0Q23iNlpsZ/dMOPl5/z9apw2bGwiP22/GYozgXq4/1R9v8APSpLqz/0q136hfg/ak25vAcnym6HHB9/wptu2xbjDmevcuwyuJLXF2gwq4Pmfd+9/s/5zVS3uGGqyJ9ujDG1tCF83nAkftt7fpnvToLJvMtf9O1D7qf8vyj+97cf59a4nVDJZfFrwxEZ7kpfaTLAsrXSlwVlicgH+H7o496G3poQ+SKlr2/9KR6Ckz7pf9MTmRP+WnX96xz938fx/CqWmyubKf8A0xD+8uv+WnX9+f8AZ79f8Kelk26X/TtQ/wBYn/L8v/PVvb/PWqtjas1pMftt+PnuhgXy4/1x9vz9etF3fYpRhyvXqvyZJ4guJI/D2qMLqM4srngycHrx93v/AJxVHwdI3/CD6APtKY+x2/G//pgn+z+FR+MYWtvCGtTfbL59lhdNta8VgevBGOfp3qPwlaM3grQT9tvxm0tzgXi4H7hO2P8APSnd32OeMYe236fqYfxPlc+MPh9m6Rv+J1Kc+Zn/AJZHn7tegea/mf8AH2n+r6+Z/sdPu/hXkPxJSc/GHwLa/bbswxzPNh7oM25iVyrYwOB+NeqfY28z/j+1D/V/8/q/3PpQm+xNFQcp/wBdBdOmcaje/wCmIP38P/LTp+4HP3fwqzaSuBFi7RcSL/y0xj5Ov3fwrO0+0Y6hdD7bfDbPFyL1QT+5HXj9fwqxaWbYi/07UP8AWL/y/KP4Pp/npSTdtjqqxhffovyI9Clf+xbH/S0H7iLjzP8Ab/3e3X/GvPNUlf8A4Xxaf6UvHh22Gd/3f9OTj7vbr/jXeaLaM2kWbfbb5cwwnC3qgD5+wxx/SvNJbk3fx8a2We4/0HQ7W3MguQGJN1E/LY7eYOO3B7VL+HYmuoqurfznsLzPvi/0xP8AWP8A8tOn71Tn7v4/h+FUJZX/ALUT/S0P+hz8eZ/01Xj7vepXsm3xf6dqH+sf/l+X/nqvt/nrVKW0b+0VX7bfc2k5z9tXP+tXjp09u9U2+xVKMO/f9TVmlcyXWbtDlX58zr93/Z/zis57toI9bma8UCOWdywkz0hTn7vtViazbzLr/TtQ+6//AC/Kf7vtz/n0rE1uLytF8TSyX16qRLckn7Ypzi3Xrxz6fpQ29NCeWCpS16f5HJfAS/ku/hHG/wBpCqst6qgvggHJ6YPXNek28r/2ZGPtSH9zFx5nX93/ALtcD8KtLWy8EXcEE9zDHFPcARxXSqn+qQnjHv8AjXbQWbHTkP22/GYozgXq4/1fpihXvsRhox+rxuyxfzP9ssD9sT/j9Q583/pk3P3fwqxDK4ktcXaDCpz5nT73+z/nNUL61YXdl/pt+c3iDm+U4/dNyDjr7/hU0Nm3mWv+nah91P8Al+Uf3vbj/PrQm9dDSUYci16f5nL/ABGkY+CPGKm5VgdCA2b85/1vGNvb61d+Fkrj4c+GsXSp/wAS6z4MmD/6CenX/OKzPiJbAeB/FwkvrsKuhhsyXYYNxLhSMcjPAHbPvWl8PrbzPAPhlku7uMHS7D5YrpUUfKO2PX/GhPyMqrh7bl8l+hy/xplc/Cu7zdI+NTBx5mf+X0H+7+P+cV6Dr0r/ANjXv+lof3EvHmf7fT7vevO/jHas3w0uCbm7Yf2moKvdqy/8fo5xjr39zzXea1aMuk3jfbb5sQS8NeqQfn7jH/66V3y7GlOMPrb9V+bNS7lciXN2jZkb/lpnPydfu/hXlPj2WCb4x+GzPOTd27R+Q+cr80rb/mxxwPSvTbuzbEv+nah/rG/5flP8H0/z0rxTxJZTH4/rI1xcNGtzZQh2uAXBKOxw+MU23YxqU4SjFX7v7lc9081/M/4+0/1fXzP9jp938Kq2Ez/2xdn7Wg+aDnzOn7s/7P4UfY28z/j+1D/V/wDP6v8Ac+lV7K0Y6tcj7bfDDQci9UE/uz1OKG3podEYw5Za9P1RpWkrgRYu0XEi/wDLTGPk6/d/CqmgSuNGsv8AS0H+jxf8tP8AaPH3e1OtLNsRf6dqH+sX/l+UfwfT/PSquh2rNpNm322+XMEXC3qgD5j0GP8A9VDbvsDjDklr1X6nA/EW7eH4ufCxjcKRunUPuzs+RRjOOOvvXqbzPui/0xDiRv8Alp0/eqc/d/H8Pwrwv4ntcf8AC6fh7b/aLgwWvkN5r3ILKZpGXhv4f9X+te1PZNui/wBO1D/WP/y/L/z1X2/z1oT12OOjySqzv3/Qjnlf+1h/paH/AESf/lp1zKv+z36/4VcmlcyXWbtDlX58zr93/Z/zisua0b+0tv22+/49bg5+2rn/AFq8dOn86tzWbeZdf6dqH3X/AOX5T/d9uf8APpQm+x2yjD3df6uLZTP5+qf6Yn/H3J/y16/uk/2fwryC5MzftGXUxlURro8kQk3dSYN2M4/oK9XtLVmm1Ifbb8YunHF8vP7peTxyff8ACvNEMV58VtTaKW4EluZLZpPtCh2K2QJye45/pSv7uxz4hRU4Jd4nqlrK/wDZ8H+lJ/q4f+Wn+x/u028mf7Rp3+mIP9Mj/wCWn/TFufu/h/nNQ21mxsYT9tvxmOLgXq4+59KbdWjLPYf6bfHN2g5vV4/ctyOOD7/hTbdtjpUYc717/kaMMriS1xdoMKnPmdPvf7P+c1x/jF2N7Z5nVsWqj7+cfM3HSunhs28y1/07UPup/wAvyj+97cf59a5TxXAY7u0BuLmT/RlOZLgMR8zcdOB7VNR6HTl8YKvo/wCtTpdImtRo9iGliDfZrbIN1GOc88dvp270moz2psYsSxHDWhOLqP8A56jP+e3ejSI7U6PYlooCxtrfJMER5zz3/wD196TUI7VbKHEUAO+0HFvF/wA9Rnv/APr709eUwtH2z/xfqjlrz4j+FYLKS8tbxb65GCkEJZZJW3grGSV2huvt3rNvLnV9E+za5eXPnssd1JqVn9ujlWO383CiEKPvKNjH+9g4r0giDcibItnmFivkxYz5nXGfT/OKz5I7X+00Aigx9kmOPIi6+avv/ntTaZy06EW9W+p5v4R1+11z43+ItStGRtJk0oWltciQBZvLkjZjuIA4L4/Cu8u9f0TQlupNZ1C2s0e7lC+ZcrltwG0hQCSDg8gYrh/ivqP9l+M9Gt9OUxy39tcWkXkRRqVeSWD5gBkZ4Jz7ZrsPCfhnRNFju0tLZJZFuph9oukjmmYAcZdjnuemB6UK9zDDcyjOC3vrv1OSk8Y6j9ht/Ed1PbQ+Gb6d7SOw+Vp442QqJmYDcCXH3cYwR3rdm8c6WbSzsdDA1DVZwqpA8vkqgEJy7s6j5QRg457DmuruEtlspmWOFXEcpBEEQIOz1zTw8dzp0BuCszCNADJHGx/1Xuf8/Wnrc6vZvlspafj8jzr+3tQ8K+ILCLxvq9nfWd5Kk63tsypHbSJDh4yqg4U7lKt3O7PNUvCOo6RrPxpl1nT75bmA28lmrmUIoVYYGIBYcfOW7V6bfJard2O2OBc3iZxBEMjym9/8/WuI+I9xBpc9vd2whtpo9F1CRZUhjBEoWPZ0zzkjk80tdTKrTUYRbei1/M7Jr2wtLm4ubq5t4oFtbUtI93GFHzvn/wDV2rlLnxNqupxXmq+Go4/7Kspk2wyPF52pqJz5gQPgx4VSFP8AETnpipdE8CeGoNUae6tTqN4BbXYuL/ZM6uSQQMkDaAgwMeuetdqEtXllZ44WZpFJJgiJP71j6/5+lCuXVi5y97RabeiONbxrpFj4M0/UbbddzamJV0+0jmUSzyNKcKQR8uP4iemDXNa5q2ueF1t7/wAUa1bXmnaqksN1a24Rk0+TkpsZeSmcKxbr1rq/CfhDQdLvdS1q2t91/qBn8xpVR1T96eI1JwgPU4rd1yK0/sW9xDBzBKOIIu7fX/PajXlLjTm6qc373N0va/8AX4Hg/wAUNTs7j4ja9qNhcRXNlL4cDJJFOrq2CHAyOCTjp1r0hvHlra6lpzeIdOl0ixaGSWO9a7jnhYtGCEJQEq2OxFc/8dbLStPNrJHb20CXkV1aFYrdE3uyxbeF4z97ntXppgs4rjTYkhgEYWZNvkRcgRgAHmk7nFhIydWSvZ2f5MtQX+n3UIntru2lheLKul3GQfkqGyv9O/tu+h+2Wvm/aYxs+2xbuIRXJ6r8PrSfX2vNL1O50mxuYyb+zs44kW4bZwVP8BPQkdfrVLVvAml2mnT/APCK6VbjVdMvre6s/wDVo8hCIZFaQk53qGGDxkjpVO50qVTlenTXXzW3/BPQG1HTrK0N1d3dvFbxEPI7XSAKoTk/5+nWvKPGNzpfjTwpoGlaNqEL3Ekxg3GUKEkNrc7Q2QMDOM+2a1tBubP4ia3pt19ieDw9p6xXDRSWyRie8IPykkjeseBz90sT6Vg6fpzXfx20ppJE+yw6NDfmIhcMwZoR8vQn9439aTvczqzU4WXwtxX5nWav4q1DSvDtvd6x4f8A3EAtHunsdThnKBXBZljA3EcHA6+tdZouu6Trmn2GoaZdRSWs7uVJuEVv9YAQQeVI5BzTtQS1SzhKxQqd9oMiCL/nqM9//wBfeuW1v4eaZqmsXU76pqdvYahIz3dhbGKOKR8qu4EcrkKMgHBI+tCvc2cXFKzbV3+SOhj1DT7nV51guoHa2gnhmAuU/dv5iHaffBB9+1aN1dWUbXTPc26KFblruPA+73rzHxToukeDta0HV9E0ixitIpHXUnKkt5Lnyg+AW3bd+7kcY9K09T07RvG3jq9tLu2gvNE0WFg6qFWOS8k2jayrgMUUNnDHBYd801e5EqrSUZL3um/c57x3A7/EKy1DTrY3t5pjm6SGOZGJTzwrkAkAnaeneu10Xxz4b8RRG0068Zb+WOfbZ3B8qb5UORtI68djXL/DO3sLbxFFYQSR3CW+mXQIeJWMf+lsFUljyQq9c/Su71/StI1bSjDqNnbzpH5k0YMKKVcJwwIIINJJ2CFpSdSk935l6Ce1FhCDNCCIo+tyn/PI1LcyWsl1bbTFJsukYkXcYCDy25z3/wDr151p/hfW7OGLRbC9hi8NN5c4vX8t76JfLJMCEj7pb+MkkDIxmrHizRrjw3aRa3o19e6k2n3AuJ7TUbiLy5YFhcuBheW9OvPWjWxc6iTbs9Lnfx3NmrWxaeADamSbuMf3vy/z615N4/vXT4v+C7uw06S/j0uwN3dfZZUaRopj5a4yQDj7wXrjNbEltp3j7xNbWdxaQPoGkqovIhsAuLh4wyIyjGQgJzk9T04rO+DqWL694kgW1VF05kso1MalUQXlywUBj2UpjrxgdKbuc1ablNRjs3+R1ll480aTWYdOvbbUtNuLyVVtTeqqLM3mgbQwyN2XAwcdCa3dPltVtJg0sSnzLrg3Uf8Az2OP89+1Ra1oula3pd9pt9Cn2a4KqxijjjdcSkhlYHKsDggjuPSuL0/w9rzo+kjVIItAhmndb9Y4zqEqCY/uGY8Dkf6wckHGO9LW50puKejauvyZ0PxIuLdfh74jMckbv/Zt1tVblCSeemP8mp/CU9qvgnQt00IIs4M5uU4/cJXmXxl0FvC/gzUdZ0fV9QmmmT7Jdx3rpKssTsY1CgfdYF92RWnDph8WmHw5PcC00Kw0m1+1Cz8tJ55pYQArHsqhCcdyRmnrc51NKs9NbfqYviyA3H7Qekaj9qR7KG7itVX7QpVcwNJnPTBPf14r3Ay2yyfNJEP3fe5T+5XnugeALHS7dNN1y4j1pLgsrebbxoNsUe2Po2c4xk569Km1D4X+HZL2K80aS60W/hj/AHU1qylA2M5aNmIf0x6e9CvqVTpyp3k1pJX897fodlp81qNRvCZYsGeLH+lRjP7kf5/SrNtPahYS00OGkUA/aoxnCZI/UfnXBaHomu6zqlw/ii+g0yKCRI1t9EEaecxiGJWduRwB8gGAScmqOueE7fQNS0XxRZ3moX15Z3sFtLFezJIjwTERsFXGNwZ1PTnbyaSvY1r1LK6i9l+R2tvq2l6T4YgvNSvLe3toIITLI9ymFy+ORjPf8K8bsvE+hRfF/VdVkvVXT5liRLgZKsV+xk/MAeMI5H0rqND0SDx9NNP4gh8vRNLl+xWtkmwLcyRuyvPL0zjJAX2ya3vBPgvT/AvhhtPtbqS8868trh5Z4oi2TIg2jngAKPrznFLXlCopVMTdbKX43/I6yw1bSdTt7e50++tbi3clw8d3GRtMi4+nHr9e1RyzWv8AaSt5sWBaTDP2mPGfNX/PvWJ4j8D6JqtxBeWYOk6tEz+Ve2McUbL85A3Lna4+djgj8cVhab4c1rUdUnl8V6qbWX7O6wQaN5cUWxXUb2yCdzkkkdsADIqncdGUlpJa67bdT0Sea1Elz++hHytj/So/9n8688+KmvaZZ+FfE2mi9iTUr4yJbRCYOX3rGgxtHqSO2azde0o/DrVl1TQItU1yDUDNFeWM0YuXkk2bo5AwB8v5uCQMYNX7HwOmvQald+KLlk1m5nUulqEEFr5eyREjXPODwWPXk96TvexnKTnCVOC1t/kGgeJPD/h+11jR9Rv0gvku7hBCXLM37pQpGFOc4rstE1rSNU0WGfT9QtJ4jEgyt3HkEJggjqOfWtC6aFbaeVFjSTbMwZYYwQSnUHOa5PVvCMF29vrGh3aaVrC28UTOLWJ4Z0wWIljz8x5ODnOcU9UylGdOCS1X4/5HT6nc2aXOns88Cob1QCbuMA4hYnn261Yt7mzdrRluIGVkQgi7jwR83euIl+HugnUNNuNakudbuxNFEZb8xsoARmJVFIVcnGRzwAM8VkaZqWkeBL/xLpiwZitkiv8ATbJ4lk3CRMFI+pC+c20DnG72pailUcUnUVlbzv13Nf4rWjah4J1mC13EXcWn2okjmVgS9yVK8Drg9OorQ+E19a3Pw78PAXELyR2FsGAuUBUK5TJHUDIx9a5Wx+Hks+q6Vf3OuXQ1SG4s9RvcqoilG7mERhgAFMUeCRnhs9a6fVPh14T1K5uLn7B9ivJJlc3NkVhkz5pJ6NjHQ4xj+dCvuYzjUlW9paysu+2n4nPfGmeJPhddNA0TzLqYZUNyhzi8GOnOPf8AHpVy58dRW9hf6d4vtU0vU0tWcNb3AuIJ9ztxGyqeQF5U8856VxHj3R9es9CW1ee3ufDkGswmCaeRXunjEqRCBwBjaGG/OfbpXtusmGLRb4RCNAYJchIoxn5vY+n/ANakr2N4qUsU2tHdea3f9dDzW38cXCaha+KNWmlTwrqhmtIbSIhmtXDYilkTG75grZPQZFUbvWNK1rx6moaTdwXNo2vWaecswAwLZ8jJA6Hv+FexXKWuZSsUG7zG5EEQP3PY1wHxIt9N0vUdC1CCzgWSTWfOuPLgjBm2QvjODg8fh3pu9tSFT5db6Wf5M77z7TzP9dD9z/n6j/uVzuueJ9L8OTXdzdF7iWRoFt7a2lV5Z32Y2qAMdWGSeBnmuc8P2XiDxHp1l4jOs2+mXF1b+ZFpg06F7ZEK/KHBIZmx/FkdRgVuaBoTnxlcavrNxBJdQJHBBBaxKluiPH85KMxyxKryTjih30NI1OaEuVPVb+V15iWXj7R08JXGt3+LJ7SR0ls5buLzfMjBUoAOpLDAPvXK+HvG+reHUtD4zslbRr8RNaXVm6N9gjZ22xz45JwASQOM8139t4Y8OnVl1RtJsDqLvHunNtEW+VOOpx2H5c1a0Fbb+ybNjHDv8iPLeRETncff/Peh3uSoVHCXNLZr577/APAPGdf13TPFPjC21DTxFNZ2WqaJaQ3SygCX55XdgSBgAvtz2I5r3N57TfH++h/1jf8AL1H/AM9V/wA/rXE/EtbKw0HRJUhght7fU9PeQJbxgBRNk5A6j69e/asbS/DmseKtPs9fn8U3+kf2jm5jsbOC3aKCNpAY1BPJOzaTn+LPajVM56bVOo42bb10N/x34nTRLuzj02OG81W9SWC2ha4BTJmTLOVHCgd+9Ul+J+kSaCbk29ydblBt/wCyxkOLklVMe4rt2hgec/d5rQ8P+GLXRdduru4v7jU9Qu7KWOae6jixtWYFVVAcKOe3pXXTGEi4ixGYsOQnkx7c4XnGcZ+n+NNXOpxk2m3b/L/P8DzPw54wPhm81HT/AIg3Mcd3c3Mt3Fewyh7baY0zECBkFCQOfvVW0UWH/CSzXttPA4vdS1Nyy3CfMotUCHP516TaRWkj6qjxQMjXMi4MEWMeUvHWvPfG0ek+CLHTZ9G0q2SC1hv5Vto4kAdzEo65J6n/AAqdbGNamqUoybulZ+Z6Laz2osYQZoQRHF1uo/7lNu5rU3Gn4liOLtCcXUfA8pv8/pXEWnhjxD/Ztve2/idE1OaONpoLnToZLVcrnakedylRxnJzyTXQWGlzWdzZS6pqSX80lxEhVbKCGJQInOQoPUk8knsO4pu9jpp1FOV+Vq6f5ep0EM9p5lt++h+6v/L1GP71cl4teF7y0Mbow+zLkrMrc7m9On0rq4YrTzLb9zb/AHVz/o8X+17/AOfyrkvFqwreWgjSNR9mXIWJBzub0NTUvY78Ao+30Om0m6uF0exUWOpMBbWoBWCIg88EfNnHp696L66uGsoR9h1JRuszkwQ4/wBaMfxfl6nrUujRt/YtifssZ/0a2OfL9T1+93/zik1KJvsMP+iRn57Pny+uZh/td/8AOKdvd3OTmh7Z6L4v1XmSteXHnRf8S/U/9Y3/ACwh/wCeo/2v8n2qlLdT/wBoBvsOo/8AHpONvkxZx5q8/e6ev6VqNE3mxD7Kn+sbjy+v70f7X4f5zVGWNv7TU/ZU/wCPOfny/wDpqvP3u1NrzJpShfZdf18zzT4v+c/xD+H161peoU1YxASRIrMSEOBtOCeOh9vevSLG6uFe9/0HUjm6uDxDFx8o4PzdfX9KoeJvD0mreI9Eu2tovs+l3Mty8ZTHzGMKhHzdmYH8a1NPibfff6JH/wAfdx/yz9h/tdqLamNDlSm2lr/l6jbm7nNhKPsGpDMcwyYYsD5P96mwXc402MfYNSICoM+TFg/uf97/ACPerF1G39nz/wCip/q5v+Wf+x/vUltG39mQ/wCioPkj52f9Mf8Ae/H/ADii2u5upQ5dl/XzIr26uDeWObHUgReoeYIck+S3A+br+mPevM/i3LPfeJ/AWmHTbyRNQkMEiOqqxiEkUj7Np5+WMjn1r1G/if7ZYD7JH/x+oMeX/wBMm4+9+NZF/oVxe+NfCeqJawmHTobncGXktIm1SBu54Dc5FFt9TDEWlRSilsvz9TQtrmcX7kWOpY+zWgCiCLgeY+P4unp696tR3lxvl/4l+p/6xP8AlhD/AM9W/wBr/J9qitom/tOX/RIz/otpz5fX53/2u/8AnFXI4m3yf6JH/rE/5Z9P3p4+9+H+c0JeZrVlC+y6fkvMy9Mup100j7DqLDFxyIYsf64/7X5/pSazdTto94psdSUGCXloYgB8/f5un+RU2kxt/Zf/AB6p0uOfL/6bHn73bpRrkbf2Jen7Kg/0eXny/wDb6/e7dKVvd3NeaHt9l8X6+p5B+01LLPH4UWS3vIP+JzjM8aKDlU4+UnmvXLy4nXU7QfYtQ+Rrgf6mL5vkA4+auF+OWlyXkelyG1KRWtxLMzpFwhAiwCcnHWvQdQib+2bX/RU+/c/8s/8AYH+1Q0cOFcfbzdlt/wC2vzB7y4y3/Ev1P/VH/ljF/wA8/wDeqOzurgapekWOpkm5i4EEOQfJHX5uv9Perbxtlv8ARU/1Wfuf7HX7341DYxP/AGrfj7JH/wAfEQx5f/TEcfe/Gm1tqdKlDllotv1XmFjdTqkCpp2pBRImAsEOB8nb5q4bQLaRviEmprZ3zPb+H7O2+WKMkh7mQ5AzjH7vHrkV6DaRsRFi1Rv3i/8ALPOfk6fe/GqWgwn+xbNhZx5MEGW8vk/Occ7u/wDnFDWu5M1CUdlo4/r5jb66uGsoR9h1JRuszkwQ4/1ox/F+XqetWZLy4823/wCJfqf+tfH7iH/nqP8Aa/z9Ki1KJvsMP+iRn57Pny+uZh/td/8AOKuPE3mwD7LGMyuP9X1/eDj734f5zRbXcpyhyrRbv8l5mLqJ+3SyW95pl9Nby2NxHJDJBEQ6mVc5G7p6/pVmxjj0m1kstN0a+tbOFZNkMVtCqrkqTwG9Tk/Wnyxt/aan7Kn/AB5z8+X/ANNV5+92q7NEwkuv9FQYVsjy+n3f9r/OaEvMcnC8XZf0/U8i+ENjNp/jnx/M0N/cyRX8tupWND5aNuk2kFsDk9vwr1C4u5zYSj7BqQzHNyYYsD5P96l06EiS/Is4gTdTgkRYzhR/tdqluo2/s+f/AEVP9XN/yz/2P96i2m5lQhGjaDSf9PzK8N3OLCIfYNSIEUYz5MWD+6P+1/ke9Qa8p1JI7O70/UzBcTiGRfKiVmVoHUgENwcE/wA+tXbeNhp0P+jIP3UfOz/pkf8Aa/Glv4n+2WA+yR/8fqDHl/8ATJuPvfjQ1pubXhzvRbP+tzP8MWFv4f0/T9O0fR9Rt7WJFKqsMRLE78sSWyxPJyeTz7VzPw1X7BrfjWKKwvWnfVLeZ2iRGwHjjZQQxGDknp1zzXfQxMZLX/RUOVXA8vr97/a/zis+wso4NXvJIdPgR54LSSVliwZG3MoY/NySFAz6AdKGvMxcKbd7LT/O3ctpeXG+X/iX6n/rE/5YQ/8APVv9r/J9qqWN1cLZzj7DqTDfdHIgix/rzn+L8/Q9OK0UjbfL/okf+sX/AJZ9P3rcfe/D/OapadG32Kf/AESMYkuv+WfT9+f9rt0/xotruaKUOV6Ldfk/M534pXE0vw38SI9jqCqdNufmeGLavPU4bPH5jtUXgPQofDegq1va61dXd4Y3ubu4WN3mIiAXkt0UHAHp71d+J8TH4c+I82qAHT7jkJ0+br97t/nNblrCY9MtlFsgChVB2f8ATNePvfjTtqc0XB172W36+pDeXU51O1JsdSBDXHBhiyfkH+1+f6VY+2XHm/8AIP1P/V/88Yf7n+9TL2J/7Vs/9EQfNc/8s/8AYH+12q15beZ/x6p/q/8Ann/sdfvfjSS31OqUocsdFt+r8yjp11cDULoix1IlriLgQxZH7gf7XX+nvVfU7OLX9Fk0vU9L1WWzuWRZFSONTwuQQwbIIIBH0z1q7p0T/wBpXuLSM/v4ePL6/uBx978atWkbERYtUb94v/LPOfk6fe/GhLTcVVw10Wy/L1Of8HW39keHra3tLLV5FcLO8kixys7vKWZtzNk5J7/yrRvrq4ayhH2HUlG6zOTBDj/WjH8X5ep607Q42/sWx/0VD+4i58v/AG/97v0/wp2pRN9hh/0SM/PZ8+X1zMP9rv8A5xSs+Xcv93GrypL4v1XmTPeXG+H/AIl+p/6x/wDlhD/z1X/a/wAn2qjLdT/2gG+w6jxaTjaYYs/61efvdPX9K1HibfF/oicyMP8AV9f3q8fe/D/Oaoyxt/ain7Kg/wBDnOfL/wCmq8/e7U2vMmlKHZdf18yea+uVluyLHVAdj5/cxA/wdcN/KqtrdXAutR/0HUiTcyk4hiyP3ScH5utaE0TCS6/0VBhWyPL6fd/2v85qrZRN9q1L/RIwftUvHl9P3Sf7X40NarUUJQ5Xotv8vMZc3c5sJR9g1IZjmGTDFgfJ/vUkN3ONOQfYNSIEUQz5MWD+7/3qnuo2/s+f/RU/1c3/ACz/ANj/AHqS3jb+zYz9lQfuYudnT93/AL1Fnfcrmhy7Lf8ArqRXt1cG8sc2OpAi9Q8wQ5J8luB83X9Me9ZeraJZa7qmh3mpaRqstxp+1rcqkajk7sEBsMMopAbuM1s38T/bLAfZI/8Aj9QY8v8A6ZNx978asQxMZLX/AEVDlVwPL6/e/wBr/OKEt9SJ+zcFeK2/z8yhbXdx/aErfYdSJNva8eRFn/WPg/e/L171aS8uN8v/ABL9T/1if8sIf+erf7X+T7VDaxsdTm/0SM/6Na8+X/00k/2u/T/CriRtvl/0SP8A1i/8s+n71uPvfh/nNCXmOrKF9l0/JeZ538TpJpvBMML2t8itrMfzyQxhR/py8cHOc8fXjpXY61dTto94psdSUGCbloYgB8/f5v8APauV+IkLN4OtlNsibtcjGQn/AE/Dj734f5zXX65G39i3p+yoP3Epz5f+31+926Ure7uTTcfrb0W6/N+ZNeXlxibOn6n/AKx+sMP/ADz9mrzH9oS+mi8OadM9veQeXqTkGZEQEmJhwVJOefpXqt3GwEubVF/eN/yzxj5On3vxryL9qKKQeAUZYUiKXrNkR4/hxjqfWnJaEScXTdkvhl+T8z0Tw3cTRaDpcaafqW1LGJRiGLp5I/2qs2N1cDVrgix1IktBwIYsj923+1RoETf2Lpo+yp/x5RceX/0xH+1+NS2MTnWLsfZEPzW/Hl9f3Z/2qGttTSlKHs3ovhX5rzJLO8uMQ40/U/8AWJ0hh/55+7VV0O6nXSbNRY6kwFvFysMRB+c9Mt0rRtI2Iixao37xf+Wec/J0+9+NU9AiY6NZf6Kh/wBHiP8Aq/8AbPP3u9DWu5TlDklot1+vmef/AB/u5j8J9QY2d9EUFmyvLFGqg+aMcq2fp+tdj4Vjn0nwvoOnix1Fha26QgrDEQdroOMtk/jXF/tFWd/dfDQR2S+TGbi089UTHmqWZVB5/vFT/wABHSvTykh8gtaoWLNn931PmL/tfh+P40Wd9zki4+3k7Lp+TM6e6n/tIt9h1H/j1uBtMMWf9auT97p6/pxVqe8uPNu86fqf3XzmCH/Y6/N/Kop4m/tYf6LGP9En/wCWfT96v+126f41cmiYSXX+ioMK2R5fT7v+1/nNEV5nXKUPd0X9P1KVpdXAm1M/YdSObqQnEEPH7peD83X/AD1rzz4y3U50yzb7LexFIrshpYY9uQkZycE8cc16RYxP5+p/6JHxdyf8s+n7pP8Aa/GvLf2gbs2GiaYTAii4NzbZC4+8ie59KX2dzHEuFrWX2f63PUft9zLCHex1IswjYkQQgE7D/tVDc3VwbjT/APQdSGLuMjMMXJ8luB83X+nvVmCNhZRf6Kg+SL/ln/sf71R3kT/aNO/0RD/pkY/1f/TFuPvfj/nFNp23N4uCk0ktn+XqPgvLjzbTGn6n91MYgh/2+nzfzrk/Fk0sl1Zlre7j/wBGUASRoCRubkYPT6812cMTGS1/0VDlVwPL6/e/2v8AOK4/xihF7Z5gVc2yn7uM/M3PWpqLQ6svcfb6Jf1fzN3SYLo6RZFJLIKba2IB05yevc7uT6nv2pL+C6+xQl5LIjdadNOfOfNHfd+f97oKt6Mrf2LYfvZf+Pa2/wCWcvr9f89sUmpI32GH97N9+z/5Zy/89h7/AOe2KdvdOf2j9s1/e7LuvIGgvPOi/e2P+sb/AJhsn/PUdt/P0/CqcsN3/aC/vLPf9kmIP9nvjHmr/tdfft0rYZW86L97L/rG/wCWcv8Az1Hv/n61RlVv7TX97L/x5zf8s5P+eq+/+e/NU0TTqu/39F5+Q6WC88+5/e2PG7H/ABLZBjlO2/j/AD61VsYLrfe7ZLIf6VcZzpz9do/2uPp2rVlRvPuf3sp4b/lnLzynv/P/AAqpp6Nvvv3sv/H3cf8ALOX+6Pf/AD3pNaoUaj5H/kv8iC4gvPsMpaWyI8uXP/EvfONnru//AFdaSCC8/s2MrLZAbEx/xL3yP3Pru/z1q5dK39nzfvJf9XN/yzk/ufWktlb+zIv3kv3I/wDlnJ/zx+v+fpTtqV7V8v8AwF/kVb2C6F3Y7pLI/wCmRgY02Tg+U3bdyPbv1qe3gvPOtcy2PMY/5hsh7N238/X/AAp9+jfbLD97N/x+x/8ALOX/AJ4t7/8A1/wqxbo3m2v72UfIOkcvHDeh/l/jSS3IlVfIvTsvPyMq3guv7Qk/eWW/7NaZJ05yCC7/AO1+Z/i6CrccF5vk/e2P+sT/AJhsn/PVv9vj6d+nai2Vv7Tl/ezf8etp/wAs5f8Ano/v/wDr7Yq5GjeZJ+9l/wBYn/LOX/nq3v8A5+tCQ6tV3+7ouy8jG0yC7Om5SSzAxP109yc+ce+79e3SjWYboaPdl5LMr9nlyBp7g/f9d3H17dKtaSrf2X/rZelx/wAs5f8Ansff/PfmjXFb+xL395L/AMe8v/LOT+/9f89+aVvdNfaP2/8A292Xf0Mfx7a6hJ4Z1SOJIrlmcDyraxeNyN8Z4yx6c8Y960tRiuW1iA+ZacyXJXOnvx8nf5uf6da07pWDyfvZT+8brHKOy+p/z+VVL1W/taz/AHsv3rn/AJZy/wBwe/8AnvTaOei7T5+6fTsn5DHgvdzfvrL/AFX/AEDn/uf7/wCv41HZwXX9qXgElkD9oi3Z02Qg/uR23fp361oOrbm/eS/6r/nnJ/c+v/1vwqGxRv7Vvv3s3/HzFz5cv/PAe/8A9f8AChrYtVXyy9Oy7ryI7SC9IizNYn94nXTnb+D/AH+fp361U0WG7OjWhSSzC+TDgNp7k/fPfdz9e/Ste0RsRfvZR+8TpHKf4PY/5+lU9CRv7Esv3sv+ph/5Zy/3z7/57UNajdV8r9Y9F5+RWv4Lr7FCXksiN1p0058580d935/3ugq08F75sH72x/1r5/4lr/8APQf7fP07dKNSRvsMP72b79n/AMs5f+ew9/8APbFXHVvNg/ey/wCtf/lnLx+8Hv8Ay5/Gi2onUfKvV9F2XkY8sN3/AGgv7yz3/ZJiD/Z74x5q/wC119+3Src8F75l3++seFfH/EucY+7/ALfH9PxpJVb+01/ey/8AHnN/yzk/56r7/wCe/NXZkbzLv97KflfrHLz93rz/AD/wppDlVfu/5Lv6GVYwXW+92yWQ/wBKuM505+u0f7XH07U+4gvPsMpaWyI8uXP/ABL3zjZ67v8A9XWp9PRt99+9l/4+7j/lnL/dHv8A571JdK39nzfvJf8AVzf8s5P7n1pJaFOo+f8A4C/yKUMN59gi2y2QHlR4/wCJe+R+6Pfd/nrTr2C6F3Y7pLI/6ZGBjTZOD5Tdt3I9u/WrNurf2dD+8l/1Uf8Ayzk/55H3/wA/Slv0b7ZYfvZv+P2P/lnL/wA8W9//AK/4UNaC9o+d+j6L/IjhgvDJa/vrHlV66c5z97/b5/z6VWt4Lr+0JP3llv8As1pknTnIILv/ALX5n+LoK1YUbzLX97L91ekcvH3vf+X+NVbZW/tOX97N/wAetp/yzl/56P7/AP6+2KGtiVVfvfLou/oCQXm+X97Y/wCsT/mGyf8APVv9vj6d+naqdhBdm0n2SWQG+566c/Xzj/tce3p0rXRG3y/vZf8AWJ/yzl/56t7/AOfrVLTUb7FP+9l/1l1/yzl/57n3/wA9+adtQVR8r9V0XZ+RhePNO1K98E61b2yW9zNJZThYYdOcO/z9FO7r6ccdK2pLa8jgCCSzXbJtwdPfI+QcE7v89adrisNEvT5sv/HvL/yzl/v/AF/z35q7do3z5llP749Y5R/CPU//AF6Lamaupe0vvdbLp8vMyryC6/tO1Bkst2642kac4A+Qdt3/AOqrPkXvm/62y/1f/QOf+5/v/r+NLeq39rWf72X71z/yzl/uD3/z3q1tbzP9bL/q/wDnnL/c+v8An6UktzWVR8sfTsu78jM0+C6OoXWJLLPnw7s6c5B/cjtu/Tv1qxaQXpEWZrE/vE66c7fwf7/P079adpyN/aV7+9m/4+If+Wcv/PAe/wD9f8KtWiNiL97KP3idI5T/AAex/wA/ShLQVWq7v0XRdvQyNGhuzo9kUkswvkRYB09yfv8Aru5+vfpTr+C6+xQl5LIjdadNOfOfNHfd+f8Ae6CrGhK39i2P72X/AFEX/LOX+/8AX/PbmnakjfYYf3s337P/AJZy/wDPYe/+e2KVvdNHUftmv73Zd/QV4L3fF+9sf9Y//MNk/wCeq/7fP0/DvVKWG7/tBf3tnv8AskxB/s98Y81f9rr79ulbDq2+L97L/rG/5Zy/89V9/wDP1qjKjf2mv7yX/jzn/wCWcn/PVff/AD35qmiKVR/n0Xn5CzwXvmXf76x4V8f8S5xj7v8At8f0/Gq9rBdfatR2yWQxcy5zpz9fKToN3H07da1JkbzLv97KflfrHLz93rz/AD/wqrZI32vUv3s3/H1L/wAs5f8Anknv/nvxSa2FCo+V+nZeXkV7iC8+wylpbIjy5c/8S9842eu7/wDV1pIILz+zkKy2QHlRY/4l75H7v13f/r61culb+z5v3kv+rm/5Zyf3PrSW6t/Zkf7yX/Uxf8s5P+ef1p21K9q+X59l/kVb2C6F3Y7pLI/6ZGBjTZOD5Tdt3I9u/WpoIL3zLT99Y8qmf+Jc5z97/b5/r+FSX6N9ssP3s3/H7H/yzl/54t7/AP1/wqxCjeZafvZR8qdI5ePvdOf5f40ktyZVHyL07Lz8jKtoLr7fL+8s9/2e1yTpzkEeY/8Atfr36CraQXm+X97Y/wCsT/mGyf8APVv9vj6d+naktUb+05v3sv8Ax7Wv/LOX/npJ7/57c1cRG3y/vZf9Yn/LOX/nq3v/AJ+tCQVajv8Ad0XZeR554/inHhS0LPa7P7bjBC2Toc/bV7lunt2HHWur1qG7Gj3heSzK+RLkLp7g/f8AXdx9e3SporGC+0uSK9T7REtxcSBJYJGAZZyVbk4yDznsevNSa4rf2Je/vZf+PeX/AJZyf3/r/wDW9eaVvdHBtYnmvu+3Zvy8xbuC9AlxNYj94/TTnX+D/f4+nbrXnvx4sJrnwTdxTyQEs8gjENm0R3fKACWY8c9Oor067RsS/vZT+8frHKP4Pc/5+lYni3R4tb8nT7m4uUikkmYskT7gVCsPvZHUCnJaGfM5wce8ZdPJ+RPYWN7bW1tb+bZDyrZUwdOftGB/e/X8aLGC6/ta5Akst26DcTpzkH92e27/APX1rVk3vcMzSy7mQsT5cv8Ac+v/ANb8KqWCN/bF3+9mHzW//LOX/nkff/PahrYqFRqEl/d7LuvIbaQXpEWZrE/vE66c7fwf7/P079aq6JDdHSLMpJZBfs8WA2nOx++e+7n69+la1ojYi/eyj94nSOU/wex/z9Kp6Arf2LZfvZR/o8XSOX++ff8Az25oa1KdV8svVdF5+Rzvj2zuJ/DEUUzWrpJdaapVLB1Y5ukHDbj+eOegro3gvA0Q82x/1jj/AJBr/wDPVf8Ab5+n4d6g1+xF9pdvFLdTxKs9hKCsErcpcKwX7w4yMZ9+BmtN0bfF+9l/1j/8s5f+eq+/+frTsrmClJVHLvbouifl5mRPDd/2l/rLPf8AZZ8H+znAx5q/7XX37dKtTwXvmXf76x4V8f8AEucY+7/t8f0/GidG/tYfvZf+PSf/AJZy/wDPZff/AD35q5MjeZd/vZT8r9Y5efu9ef5/4UkjeVR+7/ku/oZtpBdefqW2SyGLqTOdNk6+UvT5uPp2615X8edOuL3/AIQ22le2bzNUcDZatF0jB5JJB6dK9esUbz9U/ezf8fcn/LOX/nknv/n6VyHxA8Palq1/4Zktl8+2sbua9umaIjyohCQDhmJPPHA5+lK3umGKq3tHvy9P+AdNBBeNZxFZbIApFjOnv/c9d/8A+vrTbqC6FzYB5LIn7XGBjTn6+S3+1yPbv1q7bhjYQkyyf6uH/llIP+Wf1/z2qO8RvtGm/vZv+PyP/lnL/wA8W9/8/Sm1odCqPmfz6Lt6DYIL3zLT99Y8qmf+Jc5z97/b5/r+Fcp4rjmW6s/Na3ZjbKcpasn8TepOT7128KN5lp+9lHyp0jl4+905/l/jXHeMVP2yz+eQ/wCir1Rxj5m9T/LipqLQ6svqN17fovPyNzSbK3fSLJmnkBNtbEgX0w7+gOB9Og7UX9nbpZQkTyZ3Wg5v5/8AnqM8Z/8A1dRRpOqadHpFkj3lorrb2wINw4IIPIx/P07Ul/qmnPZwhbuzJDWhx9oftKCf06+naj3eUytW9q9JW5vPui21hbebF+/l/wBY3/MQn/56/X/PXrVKWyt/7QVPPkwbSY/8f02f9avv+nQ9TVttW03zY/8ATbP77f8ALw//AD0H+f161Tl1TTzqCuLu02/ZJlz579TKpA/+t3pvlJpqtfaXXv5l2WxtvPuP38vO7/l/nP8Ac9+f8+gqrY2duz3mZ5OLmccX8w/hHvz9e/erMur6b51x/ptn0b/l4c/3Pz/z6VVsdU05XvN15aDdczsP9IfkEDB/z1ofLdCiq3I9JfiSXFjbrYykTyZEcp5v5v7npn/9dJBY27adETPLkohwL6b/AJ4+mf8APTpRc6rpzWMyi8tCTHKAPPfulJBqunLp0Sm8tAwRAR575/1X+P8AhR7tyrVuXaX4jr2zt1u7LE783iA5v5zx5Td88fXr26VPb2Ft51r/AKRKMIP+YhOMcN78fh/Wq99qmnNd2RW8syFvEY4uH4HlNz9M9/wqe31bTPNts3tn9wZzcOOzflQuXUmSrci0lt5+ZXt7O3+3yL58gAtrQ/8AH/MD99/f9O3arUdhbb5f9Il/1if8xCf/AJ6t7/569aqW+qacNQkc3lntNtagH7Q/UO+f6Z9O1Wk1fTQ8n+m2f+sT/l4f/nq3+fpz1oXKFRVr6KXTv2RT0yzt303JnkziccX0w/5bHtn/APX1NGs2dumj3bLPISIJcA30x/j9CcH6d+9JpmqaemnbXu7QNifjz37ykj9Pzo1nVNPk0e7SO7tGdoJQAJ3JJ3/5+tL3eU1tW9ttK3N59y5dWFuXk/fyn943/L/Oey+9VryztxqdqonkwzXGf9PmP8A6HP8A+vvVi51bTS8mL20/1jdLhz2Wq15qmnNqdqy3loVVrjJFw/GUGP8APem+WxnSVbTSWz79mWHsLfc37+X/AFX/AD/zf3Pr+n4VHZ2dudUvAZ3wtxFg/b5x/wAsR1Oc/j+HSnvq2m5b/TbT/Vf893/uf54qOz1TTl1O9ZryzCtcREH7Q+CBCB1+veh8ugkq3LLSW3n3RPaWFsBF+/lH7xOt/OP4PY/r+FVdFsrd9GtGaeQEww9L6Zf4z2Bx/h2q1a6tpoEWb2z/ANYvW4cfwVU0XVNPTR7RHu7RWEMIINw+Qd5z/nt2ofLcbVblekt138x9/Z26WUJE8md1oOb+f/nqM8Z//V1FWXsLbzYP9Il/1r/8v8//AD0Hvx9fx61Vv9U057OELd2ZIa0OPtD9pQT+nX07VafV9N8yD/TbP/WP/wAvD/8APQfl9fx60e7cTVblWkt337Ipy2Vv/aCp58mDaTH/AI/ps/61ff8AToepq3PY2/mXX7+XlX/5f5zn7vvz+P8ASqcuqaedQVxd2m37JMufPfqZVIH/ANbvVybVtN8y6xe2fKtjFw5/u9PWhco5Kt7ukvx7laxs7dnvMzycXM44v5h/CPfn69+9PuLG3WxlInkyI5Tzfzf3PTP/AOuo7HVNOV7zdeWg3XM7D/SH5BAwf89afc6rpzWMyi8tCTHKAPPfulC5bFNVufaX4hDY27WER8+XJijPF9N/zyPbP+enSlvbO3W7ssTvzeIDm/nPHlN3zx9evbpTYdV04WESm8tAwijBHnv18o/5/SlvtU05ruyK3lmQt4jHFw/A8pufpnv+FD5bCtW53pLZ9yeGxt/MtczyjCr1v5xj73vx+H9ar29nb/b5F8+QAW1of+P+YH77+/6du1Tw6tpvmW2b2z4Vc5uHH97r6VXt9U04ahI5vLPaba1AP2h+od8/0z6dqHykpVve0l079y2lhbbpf9Il/wBYn/MQn/56t7/569aqWFnbvaTkzyZ33I4vph/y2Pv/APr6nmrSavpm+X/TbP8A1i/8vD/89W/z9OetVLHVNOS0mDXloCXuSP8ASH7zEj9Onr3o924JVuV6S3XfsxNZs7dNHu2WeQkQS4Bvpj/H6E4P0796t3dhbZfE8p/fHpfzn+Eep/Wqes6pp8mj3aR3doztBKABO5JO/wDz9at3eraad+L2z/1x6XDn+Ef5zQuW47VuVaS3ffyK95Z241O1UTyYZrjP+nzH+AdDn/8AX3qz9gtvM/18v+r/AOf+f+59f0/Cqt5qmnNqdqy3loVVrjJFw/GUGP8APerP9rab5n/H7Z/6v/n4f+5QuXUJKtyx0lt592QafZ251C6BnkAWeLH+nzj/AJYjqc/r26dKsWlhbARfv5R+8Trfzj+D2P6/hVbT9U05dQu2a7tArTxEE3DjIEIH8/8ACrNrq2mgRZvbP/WL1uHH8FC5bCqqtrZS2XfsVNGs7d9Is2aeQEwxZAvpgPv+gOB9O3an39nbpZQkTyZ3Wg5v5/8AnqM8Z/8A1dRUejapp8ekWaPd2issMQIM7gj5/wDP07U+/wBU057OELd2ZIa0OPtD9pQT+nX07Uvd5TRqt7Z6StzefctvYW2+L/SJf9Y3/MQn/wCeq+/+evWqUtlb/wBoKnnyYNpMf+P6bOfNX3/Toepq4+r6bvi/02z/ANY3/Lw//PVf8/TnrVKXVNP/ALRVxd2m0Wky589+vmrgf/W703ykUlW6qXXv5lyext/Muv38vKv/AMv85z9335/H+lV7Szt2utQzPJgXMoGL+b/nknvz9T16VYm1bTfMusXtnyrYxcOf7vT1qta6ppy3WoFry0Aa5kZf9IfkeUnND5dAgq3K9JbefkPuLG3WxlInkyI5Tzfzf3PTP/66SCxt205CZ5cmKI8X03/PP0z/APqoudV05rGZReWhJjlAHnv3Skg1XThpyKby0DCKMY89858uj3bjtW5dpb+Y69s7dbuyxO/N4gOb+c8eU3fPH169ulTQ2Nv5lr+/l4VP+X+cY+978fh/WoL7VNOa7sit5ZkLeIxxcPwPKbn6Z7/hU8Orab5lrm9s+FXObhx/e6+lC5dSZKtyLSW3n5la1srf7fKpnkwLe1P/AB/zA/6x/f8ATt1FW0sLbdL/AKRL/rE/5iE//PVvf/PXrVO21TThqErG8s9pt7UAm4cciR8/zGfTtVtNX0zfL/ptn/rF/wCXh/8Anq3+fpz1oXKFRVr6KXTv2RWsbO3exmJnfPmXQ4v5/wDnsccZ/wD19TzTNZs7dNHu2WeQkQS4Bvpj/H6E4P0796dY6ppyWMytd2YJkujj7Q/QzEj9Onr3pms6pp8mj3aR3doztBKABO5JO/8Az9aXu8ppFVvbLSVubz7ly7sLYiX9/Kf3j9L+c/we5/X8KrXlnbjU7VRPJhmuM/6fMf4B0Of/ANferN1q2mkS4vbP/WN0uHP8FVbzVNObU7Vhd2hVWuMkXD8ZQY/z3pvlsRSVbS6ls+/Zlr7BbeZ/r5f9X/z/AM/9z6/p+FV7Kztzq1yDPIArQYP2+Yf8sz1Oc/4dKn/tbTfM/wCP2z/1f/Pw/wDcqvZappy6tcs15aBWaDBNw4BxGc0Pl0BKtyy0lt590WbSwtgIv38o/eJ1v5x/B7H9fwqrodnbvpFmzTyAmCLOL6ZR9/0B/TtVq11bTQIs3tn/AKxetw4/gqpomqafHpNmkl3aKywRgg3Dgg7qHy3BqtyvSW67+Y+/s7dLKEieTO60HN/P/wA9RnjP/wCrqKtPYW26L/SJf9Y//MQn/wCeq+/+evWql/qmnPZwhbuzJDWhx9oftKCf06+narT6vpm+L/TbP/WN/wAvD/8APVf8/TnrR7txNVuVaS3ffsipPZW/9p7PPkwbWc/8f0xP+tX3/Tv1PNWp7G38y6/fy8q//L/Oc/d9+fx/pVSbVNOOp7xd2m37LOuftD9TKpA/z171bm1bTfMusXtnyrYxcOf7vT1oXKOSre7pL8e5DaWdu02pZuJOLqQDF/Pz+6X35+p+nSpJreKLS7qNJ22ukhbN3KScJx82cge3Q96itNU05ZtSLXlmA107L/pD8jylGRRc6rpzWMyi8tCTHKAPPfulC5bClCrKSupdPyFt7G3axiJnkyY4jxfzf3PTP/6qbdWdutxp+J5ObuMHN/N08lvfj69e3SlttV05bGFTeWgIjiBHnv2Sm3Wqac09gVu7QhbuNj/pD8DymGfz/wAKHy2KSrcz0l179izDY2/mWv7+XhU/5f5xj73vx+H9a5XxXbxRXVoqSMw+zL965kcj5m9en0HFdVDq2m+Za5vbPhVzm4cf3uvpXKeKry1nu7RoJ4JFFsoJWVjzubrnofapqcttDpwKq+395S/q51+jXJGi2A8244trYcSJ2P8AnHp3pNRuSLGH97cffsx/rE7TD2/L071X0m6vRpFkEtZGUW1sAftyDIzxxjj6dqL66vTZwhrWRRutOft6dpRgdP8A9XWquuU4vZfvm7L4u67rzNNrk+bH+9n/ANYx/wBYn/PUH/Pv7VRluP8AiZr+8n/485x/rE7yrUhur7zY/wDQ5P8AWN/y/p/z1Ht/nrVKW5vf7QU/ZX3fZJxt+3J081fb9O9NtE06Wuy69V5+Zry3JM1wfNn5Df8ALRP9j/Cqmn3Pz337yf8A4+7j/lonoKWW6vzNcH7FIeGz/p8Z/ue3+fwqpY3N6HvNtq7ZuZyf9OQYOBkdP/10Nq6CFL3HovvX+Zdurg/2fP8AvJ/9XN/y0T+5SW1wf7MhHmT/AHE/5aJ/zxxVe5ur02MoNo4Hly5P25OPk+lNgur0adEBaORsTB+3Jz+59Mf56UXVx+y93Zfev8y1f3J+2WB824/4/UP+sT/niwqzb3JEtqfMuBhFHEiDs3Ss6+ur03dkTayAi8Qj/T0OT5Td8fr+FT293fCW2xZyD5F6X8Y7N7cf59aE1qTKl7i0W3defmJbXJGpSjzbji1tB/rE7SP7fl6d6uR3J3y/vLjmRD/rE/56sf8APv7VlW91ei+kItZN32a0G37egwBI+O36dvxq0l3f75f9Dk/1if8AL+n/AD1b2/z1oTQVaWuy6dV2XmR6Tcf8Sv8A1k/S4/5aJ3mNLrlxnRL0eZP/AMe8o/1id3qtptzejTSFtZGGLjn7cg/5anPGP/10a1c3raPdh7WRVMEoJ+3IcfP6Y5/rSuuU19l+/wBl8Xdd/U1bm4JeT95Of3jHmRPRaqXtz/xNbP8AeT/euf8Alon9wUtzdXxeTNnJ/rG/5f4z2X2qreXN6dTtSbWQMGuMD7chz8gzzj/9dNtWM6VLbRbPquz8zSe4JLfvJ/8AVY/1if3Khsbk/wBq35824/4+Yj/rE/54Co3ur7Lf6G/+q/5/0/ufSorO6vRql6RayEm4jJH29Bg+SO+P1/ChtaAqXuy0W3dd15mjaXBAi/eTjEiniRP7mKp6Fc40SzHmT/6mH/lonZz/AJFOtLq+xFizk/1i/wDL/GP4Pp/npVTRbm9XR7QJayMvkwYP25Bn5z2x/wDqobVwdL3Xot49V5+Zb1G5IsYf3tx9+zH+sTtMPb8vTvVt7n97B+9n4lc/6xP+egNZl9dXps4Q1rIo3WnP29O0owOn/wCrrVl7u+8yD/Q5OJX/AOX9P+eg9v8APWi6uJ0vdWi3fVdl5kctx/xM1/eT/wDHnOP9YneVauzXBMl1+8n5VxzInP3ev/1qyZbm9/tBT9lfd9knG37cnTzV9v071cmur7zLr/Q35V/+X+M/3fbn/PpQmipUvh0X3rv6hp9z899+8n/4+7j/AJaJ6Cn3Vwf7Pn/eT/6ub/lon9yqVjc3oe822rtm5nJ/05Bg4GR0/wD11Jc3V6bGUG0cDy5cn7cnHyfShNco3S9/Zfev8yxb3BOnQjzJ/wDVR/8ALRP+eRov7k/bLA+bcf8AH6h/1if88WFVYbq9+wRAWjkeVHg/bk5/dH2/z0p19dXpu7Im1kBF4hH+nocnym74/X8KG1YPZe+9Fs+q/wAzQhuSJLX95Pwq9JE/2un/ANeqttckalKPNuOLW0H+sTtI/t+Xp3ogur7zLX/Q5OFTH+nxj+97cf59arW91ei+kItZN32a0G37egwBI+O36dvxobV0SqXxaLp1Xf1NVLk7pf3txzIh/wBYn/PVj6f5PtVLTrkmyn/e3H+suusid5zTku7/AHy/6HJ/rE/5f0/56t7f561Vsbq9FpNttZGG+65+3p/z2OR0/wD19aLq4Kl7r0W66rs/Mn1y4zol6PMn/wCPeUf6xO71cu7gnf8AvJz++J5kT+6Kytaub1tHuw9rIqmCUE/bkOPn9Mc/1q3d3V8d+bOT/XH/AJf4z/CPb9aE1cfsvdWi3fVeXmJe3P8AxNbP95P965/5aJ/cFW/tB8z/AFk/+rx/rE/uVl3lzenU7Um1kDBrjA+3Ic/IM84//XVn7VfeZ/x5v/q/+f8Aj/ufShNailS92Oi27ru/Mdp1yRqV6fNuP+PiE8SJ/wA8AKs2lwQIv3k4xIp4kT+5is3T7q9GoXZFrISZ4iR9vQY/cjvj9fwqxaXV9iLFnJ/rF/5f4x/B9P8APShNWCrS1ei2XVdvUZoVwRotiPMn/wBRD0kTs9P1G5IsYf3tx9+zH+sTtMPb8vTvVTRbq9XSLMJayMohhwftyDPz+mOP6U++ur02cIa1kUbrTn7enaUYHT/9XWldcpbpfvm7L4u67+pqPcnfF+8uOJGP+sT/AJ6qf8+/tVCW4P8Aai/vJ/8AjznH+sTvKtSNd326L/Q5P9Y//L/H/wA9V9v89apS3N7/AGiD9lfd9knG37cnTzV9v07020RSpeS69V5+ZrTXBMl1+8n5VxzInP3ev/1qq2VyftWpHzZ+bqX/AJaJ/wA8komur7zLr/Q35V/+X+M/3fbn/PpVa0ur0XWoYtZCTcyE/wCnJwfKTjpz/kUNq6CFL3Xotu68vMuXVwf7Pn/eT/6ub/lon9ykt7gnTIx5k/8AqYv+Wif886r3N1emxlBtHA8uXJ+3Jx8n0pILq9/s5ALRyPKj5+3Jz+79MUXVx+y93Zb91/mWb+5P2ywPm3H/AB+of9Yn/PFhViG4Iktf3k/CoOJE4+90/wDr1n311em7sibWQEXiEf6ehyfKbvj9fwqaG6vvMtf9DfhU/wCX+Mf3vbj/AD60JrUmVL3Fotu68/MLW5I1KYebcf8AHta/8tE7SSe35frVxLk7pf3txzIh/wBYn/PVj6f5PtWVbXN6L+Ui1k3fZ7Ubft6cASPjt+nbr3q0l3f75f8AQ5P9Yn/L+n/PVvb/AD1oTQVaV3sunVdl5iadck2Ew824/wBbd9ZE7zH2/P8ASm65cZ0S9HmT/wDHvKP9Ynd6hsbq9FlMFtZGHmXX/L+n/PY5HT/9fWma1c3raPdh7WRVMEoJ+3IcfP6Y5/rSuuU0jS/fLRfF3Xf1NW7uCRL+8nOZGPMif3MVnapqcEGtaZHPdSRyTyXKxK8yAu3ljgepqe7ur7EubOT/AFjf8v8AGf4Pp/npXB/Ei5vP+Ew8As9tIpGsTbR9sRtxMJGM44+tU2mc0r0oqSS7brrp38z0b7QfM/1k/wDq8f6xP7lVbC5I1i7PmT8NB0kT/nk1J9qvvM/483/1f/P/AB/3PpVeyur0atckWshYtBkfbkGP3Zxzik2tDaNL3ZaLbuu68zTtLggRfvJxiRTxIn9zFVNAuSNGsv3k/wDx7xDiROzGltLq+xFizk/1i/8AL/GP4Pp/npVXQ7m9XSbMJayMogiAP25Fz8x7Y4/pQ2rg6XuS0W66rz8zG8WeLm0vxL4V0Ly5nXVyh87zlBjMLowAGOhyep4x3rr3uTui/e3HEjn/AFif89VPp/k+1eP/ABJnuW+LHwuMkDxsrS7R9pVt3C8Bh938eleqvd3++L/Q5P8AWP8A8v6f89V9v89aLq5Cp3VtNG+q/lXmMnuM6t/rJ+bS4/5aJ3lWrk1wTJdfvJ+VccyJz93r/wDWrNmvb37aVNkSxt5zzepux5o7+nt361Ymur7zLr/Q35V/+X+M/wB325/z6UJot0n7ui+9d/UdY3P7/VP3txzdyf8ALRP+eSCud1fxXJbeLbTw75UrR3enXV15/nLlSq424x0P1rZtLq9E2pYtZGzdOT/p6cHyl46c/X8K881+4uD8Z9GJgYSjRLwFPtC5we+/ofpSv7pnWi4yja28eqPTbW4P9nwfvJ/9XD/y0T+5Tby5P2jTv3txxeRn/WJ/zxYVBbXV6LGIC0cjy4sH7cnPyfSm3V1em40/NrIuLtCP9PTk+S3tx9fwptqxsqXvvRdeq7eppQ3BElr+8n4VBxInH3un/wBeuO8Yzbr2z+eU4tVHLqf4m9K6eG6vvMtf9DfhU/5f4x/e9uP8+tcn4smuHu7QywtGRbKADcq/G5vTp9Kmo1Y6cvp2xF7L715+Z1mjeZ/YthjyP+Pa2/55+vH/ANf9aTUfM+ww/wCo+/Z9fL/57DH/ANf9ag0m0vzpFkyXLqhtrYgfYozgE8c55+vfvSX1pfiyhLXEjAtaf8uUXeUYPX/9fQ07+7sc9o+2fvL4vPuvI8k8beKtcsrv4ii11N4v7N1DTY7Xbs/crIVLheOhPX/CvYZt/wDaq/6n/j0n/uf89V/z/KmS6RPJLiRkcyykvu06E7yJQBnnkj36dKiltb7+0FBuX3fZJzu+xx8DzVz3/wD1dqbfkY0KajJtzWt+/n5HM+KbqWP4w+E7dipSW2viFWRVQMETkqOG4yBnpnI5rr9P8zfff6j/AI+5/wDnn6CuB8XQXY+Nfg6NrhjL9mvyD9kjG392nbOD/Su3sbS+L3m25dcXM4P+hxnJAGT1ovrsTQUeWfvLfz7LyLd1v/s+f/U/6uX+5/cpLbf/AGZD/qfuJ/c/54/5/wD11Bc2l/8AYZibpyPLlyPsUXPyfWmwWt//AGbGRdOF2Jx9ij4/c+ufT/HrRfXY3Sjy/Evx/wAizf8AmfbLD/Uf8fqf88/+eTVUk1OaDxRoemrHblLu1mlLnZlfL24Hpz5h6+gqS+tL8XdkGuHYm8QD/Qohg+U3v6dvxrIu7e9i8deFQ9wWe4sbyOI/ZYwQR5TE7c4bgd6ObfQxrOMacXzLp37+huW3mf2lL/qP+Pa0/wCef/PR8f8A1/1q5H5m+T/Uf6xP+ef/AD1b/P09qy7e0v8A7fIBcPu+zWh3fYouQZHx3/8A196tpZ6hvl/0p+JE/wCXGL/nq3v/AJ6dKE/I0qqN/ij079l5EOk+Z/Zn/LH/AJeP7n/PY/5/lRrm/wDsW9/1P+ol/uf36g0y1vjppK3LquLjj7HGf+Wpz39fy7Ua1a3y6PeF7l2UQSkj7HGMjf65/wD1Ur+7sa2j7f4l8Xn39DP1bxHPb/EPT/DiQWzx3dtPdvLhcoU2gAY4INbN7v8A7Vs/9R964/55/wBwV87/AB6e/j+MWhIJ5RLDJbxB1jEZ/eODjapx2/HvX0DeWl+NUtQbly264wfscYxhBnjNNyOLCTUpyi2tE+/Z+Ry3xT8dt4Ltrd4o7S4uHjMj27JktCFAYqw4B579+1cq2t+JG+JT+FLW6lF3e6pDrEd4PL8qKwEYJhPH0X0zXqd7pM92uy7dJ1WMsBLp8LAfJ15PHHeks9OujrV3IsmJ0mjTzPsEO7BhBx14Ht079aG2EqHPd+0VkvPy30OV+CHiCfXPCMD6hqNvdaj9unUrLJGZAiswXI64Ax7V2OheZ/Yln/qP9TD/AHP75/yf1qDTNDe3limtlhimLqu+PTIFY5TpnPP+TSaLa37aPaMly6qYYMD7HGcDecc5/wD196Lu+xtCCjScZTjvHv5+Ra1HzPsMP+o+/Z9fL/57DH/1/wBatvv8yD/Uf6x/+ef/AD0H+f8A61Zl9aX4soS1xIwLWn/LlF3lGD1//X0NWns9Q8yD/Sn5lfH+hRc/vB7/AOelF9dimo8q96O779l5EUu/+1F/1P8Ax5z/ANz/AJ6r/n+VXZt/mXX+o+62ceX/ALNZUtrff2gB9pfd9knO77HHwPNXPf8A/VVye01ASXWbt+FfP+hRDH3fehPyHJR933l+Pf0G6f5m++/1H/H3P/zz9BUl1v8A7Pn/ANT/AKuX+5/cqpY2l8XvNty64uZwf9DjOSAMnrT7m0v/ALDMTdOR5cuR9ii5+T60J+7sOSjz/Evx/wAie33/ANnQ/wCp/wBVH/c/55Gi/wDM+2WH+o/4/U/55/8APJqrQ2t/9giIunUeVHx9jj4/dH3p19aX4u7INcOxN4gH+hRDB8pvf07fjQ3psFo8795bPv8A5F+Hf5ltjyPur12f7XX/AOvVW28z+0pf9R/x7Wn/ADz/AOej4/8Ar/rSwWmoeZa4u35VMf6FEc/e96rW9pf/AG+QC4fd9mtDu+xRcgyPjv8A/r70N7aEpR973l079/Q008zfL/qP9Yv/ADz/AOerf5+ntVPTvM+xT58j/WXXTy/+e5/z/KnpZ6hvl/0p+JE/5cYv+ere/wDnp0qrY2t8bSYrcuoD3XH2KLtMQT19fy6Ci+uwJR5X7y3Xfs/Im1vf/Yt5nySPIl/uf3/8/wBK8qg1nxQfiHJ4RuLuYXFrqUurTXzeX5LWDJ8kf0DED0yK3vjb/adj8Ppp4r2VX+0wqCttHGeblB1B/wA9OldteaZdGWaRpR5jSGNnOnw5I2j5Sc9PbpRfU55KNSSpqSVnfrrfpt5Hm/gq/utQ8fZsfEMmraTBHcwyy3c0J8+4xktDGPuoo4z0PavVPn8z/lj/AKv/AGP7lcjcLa6f4507SIY0h1OeC6uEeLTIEAjUAHJB9e1dL9k1DzP+Pt/9X/z5Rf3PrQm+xVKMVFLni9PPv6Bp3mf2le48j/Xxf88/+eA/z/8AXq1ab8RY8n/WL12f3P8AP/66ztPtb86hdBblwRPECfsUR3HyRjv6f41YtLTUCIcXbn94v/LlEf4PrQnpsbVVH+aOy79vQj0Lf/Ytj/qP9RF12f3/APP9afqPmfYYf9R9+z6+X/z2GP8A6/61V0W1vm0iyKXLqphhIH2KM4G/jnPP9e9V7qS4edrD7RM08KWEzj7DFt2yTlUIO7k5RvrxnrSv7uxcuRVtZL4vPv6G8/mb4v8AUf6xv+ef/PVf8/T2qhLv/tRf9T/x5z/3P+eq/wCf5VK9nqG6L/Sn5kf/AJcov+eq+/8Anp0qnLa339oKDcvu+yTnd9jj4Hmrnv8Ar2pt+RFJR/mXXv5+RqTb/Muv9R91s48v/ZqrZb/tWpf6j/j6k/55/wDPJKWe01ASXWbt+FfP+hRDH3feq9paX5utQC3Dgi5kB/0KLk+UnvxQ3qtAgo8r96O3n5eRaut/9nz/AOp/1cv9z+5SW+/+zY/9T/qYv7n/ADzqmY7m50t57e/E8DRzYeO0iZWwnOCD7VJBaX/9nIRdOB5UfH2OPj9365ovrsUlHk+Jb+f+RYv/ADPtlh/qP+P1P+ef/PJqsQ7/ADLX/UfdXGfL/wBqqF9aX4u7INcOxN4gH+hRDB8pvf07fjU0FpqBktcXb8qmP9CiOfve9Ce+hElHkXvR28/PyG23mf2lN/qP+Pe1/wCef/PST/P86uJ5m+X/AFH+sX/nn/z1b/P09qyBHdQXFzNPe+VHHa2zyTPaRBQvmSckk4A4PPfv0q9HaagWkIu3I3p0sov+ere/+enShPyHVUb/ABR6d+y8huneZ9gm/wBR/rbr/nn/AM9j/n+VeWfGHXdc8OaoyxPLNYa7YSaZZRweXttrwyZ8xvqDxj0rrvEtxqOl+H7e4iupI9+rrAf9FjXKtehXHBOcgkEe+BWvr2n3UmkXD3EvmiOKV1DWMXBD9Qc8H3HSlf3TOcY1qzpqSXvb69W9tDybxbf674e1S7mvvFi6mtvcWdtLplncmG4VnRVZlXbhgxy3p1710HxRu2/4Wn8O7MmPd9vmmAG3b93HbivQb/R5nuGuZmja4jkYLK+nQ71wmeGzkfh9a8p+JVreN8cPAuZ2Z4mfJ+zIuzcxA+UHB/Gnc46tNQgveT1Xfv6Hsvz+Z/yx/wBX/sf3Kq2O/wDte7x5P3oP+ef/ADzNL9k1DzP+Pt/9X/z5Rf3PrVeytb86tcgXLht0GT9jiOf3ZxxmhvbQ9CKjyy95befdeRpWm/EWPJ/1i9dn9z/P/wCuqeg+Z/Y9l/qf+PeLr5f94/5/nT7S01AiHF25/eL/AMuUR/g+tVdDtb5tJsyly6qYIiB9iiOBuPcnn+tDeuwNR5Je8t138/I8/wDiPDNP8XfhWkKI7gzvhduNqqpJPbgAk5r1R9+6L/Uf6xv+ef8Az1X/AD9PavMfF8RPxj+GFvPI8lz5V44byFXgwjYQoOG5B69a9Faz1DdF/pT8yP8A8uUX/PVff/PTpQnrsc9OcZSlHmWj8+3p5Ec+/wDtYf6n/j0n/uf89V/z/Krk2/zLr/UfdbOPL/2ay5rW/Gp4Ny+77LcHd9jj4Hmrnv6/l2q3PaagJLrN2/Cvn/Qohj7vvRF+R0yUfd95fj39BbHzPP1T/Uf8fcn/ADz/AOeSV5Zq05k+P9tCDHui0K5znbjlc/SvS7O0vzNqQFw6kXTg/wChRcnyl9+K8cmjuT+0rdxGZjKmiOS32dM48rONucD6ilf3TDEKPND3lvHv/ke2Wu/+z4P9T/q4v7n9ymXm/wC0ad/qP+PyP/nn/wA8W/z/APXqK2tL/wCwwkXTgeXFgfYouPk+tNurS/E+ng3LsTdxgf6FFwfJb35+n4029NjoSjzv3l179vQ0Yd/mWv8AqPurjPl/7Vcf4x3fbbPPl/8AHsvTb/eb0rp4LTUDJa4u35VMf6FEc/e965PxZDcpd2gllZybZSCbdE43N6Hn61NR6HTl6iq+kl+Pn5HWaNa50WwPkz821sc+Unc/5x696NRtc2MJ8mfl7M8RJ3mH+R696p6VpmmvpFk72lmztb25YmB8kk859/X17Ul/pmmpZwlbWzBLWgP7h+8oB/Tr69qd3ymGntnq/i/l815mw1r+9jHlT8yMP9Un/PQD/P8AhVGW2xqi/upv+POc/wCrTtKtQX9potjA91dwWEVtBvkkdoWUKokzk5Pp/hXD+BtbTxDrFxa6p4ftdNb+zmvrX5GYTwSS/IxH8LAYyMn71NtmUKlOMknJ636f8EoeJrgf8NJ6BYsrBYLGchWQAgvGew4/hr1DTrUb7791N/x93H/LJOwFeQ+IrPTY/jravCkW0TW9qyJEQnzW85Iweey16lY6ZprvebrSzO25nUfuH4AAx/ntSu7mOFacZ6vft5epoXVsP7Pn/dTf6ub/AJZp/cpttbY0yE+VN9xP+Waf88c/5/xqnc6Xpq2MzC0swwjlIPkP/c4qI2OkQaN9pubeySOOJZJJDA/yqIck/wBf1qru503jybv7v+CaWoWg+2WA8mf/AI/UH+qT/nkxri9bmA+MXgewCzfPY3UhTy0ydynBA6H7h6+lZvg7xHFr2s2dnq3h2w0mS5Md9ZjLSG4tmWQD5eCCNo3e59Kj1XTtPPxr8MhIbTy0slWWMRMVyy3R+YdSflHIqbs48TOMqUHFvddPN+Z6RbWudTlPkz82tof9UneR/wDI9e9W47X55P3U/EiD/VJ/z1Yf5/wrHt9M0038iG0s9otrUgeQ/Uu+f5DPr2q2mlaZvkzZ2X+sX/lg/wDz1b+n6cdaabOury33fT7PkvMTSbUf2Xnyp/8Al4P+rTtMaNctsaLenypv9RKf9WnZ6zIrbSbXQbi8urexEcMdzI7tEwwFkbuTgcDg9u9croXiGy1601O3vNAtNHu009b22jd/MeaGUkq4A6EAe+MjNK75S+eCxCTk783bz9ThvjfDEfijptuVdZTqNkApVQQpVu3TrXvF9a/8Taz/AHU33rn/AJZp2QV4d8WLC1j+J+lC3SONW1SyQrHGQpXy3J4PP4V7JeaZpq6naqtrZhWa4yBA/OEGP89qHc4cFb2s9Xs+nk/M1XtsFv3U3+qz/q0/uZqGxtB/at+PJn/4+Ihjyk/54g1A+laZuI+x2f8Aqv8Ang/9z/PNRWemaa2p3qta2ZVbiMAfZ3wB5IP5Z7U23oda5eWWr2/l815mraWu4RfupjmRRxGh/gzVLQrUHRLM+VN/qYekSd3P+f50lrpWmYizZ2f+sXrA5/grC8LzaJqDXOnLZwG7sIbQzs9u2CZMsMHPPHXge1DbuDcVFrme66evmdDqNrmxhPkz8vZniJO8w/yPXvVt7XEkH7mbmVx/qk/56Af5/wAKx7/TNNSzhK2tmDutAf3D95QD+nX17VafStL82EfZLL/WPnED/wDPQdf89OKLu4Pl5Vq939nyXmEttjVF/dTf8ec5/wBWnaVauzWuJLoeVMMK/WNOPu/49qxZNM07+0FQWtntNpM2PIfr5i4q5LpOmGW5As7L7rYxA4/u9PSmmxy5fd1f/gPn6j9Otfnvv3M3/H3cf8sk7AVJdWw/s+f91N/q5v8Almn9ysXw9FpGqWlzdQWtoYjd3UahrdsjYSuMZ45U4HbvVy50vTVsZmFpZhhHKQfIf+5xSV+UFKEpJqT+7/gly3tsadCfKm/1Uf8AyzT/AJ5E0uoWg+2WA8mf/j9Qf6pP+eTGqMOl6abCJjaWhYxRknyH/wCeZpb3TNNW7sgtpZANeIp/0d+R5TcfTNDbsNcvO9Xs/s/8E1YbXMlqPKnOVXpGnP3v8O9Vba1zqcp8mfm1tD/qk7yP/keveo4dK0zzLbNnZ/dXOYHP97r61i6DNoOravq1vZwWUg077LbSkQsy+bkswBBPQMAenII7UO+hKcfe1fT7Pn6nUpa/NL+6n4kUf6pP+erD/Pv7VS021xZT/uZ/9Zdf8sk7TkUiaVpm+X/Q7L/WL/ywf/nq3+fpx1qpYaZpr2kxa1syQ9yM+Q/aYgfp09O9O7uC5eV6vdfZ8n5nK/Hi2A+HUm6KbBvLcHMaj/l6Qdq9Cu7XaX/dTD98RzGn90eleefF/TLFPB8P2e2tkkOoWyhkiZTzdJ3PHT9OOtdrdaVpnz4s7P8A1x6QOONo/wA4ou7nPDl9tLV7dvN+ZwurvFL+0Fo1okcnmW+k3ZcbF3DJyMjpXo/2UeZ/qpv9Xn/Vp/cryT+xbR/j7PdFLc2scD2yw+W2wE24fIXqOfWvTf7K0zzP+POz/wBX/wA8H/uUJsjDuL57t7vp/wAEl061zqN6PJn5niHESf8APAGrVpa7hF+6mOZFHEaH+DNZOn6Zprahdq1rZlVniABt3OB5IP8AP/GrFrpWmYizZ2f+sXrA5/gpK9jrq8vd7L7Pl6i6Fag6LYnypv8AURH/AFad3rl1kjl8e6vaiJjIlnpOcRru/wCPiQnv33j9K29G0zTpNIs3ktbNnMMRJMD5J38/5715vp08DfGbX9N+zWws/stiF/dMVLI8JPA56TnPr+VS78pFdpYiNm/j7f8ABPY3tfni/cz8yMP9Un/PVR/n/CqMtt/xNFPlTf8AHnOf9WnaVaH0rS98X+h2X+sb/lg//PVf8/TjrVOXTNOGoqn2S02m0mbHkP18xcVTbNKXL3fX7Pr5mzNa4kuh5Uwwr9Y04+7/AI9qrafbpHe6g0kM+xbuQt+7ToIkNRTaVpnmXOLOy+62MQOP7vT0rivH+saH4V0i/nvLazJuL2S0iAiZSuYAdwz1CnnGR1obehm5QjSk3J7dvTzLHwqkjv8A4Y28kUchRPtsYKopHDv3P1rs7e2xpsR8qbiGL/lmn/POvKPgFp0B+E6fb7aA3Uct2CZImZhxkcj616VBpemtpyMbSzLGKM58h858uhN3Jwtvq8bt/d/wS7qFoPtlgPJn/wCP1B/qk/55MasQ2uZLUeVMcqnSNOfvf4d6yr3TNNW7sgtpZANeIp/0d+R5TcfTNTw6VpnmW2bOy+6ucwOf73X1oV9TWXLyLV7fy+vmc58RbcJ4J8Xv5UoxoYbJjUDnze/XFa/gMm/8G6LdskrtNaW0hZY1IO4+p5/zzXFfF+60jQvA+v8AmQWaz3enxWlqnkPuaWQyj5T03bQTn/Z4rf8Ahlpuly/Dzw25trV2On2m5nhZiW/i5HH/ANbjrQmzGrOHtnG72XT08yDxxa48N6eNkqZ16MZaNQP+P0DtXVa7bAaLenyph+4lP+rTs9cd4z06y/4R6wligtllXXIlDLEy8fbQMEntj0rpdZ0zTo9Hu3S1s1cQSkEQPkHfxS15TSm19ber3XTzfmbN3a7RL+6mGJGHMaD+DNeO+MLtX+OlhpxXLQtahV8ob1y7se+B/hXql1pWmYlxZ2f+sbpA4/grx/xHpNonxkMqQxCE6nYwFBGQhHku33evWm27GNSMZKKbfXp2Tfc9t+yjzP8AVTf6vP8Aq0/uVVsbUHWLseVPy0H/ACzT/nmaj/srTPM/487P/V/88H/uVXstM046rcq1pZlVaDAMDkDMZzQ29Dpjy8stXt/L5rzNe0tdwi/dTHMijiND/BmqegWudGsv3U5zbxHiJO7Gm2ulaZiLNnZ/6xesDn+CquiaZp0mk2byWtmzGCMktA5JO7mm73B8vI9Xuvs+vmeaeMSy/tF+AYjHKI1sgcGNeTIJhx2P3e9eyPa4aL9zPzIw/wBUn/PVR/n39q8c8VWOnp8W/D0kcduEjewheNYyFJdbsnd3J4H17V6q+laXui/0Oy++3/LB/wDnqv8An6cdaSbucGHt7Ser37evmE9sBqw/dTcWk/8AyzTtKv8An+VXZrXEl0PKmGFfrGnH3f8AHtWNNpmnf2nsFrZ7TaztgQP181cfp09O9W5tK0zzLrFnZfdbGIHH93p6UK53y5fd1f8A4D5+pLY2g8/VP3M/F3IP9Un/ADyQ15HNZf8AGQt/K0cg/wCJU6AeWuf+PfP0Ar1Cz0zTWm1ENaWZ23Tqv+jvwPKXgfjXndxBZz/FW7UJE0UMbRhCjFVK2WcAdRg0ruxzYlrngrvePT/gnqVrbD+z4P3U3+rh/wCWaf3KZeWo+0acPJn/AOPyMf6pP+eLGqltpemtYwsbSzLGOIk+Q/8Ac5pt1pmmrPYAWtmA13Grf6O/I8puPpn/ABptux1Ll53q+v2fL1NeG1zJajypjlU6Rpz97/DvXHeMYdt7Z/u5Bm2U8ooz8zeldHDpWmeZbZs7L7q5zA5/vdfWuV8VWlpBd2iwQ26KbZSQsbDnc3XPU1NS9jpwFvb6N/d6+Z0mk3lumkWSmGTItrYEjTZT39QMH69+1JqF7btYxbYZCwa0POmyjP70d8d//Hugq3ozN/Yth+6l/wCPa2/5aS+v0/z2zSak7fYYf3U337P/AJaS/wDPYe3+e2aevKc14+2ej+Luu68jgdT1HxB4p0W00u/8IXOjR6hMYb64dFlWCHzCT5YQl2Y7doBUAZxzTviRqX9l6noHiCytZjHYNMl+RaSoBaSOFclcYbaSrA9F24616QzN50X7qX/WN/y0l/56j2/z9az7j95qGx4pSr2M6t+8k5BlXPb/AD35ptM5o0lJO979NV0vY8Wu7jT5/HsOuWEqXFtfeKEVZYoX2MiWqqNo6HlzxkmvZLG7t1e8/cyHN1ORjTZT/CPbj6dq80+LOiReFfCeiWvhG2/sqO01iJodheQxM7KN2HHzHJ75/lXX6L4Rt44LiK8vfEF5OlzOHnfVbtGkbA+YqhCg89gPelrczoNwhKPLd+q6/IzrjxvLqtzqVn4T0q01O3s4XE93KskcfmMv+rXajksACTu2gHvWfd+IL7xd4YfQ7Xw3reky3CLFdXVzYGNIIRGu8o3zBywyFAGTndwBXfWOn2uj+HfsGnWskNrDDMEUSynGUJPJGScknPvzVu2dv7Mh/dy/cj/5aSf88fp/n6VVnc1lCUo7u19djifGd9ZaL4k8IaxOIINKsbl7S4murOSJYllgG1ucZ5jxj3z6Vh6Rdafe/FGbVImll26jbWij7LJIgVbCYkbR33MT2PfFek+IrO31SOCx1Cze4tLi5WOWJ5JcMphYEdM/j19K858dWNh8PfCttd+Gon0yYzvOJmmlkJm+yXCo2XznsAOnH1panNXp8seZ3to91pbQ9Dt7y3/tCRvJkwba0H/INlJ+++e36/xdBWBf+Mbl/Et1pHhvR7fUZLRUkvZZ45YUt3aU+XFhUdtzDJwQBtwM5pNC8JqhC6pqGu396ba1kluf7Suod7NI5OEjIVV7Ko4AHGTmul8P6RZaHBcW2mWcsUctyJ5SZpmeSRpTl3YgszHAGSc8cc8ULmOqo23rFrbquy8jytvElx4w0nS9Dt/Dt8N127azIttIsNqkc5eSEyYG9iABgAcMB14rW+KV9ZWOp+F9UNnjbLc2UtxJbPbxwxyqyhnZhtwG2n2xivQNJYjS+IpRkXH/AC0k/wCex56f5781F4miju/Dmo29zbNLBJazI6O8hDAvzkY/z35ot7oKlL2lm7y5t9Oj6nkXxS1HT5tZuNW0y3bVJ7XUtLlto7e2ddxZJCUHoWUqQDycgiuobx9Nq032zw74Vv8AUbeFpkilNusKSSkBXUgtvATnJCkgjpjmqWs+ErfwnY2Fvby3c8Nz4otZk8+R2aNAoVY9xGTtAwD1xgdsn0m8YjVbPEMo+a5/5aS/3B7f570NM5cNCftHutHfbs/08jyrULHVvD0lj4pkNxqWrRyyHU4jBcGFLOQfMsSkYAjHzZCgnBNa/wDwtfwubm7OhM+sahdTIbCyg0yZWuyIwuFLAADcDnPoT7V6O7ElsxS/6r/npJ/c+n/1vwqvYYGrXxFvJkXEWMPLn/Uj/Zz/AF/ChpmypuKl7PRW1vZ9V6Hnum/GPwzBYxLr0U+l62jDzdLm06V5QwQjapAwwY4xkjOQTiuc+Fviq107WfFmoeKlOjQ3J08232+3OWj2vt6cDKqTjvg+le22uD5RMDsfMTnfJ/c9h/n6V5OiAfEXQi0RIb+z2wWc5xBfD06+np2od7ozmpxs5O+q7LpL1/I3NX8d6VqUFjYeE5tO1bUbh4cqIZNsAjO4vIUViAW2J0+YuAOhrGl0e28D2+m+JII9Qvb+3ffrk0v2lRcxKpRn2yHYxUsGC/LwMDmvS9QwtjDtgcfPZ8h5B/y2HoO//wCrNXJGJkgBhlI81+DJLz+8Ht/L+dFnc2lC8bu+7ttpojhn+IngxtQV11/Stv2aWPPlEfMZFI/QHntRqPxU8ER2+pyxa/pzPGkoREt3DOwxjYOvJBwefXvXUyqv9pr/AKO3/HnP/FJ/z1X2/wA9+ade6Vp8+qPfT6VC97Ar+TO6uZIs7ejFcj9Ov0ppMupzO1uz7dzzH4SeJtN0LwEsvim9gsprjULt99zC7BnfD7Q/AY/N+Fa/iHx/YX2nw2Pgu707UtVu5HiIW1eQW8Xl5aZgvOB27ZNZWl38F38V10qS2WV7bUdVvNjbj5ZMcahsYyD15969RuAF0+crA4Plzch5B/B9KSvY5MK3OCgrq2m6PLtC1I/D2dbLxFqF5eaBfIksWsalG+YLjyjmAggbVbqpzjiuy17xh4b0+bTZb/UrG1ia5SZWntXQNGIiCwz1HzDp65rTvtNsdX0SG21bTY7222RP5VyHkTcIjg4ZcZ/z0rOTwh4c0y6tRp/hyyt/OuBBJsicF4miYtGTtyVJAOPb0pO9jqinGbSTtr1X+Wpm6l8T/CFjaySQ6zpU95bwFltjGQXkVXIQ+5OBn3HpXL/CaW38Ip4xl8TX0Ks19bXVzdSWbrGskqI7DoNq7nwM43DpXoWmeEPDVjdW8tn4Y0yGUhCXityrHknqEz1APHpXm0GkWXiH40axp+s2rXunoEuvskkknltKsVoqsyj72FdwMggbjjtTle6Je7lZ/eu68jtvFXjaw0yFrTS5LGbxBdyRJY2dxayr5hacruwAW2DqcDkDHWsvwp41jtb2+0HxatrZasJZjaOlpIEvleVjmIHlSp+XaeRjvXYaN4d0TR7qafSdCtLKcsqGS3jaNtvmnjIXPYfl61n6v4b0jxVokln4g0v7ZBHPcyoHklBRhM3zBgAR6HnnvRrcOWWs1fdaXVtn/WxzXxY1/RJ9OsNFN3brqct/ayLaNbtFKyfaVOQD2wD+AIrsvEmv2OkaTf6jNGVjtS8v7ywliU4QEAsRgAnj8c15v8Qfh7pGnz+GNX0m0lguLXVLaOV5Z553ki80Roil87QuRwPT14roNUiXx34vvLaWW4l8L6RKElhjll8u7u+CVdtvzCMKMj1YZ6Ue9c54zaqSvF3e2q8/I8n+C2tWlhqc2pa40VlGb+6lkaWJpEj32+QNw479O3WvoDSvEWj6vALrSp4721KFRLb2MkibgnIyO4P+NcL4R8Etb63rEnibSLaeG+1a4u7WCVS4jCx4VsYIB6Ed8dcV0GpeCkt2nufBs0/h3UnQufspc28zbP8AlpCV2nPOWAB560RuPDwlSppuLd13S627eRvWF7bLqF0WifDTxH/kGynjyR1GP079ai0jxNol7evZWl1DcXltInnwR2UkjxfIR8wHI5B479a5nRvBQ1iS5n8brLqGsPKI5WtLy7hhWJ41byUUH7owvPU4qiPDmleAvEXhLUtA0iGy043MljfThpDIfPRfLy+Cx+dcDnjdjoaFextVqte9KDSsuq+XQ2tb1mfTvAatpFqsuqPDb29sJbORE82SUIpLkYwC2ffGK8m+E2sQXWo6beXCpGxTyG3xFgRF/Z6Fl/vElG4HPX1rvvC2nXfjC/sdb1GYvoOlSGLTbBDLtllRyguXbAPUMVXHGR3yDpab4D0XT/BOiaZqOiWl5JaC2DPIryDfJKDKVJXgMSf0xmlZ2JletilUhe19Nu6/M7Fr+1LQkRSEGR+RpsvP71fbn6fh3qnLeW/9oK/kyYFpMP8AkHS5z5q+369ulc5P4N1Dw/Fbn4fX82nLEzBdMvpJ7izf94eBkb4zuYElG52jIzWbF4a8Zx6sdQPitk1KaKW4mtDBLJZBQVXyUUneq7uS27njIyKbua06lvsPr1Xn5HoE99beZd/uZfuvj/iWzD+77cf0/GvDP2gLWXX5Ly0tkjS204S6g+6BoWLOYolAU89ycfpzXT61b+NPCk82ofb9Q1251O3uIruFY53itrgoDE0SKuUjBwpLHngnHWtzQvAWnQ6Zq9perd3epXTiK91KWWV55zGkbcsynA3DOPT8DSd3oc8261OVOMWtOrXlboY/hrxL4Y8Jabq+hatq2n2d5DdXC+TPGd2GiXacn1PT0rv7XUbR9MjMaO48mLDJp8pH+r7HH/6+tQeIfD+i6xHLd6roVne3Kxy7ZZ4mkZflzgEqeh5rD0n4d+HtN05jpNpqWmmdYpJfsmpXcQY7CeQDj/PHFOzTNqalTpKKV7eaX6Mm1L4g+Dk1C3jk13S0eC8Uyq0DAoBGwOR7E4x681taF4i0jWLWxvdLlF3aOABLFp8rqSC4IOByQRz/APWqOy0PTNBj0yz0jSltbdL1MIjSZP7pySSVySSScnmuATTr9/EWv+FrOHU/smsalHd3F2qyiOC3aIPKquMfM7ZTAycFzijXUKlTkhFtPbuv8jmPHGo/8J94y8LSaJHJL4ftr+2glf7O6C6lHmOxVOrBFV1ycEkkAHBNdN4A8XP4T8F2+meKPDmt2s+mCNJpzpbyxCPzWJk3qcbVXG7PPYdK7+y0izi1LT1trSSGLS4bZ7WON5Aq/wCujxjb02uw479Oa3kYlpQYpSPMXjzJf+ere3+frQk9zKdGam5397Tt2X9I8t8Q+LvDOoaPp8dlrGmzNDq8F3L5Q2+XC12rBmOeBhhx1HQ812uu6rYr4evZn+SAWsrmV7CRUA39SxGAMd+g6Vyfjzw9o+oWujXt9o9vNdDW0tzJKjOXja8wYzuXleTxz1Peodc8B31pbXEWkaxPB4ZZvtEmkTpJKkYSUOUibjajEYKnI5PfAqdbFwlNYl6Xd11S118npf7l3NOL4l6He63FZxwtFY3rTfYr+S1KpeSLsTZEuSxGW6kDkcZrnPEtxEfiVv8AKcKNdsjg2UinH2Z+ikZ/4D1716b4o0mz1zSbzT9RsjJbyu+AzSHY2zhhxwwOCDwa85u/D+oaFeeGpNb1GbVdWvPECPPdsJE3BIWVFA7YHpzyciqdyY8+ikrqz107P+v0PS/t9t5v+pl/1f8A0DZf7n0/X8aybnxFo2i3dzeaxcQWNoXt1825spEXPltwc/y79aTUPGmjWeqT2Alubu/ghLS21ks9xJH8mMMEU7TnscflWZ4e0qTXvEc+s+KNFKTKsMdpYTzvMII3iYMWAXbvcYz1wPlHGaHfQ1daNnGKbdu601XkdPa6rYLbxTyfJbhkdppLCTYE8vJYtjG3HJ/PpXFaJ47GnQ26+JNFbStGlhQWepvA0kci+YdplwP3ZdcEckEcEg0un+B9bSzm0T+3n/4RWe5BFokMonSAgn7KsuThNuBnG7BIGBXV2OnWeo+EINLvbJprCayjgeFpJdpTdjHA9OPbtzRrcmTnJNxTSVtNHd6+W3+fkeQeIbsyfEiO7KfuF1/SLaPNs+SBbyM3B9fN+71bqK9te/tt8X7mX/WP/wAwyb/nqvtz9Pw715R4u8OWvhO28Jx2kl9OLrxVY3TPdTyO6/KyKittztVVAGcnA4JrodN1LxF46js9T0fUF0Xw4803kvbiSa6uAszJkmRNiKTsbAVjxycnFCvc56MlCo1JO7fRrz8ifxZ4uGn60lpoekPq+q/ZZnktVt2g8iLzQfMdn4UYBC+/HvVm78faFJ4cuNXsJBcrNHst4oLJpGad1QpCMEgPlgCM8c1a0HQItD1Kd999e391azG6vbqaRpJiJhjPygBV3EBQAOfWrF34S0OTxJPrb6T/AMTJSZBJ5s2A6qFVyuNpYBiAxGeevShXOmSqOz7ry01/H8DhdIvtW8Eu13rFxPqOi3Vwzak9zYyF9OlaJSzqwA/dbjt2nlQFI4JrP8NXEF74xvNat54rqx1G/v8A7NLHbs6tHHZqvGPft7Z6V69bASvq0ctvI8b3UoZWeUggxJkHjn8fx4rzr4m3lp4W/wCETltrJbWytGvVSGHciKDbHgDAA5POOaVnYxrwVOSkr2Vnujr77xLomiaRDPrN1FYQbYV82eykRc7OxPX8OvasTwfreoa3Hb6trFsttbz36GytorCR1+ziN9kjHbkuwIJAOMYOBzUHgzwfa32gadq3i6yfWNdmhikaW+Z5VgBG4JEm3aijjGBn3NdxeM32jTf3Uv8Ax+R/8tJf+eLe3+fpTadjpg1Unz2drPqu3oNgv7bzLT9zL91M/wDEtlP9725/r+Fcp4rnilurNkjYD7MoObR4z95vXr9a7eF28y0/dSn5U6SS8/e6cfy/xrjvGLH7ZZ/JIP8ARV6u5z8zeo/lxU1L2O/L2vb6J/evPyNzSpbwaRZBDYbfs1sBuu5QcZ7gLgH1HbtRfy3n2KHebADdadLubOfNH+z+fp2q3o0z/wBi2A+1oP8ARrYY8zpg9Pu9v096TUpn+ww4vEHz2fHmdMTDj7vbr7e9O3unPf8AfP3ftefdCNLfebEf+Jf/AKxv+Xyb/nqP9n/PXrVOSW8/tBf+PHf9kmAH2uXGPNX/AGevt36mthpn82P/AEtP9Yxz5nT96Dn7v4/5xVGWV/7UUfa0P+hz8eZ/01Xj7vem0RSlr8Pfv5nOePbG81T+zQ9va3KQ6rbzMkVzI42iRMsxIyFHXI549q27GW833mw2B/0mfObuXrgdPl6fzrWllfzrg/a0OQ3Pmdfuf7P+cVU0+Z999/paf8fdx/y09h/s96GtUTTVoyly727le4lvfsM277Bjy5c4u5c/c/3f/wBdJBLe/wBnRBfsGNiYzdy5x5Xpt/z06VcupX/s+f8A0pP9XN/y0/2P92ktpX/syH/SkPyJx5n/AEx/3fw/zmnbUvm934fzKt7Lefa7HcbAf6YhGLybr5TdTt6e/Xt0rzT9oC1vdV8KaDp5a2Q3WqWtuGhnkdgWEg6EYxz/AJzXqt/M/wBssD9sT/j9Q583/pk3P3fwqK80+11STTBqEkcotJI7mEtMV8uRN+1uB2yeORzSUdzGunOko26eZWtZLxb1xmw3i1tAQbuUDAd/9nr6jt2q4kt9vk/5B/8ArE/5fJv+erf7P+evWi3mf+05f9MQf6NaceZ0xI/+z2/T3q5HM++T/S05kT/lp1/esc/d/H8fwoSNKstfh7d+yMbTJbz+zcJ9hIxP967lz/rj22//AK+po1mW8Oj3Yf7Dt8iXO27lJ+/6Ff0796taTK/9l/8AH2nS448z/psePu96Nclf+xb3/S0P7iXjzP8Ab6fd70re6a837/4ftefc5j4iyXTHQBMbPZ/b9scx3MrnOOOo6e/Wt+8lvP7TtSxsN26424u5SPuDvt//AF96zfiUzPZ6OxugzL4gtCNr59efuj8/0rcvZn/tWz/0tD81z/y0/wBgf7Pem0cmHnerL3enn2Yx5b7Lf8g//Vf8/cv9z/d/T8Kjs5bz+070qbDP2iLdm8mx/qR0O39fw6VoPK+W/wBKQ/usf6z/AGOn3fwqGxmf+1b8/bE/4+Ijnzf+mI5+7+FDWxupe7L3enn3RHaS3wEX/IPH7xet3MP4P939fwrycy6hP8X/AAxZ2gt3jj0yC/mJmfagQ3EQycZBzP26V7JaSuBFi7RcSL/y0xj5Ov3fwrzrw9ZSS/FGHUhcKFtvDltblt3GXuXYAnHUbKGtUYV9YrT7Ue/mdjfy3n2KHebADdadLubOfNH+z+fp2qy8t95kH/IP4lf/AJfJv+eg/wBnj6/j1pdSmf7DDi8QfPZ8eZ0xMOPu9uvt71beZ/Ng/wBLQ4lc/wCs6fvBz938f84otqbuXur3er79kY8kt5/aC/8AHjv+yTAD7XLjHmr/ALPX279TVueW+Ml1/wAg/lW/5e5jn7v+zz+P9KSWV/7UUfa0P+hz8eZ/01Xj7vers0rmS6zdocq/Pmdfu/7P+cU0hyl8Pu/n3PGPAQnk+OnjlnNuJ7aORkDTyBCJGXOGxk9O4r1W4lvfsM277Bjy5c4u5c/c/wB3/wDXXn/hNGg/aD8cN5ygy2EUnmbvvZx3xz+Vel3Ur/2fP/pSf6ub/lp/sf7tK2hx4LRbbt9ylDLe/YItv2Ajyo8Zu5c/6o/7P+elOvZbz7XY7jYD/TEIxeTdfKbqdvT369ulWreV/wCzof8ASkP7qPjzP+mR/wBn8KL+Z/tlgftif8fqHPm/9Mm5+7+FDWh283vv3ej7kcMt95lr/wAg8YVf+XuYY+9/s8fh/WvL/DVxI/xw1uOKK2F5Bbq08jXEgTa6WewAgZz8jfr6CvXIZXElri7QYVcHzPu/e/2f85rzzwLDIPir4/vGkRf+QZDHKXIziIFlHHb5SfTjrTaOSvJ80Ul1XfzO5SW+3y/8g/8A1i/8vk3/AD1b/Z/z161TsJbz7JNsNgRvuet3L184/wCz+Xr1PNbCTPul/wBMTmRP+WnX96xz938fx/CqWmyubKf/AExD+8uv+WnX9+f9nv1/wpW1OlS91+71XfszjPizBqmo+E7eztJ7G3up7+2SGZbqZvLc3K7SRjp345xz1rX8L6Rf+HvD6WEk2l3Nx9plnnnjmljEskhLs23Hq2M9SAM0vxAu0g0vSZrq6UwR6taM+HLcfak7bfx/ziumupXO/N2jfvieJM/wjn7tO2pzQT9s5uP5mVeS3n9p2pJsN26424u5SD8g6/L/APr71Y82+8zP/Ev/ANX/AM/c39z/AHf0/Cn3sz/2rZ/6Wh+a5/5af7A/2e9WvNfzP+PtP9X18z/Y6fd/CkludMpe7H3enn3Zl6fLeDULsg2GfPi3ZvJgB+5HT5f17dOlVdX0ybXdH/s68e0jgkmhdmivZUYFMOMHbxyoGRyO2OtaunTONRvf9MQfv4f+WnT9wOfu/hVm0lcCLF2i4kX/AJaYx8nX7v4UJaCrO9049F37GD4YhmsfD2nWtklgltHBEqK15NnG/vwefX8+tWr+W8+xQ7zYAbrTpdzZz5o/2fz9O1T6FK/9i2P+loP3EXHmf7f+726/40/Upn+ww4vEHz2fHmdMTDj7vbr7e9K3ummkavKo/a8+4PLfb4v+Qf8A6xv+Xyb/AJ6r/s/569apSy3n9orzY7/skwA+1y4x5q/7PX279TWy8z74v9MT/WP/AMtOn71Tn7v4/h+FUJZX/tRP9LQ/6HPx5n/TVePu96bRFKX93v38xZpb7zLrH9n8q/8Ay+THP3f9nn8f6VXtJbz7TqG02BzcyZzdy9fKTp8vP9elak0rmS6zdocq/Pmdfu/7P+cVVspnN1qX+lp/x9S8+Z1/dJ/s/hQ1qghL3X7vTz8ivcS3v2Gbd9gx5cucXcufuf7v/wCukglvf7OTb9gI8qLGbuXP+r9NtXLqV/7Pn/0pP9XN/wAtP9j/AHaS3lf+zIx9qQ/uYuPM6/u/92nbUfN7vw9fMq3st59rsdxsB/piEYvJuvlN1O3p79e3SpoJb4SWv/IPGFTP+lzD+9/s8f59akv5n+2WB+2J/wAfqHPm/wDTJufu/hViGVxJa4u0GFTnzOn3v9n/ADmkluTKXuL3enn5mVbS3gv5ebDf9ntcg3cwGPMf/Z/P06iraS32+X/kH/6xf+Xyb/nq3+z/AJ69aLWZ/wC05h9sQf6Pa8eZ0xJJ/s9uv+NXEmfdL/picyJ/y06/vWOfu/j+P4UJDqy1+Ht37I4jxJJObDRVc25Q+IIuY55HIP2wdQRwPccmt3WZbw6PdiT7Bt8iXO27lJ+/2BX9O/esbxZcMulaLm53n/hIo8bXzg/bM56Dr1rpNclf+xL0fa0P+jyjHmf7fT7vepS90im/9rlp1XfuxbuW+Il/5B5/eN0u5j/B/u/r+FcJ8Xrq7gg0OYtarJHqcjxtFdSsQ3kvzkjj2I5r0e7lciXN2jZkb/lpnPydfu/hXkv7TF7NbeD7CeKdZJF1I7QG3cshXPQetVJaEyl+7enR9+zOt8C6WujaDaf2ZbabD9qt0uJn+1zF5ZGiBLOxBJJPv7dK2LKW8GrXJBsN26Ddm7lAH7s99v8A+qp9EMkWk6fG10m5LONT+89IgMfdqSwmf+2Ls/a0HzQc+Z0/dn/Z/ChrYuk7U2lH7Pn3Q20lvgIv+QeP3i9buYfwf7v6/hVXQ5bwaTaBDYbfIiA3XcoP3z1AX9O1a1pK4EWLtFxIv/LTGPk6/d/CqmgSuNGsv9LQf6PF/wAtP9o8fd7UNalOXuS93qu/medfGzUJdN8PaBqN8tu1tZanY3EnkXEjMApcnggY/pniui+HXmw+APCq2QtBAbGJ8S3UqsCxRmyACByT07c9a5j9pZZJvhW5FxvWKW1YhZOg3MORgdM/rXpGh2q6Vouk6fbXSiC0iEMY8zoFdQP4fbPfp+FO2pxR/wB4crdu5WnlvP7S62G/7LPgfa5SCPNX/Z6+3fqatTy3xkuv+Qfyrf8AL3Mc/d/2efx/pRPK/wDaw/0tD/ok/wDy065lX/Z79f8ACrk0rmS6zdocq/Pmdfu/7P8AnFJI7ZS+H3fz7mbZy3nnaltNgc3Umc3k3Xyl6fLyPc/SvHP2mPtk+jeGYCbcNPqDwL5E8jn50C9COK9tspn8/VP9MT/j7k/5a9f3Sf7P4V5L+0xHJL4Q0ScTB/I1VD8rZKkjGegxSt7pz4xc0HG29u56jBHfWdnHagWA8hIosG7mJ+VMf3famXUt559huNgP9Ljxi8m6+S3X5env+HStCKeRrSNmvFZikRJMmSfk/wB2oryZ/tGnf6Yg/wBMj/5af9MW5+7+H+c02tDop+77tunn2GQS3wktf+Qfwq/8vcwx97/Z4/D+tcp4rec3dp532YMLZf8AVzuw+83qOD7V28MriS1xdoMKnPmdPvf7P+c1x/jF2N7Z5nVsWqj7+cfM3HSpqLQ68vd6+35+Z0GkwStpFkRqGoKDbW3yrcQgDnoMrnA7enekvoJUsoT/AGhqDfNZjBuIcf60f7Pbt6d6dpE1qNHsQ0sQb7NbZBuoxznnjt9O3ek1Ca1ayhAliJ32h4uo/wDnqM/57d6LLlOe8vavT7XZd0WGtpvNi/4mWpf6xv8AlvD/AM9R/s/569Kpy28v9oKv9oahzaTnPnxZ/wBavH3en+RV83Fp5kf76H77f8vUf/PQf5/WqUs1r/aSt5sWPskwz9pjxnzV/wA+9U0iablfbv0XmWpbabz7j/iZal0b/lvD/sf7P+fzqrYwSs95/wATDUFxdTjieHngcn5ev+RV2We086f99D0b/l6j/wBmqlhNah73MsQzdTkZuo+mBQ0roIuXI9PwQtzbyixmP9o6icRynBnhwfk/3aSC3lOmxH+0dRGUQ4E8WP8AU/7v+R70+6ntTYzATQkmOXpdR/3KS2ntRpsWZoQQiD/j5T/nl/n+VFlcacuXb8EJewSi8sf+JhqJzeIMm4hyP3Tcj5ev6fjU9tbTCa1/4mWpDEa9LiEdn/2f5/4VDfzWpu7HEsRAvEJxdR8Dym/zmrNvPaebbZmh+4P+XqMdm/KhJakycuRadOy8ynbwS/b5F/tDUBi2tDkXEOf9Y/H3eg7enerSW02+X/iZal/rE/5eIf8Anq3+z/nr0qtbzWv9oyt5sWDbWnP2qPBO98/57d6tpcWm+T99D/rF/wCXqP8A56t/n9aSSCo5X27dF2RQ0yCVtNyNQ1BeLgYE8OP9cf8AZ/8A19uKNaglXR7snUNQYCCX5WniIPz9/l/z2p2lzWq6bhpYgf8ASOtzH/z2P+fejW5rVtGvAssRYwS4AuYz/H/n60WXKa3l7fb7XZdyp4s0S41WG0hW+uHEGqQ3jNcTRkhY8E7NoHzHI56VbvIJRqdqP7Q1AktccmeHI+Qf7P5/pVy5ntN8mJofvt/y9RnstVbya1OqWhEsWA1xk/ao+PkFNpWMaMWpc1tWn08mTiCVJCxv79x5RGGniwf3eOwqGzglOqXg/tDUQVuIuRcQ5P7kcn5cZ7emPep3ntMt++h/1f8Az9R/3KisprUapfEywgG4ix/pUfP7kd/60NLQa5uWWnTsu6JLS2mxD/xMtSH7xOk8I/g91/z9a5nw0kkmv3Ci8vY9ukadyk8Qz+/uSOo7dvTvXU2s9piL9/D/AKxf+XqMfwVm6DHp0dlBc/uFupLa3jkc3KBiquxAP03N9M80NK5M1KSvbZrp6k99BKllCf7Q1Bvmsxg3EOP9aP8AZ7dvTvVl7abzYP8AiZal/rX/AOW8P/PQf7P+fpVfUJrVrKECWInfaHi6j/56jP8Ant3q29xaeZB++h/1j/8AL1H/AM9B/n9aSSuU3LlWnV9F2RQlt5f7QVf7Q1Dm0nOfPiz/AK1ePu9P8irc9tMZLr/iZalyr9Z4f9n/AGf5f41Wlmtf7SVvNix9kmGftMeM+av+ferk09p5lz++h+63/L1Gf7tNJFScvd0/BdzjdN0O6Hxc8TauLm9W2ksYbVLgSx7pHVSXUtjaccZwK6m5t5RYzH+0dROI5Tgzw4Pyf7tJYTWoe9zLEM3U5GbmPpgU+6ntTYzATQkmOXpdR/3KWljOnTdJqCX4LzI4baU2ER/tHUBmKPjz4sD90f8AZ/z9adewSi8sf+JhqJzeIMm4hyP3Tcj5ev6fjS289qLCEGaEERR9bmP/AJ5Gi/mtTd2OJYiBeITi6j4HlN/nNDSsa3lzvTo+iJYLabzLX/iZal91Ok8I/vf7P8/8K5fwaHfxF4wtlur1GjvrNzKs8QZ828OAcr2xxjpnmurhntPMtszQ/dX/AJeox/erO06HTbXV76eDyI3u4rSWZxdJ+8cFlyffaqj2wM03YycXJttbW6edv1NBLabdL/xMtS/1if8ALxD/AM9W/wBn/PXpVSxgla0mP9oagPnuhgXEP/PY/wCz37+p6cVdSe03Sfvof9Yv/L1H/wA9W/z+tVNPmtVs5syxA77k83Uf/PY4/wA9+1FlctOXK9Oq6LsznPiZp93ceGYBBcajdGO9gldDLGwCLcqWYgDOABn8M9K6q7tpiX/4mWpH98es8J/hHotVtbmtW0a8CyxEmCXAFzGf4/8AP1q5dT2nz4mh/wBcf+XqM/wihJXEuZJO3V9F5FO8glGp2o/tDUCS1xyZ4cj5B/s/57VY+zS+Z/yEtR/1f/PeH+5/u1DeTWp1S0IliwGuMn7VHx8gqz59p5n+uh+5/wA/Uf8AcoSWo5OXLHTp2XdlXT4JTqF0BqGoDE8XInhyf3A/2fw+nvVi0tpsQ/8AEy1IfvE6Twj+D3X/AD9ah0+a1Go3hMsWDPFj/Soxn9yP8/pVm1ntMRfv4f8AWL/y9Rj+ChJWCq5a6dF0XYo6LBK2kWRGoagoMMPyrPCAPn7ZX/8AV3qTUIJFtIiL/USu+0AU3EPH70Y/h7dvQ9abok1qNHsg0sQIhiyDcxj+P/P0p2oTWrWUIEsRO+0PF1H/AM9Rn/PbvU2XKXJy9s9Ptdl3LL202+L/AImWpf6x/wDl4h/56r/s/wCevSqUtvL/AGiF/tDUMm0nO4zw5/1q8fd6fz7Vfae03Rfvof8AWN/y9R/89V/z+tUpZrX+0lbzYsC0mGftMeM+av8An3qmkRScu3fovMsz20xkuv8AiZalyr9Z4f8AZ/2f5f41XtYJWutQ/wCJhqAxcyDInhyf3Scn5etW5p7TzLn99D91v+XqM/3aq2c1qLrUcyxAG5kIzdR9PKShpaBBy5Xp07LyFubeUWMx/tHUTiOU4M8OD8n+7SQW8p05D/aOoDMUXHnxY/1f+7T7qe1NjMBNCSY5el1H/cpLee1GnRgzQgiKPrcx/wDPOiyuO8uXbr2Ql7BKLyx/4mGonN4gybiHI/dNyPl6/p+NTQW0wktf+JlqXCp0nh/2v9n+f+FRX81qbuxxLEQLxCcXUfA8pv8AOasQz2nmW376H7q/8vUY/vUJK7Jk5ci06dl5lO2gl+3yr/aGocW9ryLiHP8ArH4+727emeeKtpbTbpf+JlqX+sT/AJeIf+erf7P+evSq1tNa/wBozMZYsG3teftUf/PR8/57d6tpPabpP30P+sX/AJeo/wDnq3+f1pJIdVyvt26Lsji/FtjfXNjoZtmvbtYtdEsql0fYi3JLONo49STxXS6zbyro92TqGoMBBL8rTxEH5++F/wA9ql0+a1WxmBliB8y6PN1H/wA9jj/Pema3Nato14FliJMEuALmM/x/5+tKy5QhFrEc1t5dl3ZZu7abE3/Ey1I/vH6zwn+D2X/P1ry79oiAjw9ownurqdG1qIETSRuByMnCgc/pXql1PaYl/fw/6xv+XqM/wV578Z7W11aHw1ZGdFSTXI97JMkm0AE9B9OtOSVjJ8zg010fRdmehT2ri6kEeo6iECnbieEcbP8AdqnYwSnVrkf2hqAIaDkTw5P7tv8AZq41xaGUnzofuf8AP1H/AHKq2M1qNWuiZYsFoMf6VGM/uz3ptLQ0hzKElb7PZd0T2ltNiH/iZakP3idJ4R/B7r/n61V0OCVtJs2GoaggMEXyrPCAPnPTK1dtZ7TEX7+H/WL/AMvUY/gqpoU1qNIsw0sQIgiyDdRj+L/P0oaVxty5JadV0Xmcd8ZdJk1DwGtm11dTme4sIlWaRHALTAZAUZHX9TnqK7o2sw8gf2lqXDt/y8Q/89V/2f8APXpWJ4ykgfQ7RopYiUvdMdiLlOB9rj59vx6d63nntN8f76H/AFjf8vUf/PVf8/rRZXOWHN7aTt26eTKM8Ev9pFf7Q1DJtbg7vPhz/rV4+70/n24q1PbTGS6/4mWpcq/WeH/Z/wBn+X+NVpprX+1A3mxY+yzjP2mPGfNX/PvVyae08y5/fQ/db/l6jP8AdoSR1Scvd0/BdytZwTNNqX/Ew1EYupAcXEPP7peT8vX/AD1rzj9oKwll+H1qRPeXUg1WAJHI6PyeuAoBzXpFnNaibU8yxDN05GbqPkeUv51wnxkvBFo2gm3dHh/tePzSsqOB8jbcgcjmpsuUxxLly7fy9PQ7uG3lNnGRqOogFIjgTw4+5/u0y6glW40//iYagc3cY5nh4/ctyPl6/wCetS201qLGEGaEERxD/j6j/uUy7mtTcafiWI4u0JxdR8Dym/z+lNpWN05cz079F2JoLaYSWv8AxMtS4VOk8P8Atf7P8/8ACuU8WRul1Zhrq6l/0ZeZJYyR8zcDA6fXmuuhntPMtv30P3V/5eox/erkvFrwveWhjdGH2ZclZlbnc3p0+lKolY6sA5e31X4ep0mkQ2p0exLRRFvs1tkm1jPOeee/1796TUIbVbKEiKIHfaDi1j/56jP+e/ejSbmZdIsVGnXzgW1t8y28RB56j5uh/XvRfXEzWUI/s2+HzWZybeLn96Mfxd+g9e9F1ynNaXtXr9ruu6LZt7TzI/3MP32/5dY/+eg/z+lUpYbX+0lXyosfZJjj7NHjPmr/AJ9qttdTebF/xLL/AP1jf8u8X/PUf7X+enSqUtzL/aCt/Z19/wAek4x5EWf9avP3un8u1U2iaalffv1XmX5YLTzp/wBzD0b/AJdY/wDZqpYQ2pe9zFEcXU4GbWPpgVZlupvPuP8AiWX/AEb/AJd4v9j/AGqq2NzMr3n/ABLr45upzxbxccDg/N1obV0KClyPX8USXUFqLGYiGEERy9LWP+5SW0FqdNizDCSUQ/8AHsn/ADy/z/OkubqY2Mw/s2/GY5Rk28WPuf71JBdTDTYx/Zt+cIgyIIsf6n/e/wA9etF1cq0uXf8AFDr+G1F3Y4iiAN4gOLWPkeU3+cVZt4LTzbbMMP3B/wAusZ7N+dVr64mN5Y/8S2+BF4hwbeLn9y3A+brU9tdTGa1xpmoH92v/AC7xHPD/AO1zSTWpMlLkWvTuvMrW8Nr/AGjKvlRYFtacfZY8A73z/nv3q2lvab5P3MP+sX/l1j/56t/n9KqW1xN9vkb+zb45trQYFvFn/WPg/e7/AK96tR3U2+X/AIlmof6xP+XeL/nq3+1/np0oTQVFK+/bquyKelw2rablooif9I620f8Az2P+fajW4bVdGvCsUQYQS4Itox/H/n6Umm3My6aQNOvmGLjkW8WP9cf9rt+nak1q5mbR7xTp18oMEvzNBEAPn6n5v/1UXXKa2l7ff7Xddy9cwWm+TEMP32/5dYx2Wqt5DajVLQCKLBa4yPssfPyCrF1dTb5P+JZfj943W3iHZf8AaqteXMx1O1J06+GGuODbxZPyDp83b/8AVTbVjOkpaa9H1XZll4LTLfuYf9X/AM+sf9yorKG1OqXwMUJAuIsf6LHx+5Hb+lPe6my3/Esv/wDVf88Iv7n+9UdncTDVL3/iW3xJuIuBbxZH7kcH5vxobWgJS5Za9O67osWsFpiL9xD/AKxf+XWM/wAFU9EhtTo1mWiiJMMOSbaM/wAZ/wA+9WrO6mxDjTL8/vE6W8R/g/3qq6LczLo9oBp184EMHzLbxEH5z6t/+vvQ2rg1LlevWPVeY7UIbVbKEiKIHfaDi1j/AOeoz/nv3q29vaeZB+5h/wBY/wDy6x/89B/n9KqX1xM1lCP7Nvh81mcm3i5/ejH8XfoPXvVl7qbzIP8AiWX/APrX/wCXeL/noP8Aa/z0pXVxNS5Vr1fVdkVJYbX+0lXyosfZJjj7NHjPmr/n2q5NBaeZc/uYfut/y6xj+7VGW5l/tBW/s6+/49JxjyIs/wCtXn73T+Xark91N5l3/wASy/Hyv/y7xDH3f9qmmhyUvd1/FdyvYQ2pe9zFEcXU4GbWPpgU+6gtRYzEQwgiOXpax/3KjsbmZXvP+JdfHN1OeLeLjgcH5utOubqY2Mw/s2/GY5Rk28WPuf71JNcpTUuff8ULbwWpsISYYSTFH1to/wDnkaL+G1F3Y4iiAN4gOLWPkeU3+cU2G6mFhEP7NviBFHyIIsH90f8Aap19cTG8sf8AiW3wIvEODbxc/uW4HzdaG1YVpc716PqixDBaeZbZhh+6v/LrGf71VbeG1/tGVfKiwLa04+yx4B3vn/PfvViC6m8y1xpl+flT/l3iOfv/AO1Ve2uJvt8jf2bfHNtaDAt4s/6x8H73f9e9Da0JSl72vbqu5bSC03SfuYf9Yv8Ay6x/89W/z+lVNPhtWs5sxRE77kc2sf8Az2OP89u1Wkupt0v/ABLL/wD1if8ALvF/z1b/AGv89OlVLG4mW0nH9m3x+e6ORbxf89j/ALXbofTtxRdXBKXK9eq6rsxNbhtV0a8KxRBhBLgi2jH8f+fpVy6gtPnxDD/rj/y6xj+EVR1q5mbR7xTp18oMEvzNBEAPn6n5v/1Vcu7qYF86Zfj98etvEP4R/tU01cdpcq16vqvIr3kNqNUtAIosFrjI+yx8/IKs+RaeZ/qYfuf8+sf9yqt5czHU7UnTr4Ya44NvFk/IOnzdv/1VY+1TeZ/yDL//AFf/AD7xf3P96hNahJS5Y69O67sh0+G1Oo3gMUWBPFj/AEWM4/cj/P61ZtYLTEX7iH/WL/y6xn+Cqun3Mw1C6I02+JaeLgW8RI/cDg/N+P8A9erFndTYhxpl+f3idLeI/wAH+9QmrCqqWuvRdV2KuiQ2p0eyLRREmGLJNtGf4/8AP1p2oQ2q2UJEUQO+0HFrH/z1Gf8APfvTNFuZl0iyA06+YCGH5lt4iD8/b5v/ANfen31xM1lCP7Nvh81mcm3i5/ejH8XfoPXvU3XKaNS9s9ftd13LbQWm6L9zD/rG/wCXWP8A56r/AJ/SqbxWq6on7iAj7JMdptY8E+av+farb3U2+L/iWah/rH/5d4v+eq/7X+enSqMtzN/aAb+zr4YtJxj7PFn/AFq8/e6fyqm0RTUu/fqvMvTQWnmXP7mH7rf8usY/u1Vs4bU3Wo5iiIFzIBm1j6eUlWJ7qbzLv/iWX4+V/wDl3iGPu/7VVrW5mW61D/iXXxzcyHAt4uP3ScH5qG1dCgpcr16d15El1BaixmIhhBEcvS1j/uUlvBanToyYYSTFH1to/wDnnSXN1MbGYf2bfjMcoybeLH3P96iC6mGnIP7NvjiKLkQRY/1f+9RdXKtLl3690Lfw2ou7HEUQBvEBxax8jym/zirEMFp5lt+5h+6v/LrGf71V764mN5Y/8S2+BF4hwbeLn9y3A+brU0F1N5lp/wASy/Pyp/y7xHP3v9qhNakyUuRa9O68yvbQ2v8AaMymKLAt7Xj7LH/z0fP+e/eraQWm6T9zD/rF/wCXWP8A56t/n9Kp21xN9vlb+zb45t7UYFvFn/WPz97v+uOatpdTbpf+JZf/AOsT/l3i/wCerf7X+enSkmgqqV9+3VdkVrCG1axmJiiJ8y6HNrH/AM9jj/Pama3Daro14ViiDCCXBFtGP4/8/SnWVxMtjMP7NviPMujkW8WP9cf9rt0Pp2qPWrmZtHvFOnXygwS/M0EQA+fqfm//AFUrrlNIqXtlr9ruu5euoLTEv7iH/WN/y6xj+CsbxJomm6rqGlR3CFFgupbpDDEkZ3ony5x1HJ4rXvLqbE2dMvx+8frbxD+D/eqteXMx1O1P9m3ww1xwbeLJ+QdPm7f/AKqptWM6cZPRvo+q7MteRaeZ/qYfuf8APrH/AHKrWMNqdWugYosBoMf6LGcfuz2qf7VN5n/IMv8A/V/8+8X9z/eqvY3Mw1a4P9m3xLNBwLeLI/dt/tUNrQaUuWWvTuu6LdrBaYi/cQ/6xf8Al1jP8FVNChtTpFmWiiJMEWSbWM/xf5+tWbO6mxDjTL8/vE6W8R/g/wB6quh3My6TZqNOvnAt4vmW3iIPz9Rlv/10Nq4NS5Xr1XVeZHrdhZXGmwRyRoqiaxf5LdBkrOrAH1GQPr3rReC03x/uYf8AWN/y6x/89V/z+lVL64mayhH9m3w+azOTbxc/vRj+Lv0Hr3q091Nui/4ll/8A6x/+XeL/AJ6r/tf56dKLq5PI1Zpq9+67IpzQ2v8AagXyosfZZzj7NHjPmr/n2q5NBaeZc/uYfut/y6xj+7VKe5m/tPd/Z18MWtwMfZ4s/wCtXn73Qfp2q3PdTeZd/wDEsvx8r/8ALvEMfd/2qE0VJS93X8V3IbOG1M2p5iiOLpwM2sfA8pfypbqC0+wTfuYchJWH+ix8EJwaS0uJhNqX/Etvjm6kJxbxcful4PzdaS5upjYzD+zb8ZjlGTbxY+5/vUk1YHGTkk2unVdh1rBamwhJhhJ8uL/l1j/uU27htRcafiKIZu0Bxax8jym/z+tFtdTCxhH9m35xHEMi3ix9z/epLm4ma40//iW3wxdxnBt4uf3LcD5uvehtWGlLmevfquxahgtPMtv3MP3V/wCXWM/3q5LxakKXloI0RR9mXIWFV53N6dfrXVwXU3mWn/Esvz8qf8u8Rz97/ark/Fkskl3ZlrS5i/0ZeJIkBPzNzwTxSqNWOnAKXt9X+K8zq9Ghf+xbA/ZEP+jWxz5fXJ6/e7/r7UmpQv8AYYcWaH57Pny+uZhz97v09/aq2kxXZ0iyKHTgv2a2I3WspPXud3X1PftSX0V39ih8w6cRutOlrLnJlH+1+fr2p3905rfvn732vPujVaF/Nj/0RP8AWMMeX1/egY+9+H+c1Rlif+1FP2RB/oc/Pl/9NV5+92ryXxb418R6ZdeOlt7jT1Gj3thDbj7HnaJmUv1+v8WT2GK3fCet6xqnxI8baXcy2DQ6Sojtx9lbCq+GPQ7s5xyxOKpswo1E58t+/wCv+R6XLC/nXGbRBgNx5fT7n+1/nNVNPhffff6In/H3cf8ALP2H+12ri/EAvE+Lnh+PfZgvY3uAsEoTgxdVLZPt6c11NjFeb7zYdPH+lT5zay9cDp83T+VK+qKpPmjJX29exeuon/s+f/RU/wBXN/yz/wBj/epLaJ/7Mh/0VB8ic+X/ANMf978f84qrcxXv2Gbc2nEeXLnFrLnGz/epLeK9/s6LadOxsTGbWXOPK9d3+Tz0p31NFH3fi/Mt38L/AGywH2NP+P1Bjyv+mTcfe/Gljnhj1PTrKSKL7XcwtJDEYiTIqZ3N97HG5e47VUvYbv7XY7jp3/H4gGLSXGfKbr83T2696xbuK8/4WB4WBawybC8P/HtLt/5ZZyN2SfcUk9yKitTXvdPPzOitoX/tKU/Y0P8Aotpz5fXMj/7Xf9farkcL75P9ETiRP+WfT96wx978Pw/Gsm3iuzfyc6dv+zWuSbWXGN7/AO119fXtVpIb7fJzpv8ArE/5dJv+erf7X+enWhMdWOvxdu/ZDNJif+y/+PROlxz5f/TY8/e7Ua5E/wDYt7/oiD9xLz5f+31+92qrpkV3/Z2UOnhcT9bWXP8ArT33fl6dDRrMV2NHuy508r5EudtrKD9/sS3/AOqlf3TW37/4vtefcj1TW1tvGlp4ffTh5t5BPdLKFwF2bAVxn3znNaN7C/8Aatn/AKIg+a5/5Z/7A/2u1cH4ijux8afDwJsPM/s69xi3kC4zH1Gc12N5Fef2naAnT926424tZcfcH+1/+qm3oc2Gbbd5bX7/AMppvE+W/wBFQfus/wCr/wBjr978ahsYX/tW/H2NP+PiIY8r/piOPvfjXG/EPxhJ4OtopZl0m5doy7wCOVJREFAaRV5zjPcqM965ZvFXiVPiDJ4XtjaHVbzVYbyFxYMYRp3lAkMeoOODwTn+KhsmdaNNON7tron3R7HaRORFi0RsyL/yzzn5On3vxqnoUT/2JZn7Ih/cw8+X6uf9rv0/wrzr4Nat4l8T276lqN8rWy3EkKxS6aogfBZQVdDvJAXkHHXvXYaDdySLHp0TWAnhs7W4Ie0lPyPI6jkNycoc8emKHLU0jNSp83Na7j38zX1KF/sMOLND89nz5fXMw5+936e/tVt4X82D/REGZXH+r6/vBx978P8AOayr6K7+xQ+YdOI3WnS1lzkyj/a/P17VaeK+8yD5tN5kf/l0l/56D/a5/wAii+pTXur3ur79kMlif+1FP2RB/oc/Pl/9NV5+92q7NE4kus2iDCvx5fT7v+1/nNZEsV5/aC86fv8Ask2D9llxjzV/2uvv271cmivvMuvm03hX6Wso/u/7XFNMqUfh978+4unwvvvv9ET/AI+7j/ln7D/a7U+6if8As+f/AEVP9XN/yz/2P96qNhFdl73YdO/4+pwc2svXA/2v/wBVPuYr37DNubTiPLlzi1lzjZ/vUk9ByXv/ABfmWreJ/wCzof8ARUH7qPny/wDpkf8Aa/Gi/hf7ZYD7Gn/H6gx5X/TJuPvfjVSCK9+wRbW04Dyo8f6LLn/VH/a/z1pb2G7+12O46d/x+IBi0lxnym6/N09uvehvQOX3373R9zShicyWuLRDlVwPL+997/a/ziqttC/9pSn7Gh/0W058vrmR/wDa7/r7UkMN8ZLXLabyq9bWU/3v9rms3SboX9/d/YbvR7l4I7aGcxQyOI3DvlGw3DDuD14xQ3sSo/F73bv3N9IX3S/6GnEif8s+n71hj734fh+NUtNicWU/+hoP3l1/yz6fvz/tdun+NKkN7vl+bTf9Yv8Ay6Tf89W/2v8AI461UsIrv7JNsOnAb7nray9fOP8Atfl6Dg80X1BR91+91XfsyxrkT/2Le/6Ig/cS8+X/ALfX73art3E435tEX98R/q8fwjj71ZGsxXY0i7Mh08p5EudtrKD9/sd3/wCqvNP+Er8UP4zm8J3E1pBqVvqM1zc3P2AiFNP8vKMGPocdQORgsaE9TOc1CMU3u338j1i9hf8AtWz/ANEQfNc/8s/9gf7XarXlP5n/AB6J/q+nl/7HX73414/4K13XtQ8ffYtT1SO4tWhnm05pdPjCXUYG1pQ0J45HCn6+1eqeVfeZ97Tf9X/z6y/3P96mnuOMlOKs9k+/dj9Ohc6je/6Gh/fw/wDLPr+4HH3vxqzaRORFi0RsyL/yzzn5On3vxrL0+K7OoXeDp2fPi3ZtZSD+5H+1+nrz0qzaRXxEXzaaf3i9bWU/wf71JPQurH+90XfsN0KJ/wCxbH/REP7iLny/9v8A3u/T/Cn6lC/2GHFmh+ez58vrmYc/e79Pf2qlosV2dIs9h0/b5MWN1rKT9/uQ3/6+1Pvorv7FD5h04jdadLWXOTKP9r8/XtSv7pbX75+99rz7ms8L74v9DT/WP/yz6/vVGPvfh+P41Qlif+1E/wBEQf6HPz5f/TVefvdqe8N9vi503/WN/wAukv8Az1X/AGv89OtUpYrz+0F50/f9kmIP2WXGPNX/AGuvv2ptkUo/3u/fzNeaJxJdZtEGFfjy+n3f9r/Oaq2ULi61L/RE/wCPqXjy+n7pP9r8aSaK+8y6+bTeFfpayj+7/tcVWtIrv7VqG06cP9Jkzm1l6+UnT5uKG9UEF7r97p5+Rduon/s+f/RU/wBXN/yz/wBj/epLeJ/7MjP2VB+5i58vp+7/AN6qtzFe/YZtzacR5cucWsucbP8AepIIr3+zk2tp2PKjxm1lz/q/96nfUfL7vxdfMt38L/bLAfY0/wCP1Bjyv+mTcfe/GrEMTmS1xaIcqnHl9fvf7X+cVm3sN39rsdx07/j8QDFpLjPlN1+bp7de9TwxX3mWvzabyqdbWU/3v9rmknuTKPuL3unn5i2sL/2nMfsaH/R7Xny+uZJP9rv0/wAKuJC+6X/Q04kT/ln0/esMfe/D8PxrJtorv7fLzp2/7Pa5JtZSMeY/+119fXtVpIb3fL82m/6xf+XSb/nq3+1/kcdaEx1Vr8Xbv2QadC4sJv8AQ0H72658v0mP+126f40zXIn/ALFvf9EQfuJefL/2+v3u1QWMV39hm2HTgPMuutrLnPnH/a/L0HBrzb4q+KNd8MahLazfZnsdW0+S203yLFm23nmfxEnI4Ixy3Q/LSv7oqlRUqnO39rs+56hrN7FZF1e03yG6SFo4Id7RmQYUsA2VXqcngYJrI8Y6nLpOt+Go0soGa/1KSzIeMjCtGSSMN1GK89vvG+s2fii6s9YlgsLbSJbW1v7q104SR3E0sa/fZiGRc5ACL3J44Fb3xMjul8W+AQ7afuOsy7QtvIvIiPUFskfSqbucjq+5zRlbp19D0jyn8z/j0T/V9PL/ANjr978aq2EL/wBsXY+yIfmg48vr+7P+1+NN8q+8z72m/wCr/wCfWX+5/vVXsorz+1rkA6fu3Qbs2spB/dnHG7/9dJvY7Ix92XvdPPujUtInIixaI2ZF/wCWec/J0+9+NVNAic6NZf6Ih/0eL/ln/tHn73ei0iviIvm00/vF62sp/g/3qqaHFdnSbModO2+RFjdayk/ePUhqG9Qcfcl73Vd/MualC/2GHFmh+ez58vrmYc/e79Pf2q48L7ov9DTmR/8Aln1/eqMfe/D8fxrltdvL631Hw5p+zS2TUriKNpDBKCmxXlyBu+bJjAP14rdeK93Rc6b/AKxv+XSb/nqv+1/kcdaL6kcyfuKWqfn1SGzxP/aw/wBEQf6JP/yz6YlX/a7dP8auTROJLrNogwr8eX0+7/tf5zWTPFd/2n10/f8AZZ8EWsuMeav+119PToatzRX3mXXzabwr9LWUf3f9rihMuUfh978+4+yhfz9U/wBDT/j7k/5ZdP3Sf7X40t1E/wDZ8/8Aoif6uX/ln/sf71VLOG787Utp04Yunzm0l6+UvT5uBXLeIxcjxj4fjY2XmG11A/LDIFKiJeCueT6HtQpe6TUfJJO/budpaxP/AGfB/oqf6uH/AJZ/7H+9TbyF/tGnf6Gh/wBMj/5Z/wDTFuPvfj/nFVraK9+wxbW04Dy4sZtZc42f71Nuorvz7DcdOP8ApceMWsvXym6/N09vXnpQ3oaKPvv3u/fsakMTmS1xaIcqnHl9fvf7X+cVx/jFGF7Z5gVc2qn7mM/M3PWulhivvMtfm03lU62sp/vf7XNcp4rScXdp5xtSxtl/1cLqPvN1yeT71NR6HTl6tX3/AD8zrdGVv7FsP3sv/Htbf8s5fX6/57Yo1JG+ww/vZvv2f/LOX/nsPf8Az2xVXSbO2bSLJjM4JtrYkDUpV788A4H07dqS/s7ZLKEiZ87rQc6lL/z1GeM//s9RT15TmtH2z1fxdl3XmSXXh7Srme4NzYW8pvZg10XtHPnskgCF8n5iO3cdOtQxaZaWmvXN1awJDc3dpK9zLHburTlZFALnPzcdz0q41jbedF++l/1jf8xOb/nr654+v41Tls7f+0FTzpMG0mP/ACEZc581ff8ATv1ptsmko33fXovPzOb8TKw+M/hgeZIf9Bv+THJn/ll6nP8AnntXYaerb7797L/x93H/ACzl/uj3/wA964LxXBBH8Z/CcSyuUmtb8E/bpGPCIRhicjp26/hXZ2NnbM95mZ+Lq4AxqUvTaPfn696NbmFBLlnq9+y7LzL10jf2fN+9l/1c3/LOT/nn9f8APektlb+zIv3sv3I/+Wcn/PH6/wCfpVW4srZbGUiaTIjmPOpS/wBz0z/+vpSQWVs2mxkzSZKIeNRl/wCePpn/AD0p3dzoSjy7v7l/mW79G+2af+9m/wCP2P8A5Zy/88W9/wD6/wCFc9dSsfih4XtvMmyNLu5M+XJxloxxzk9O3Fa97Z2y3djiZ8G8jBzqcvTym754+vbpXFNb24+O+iQtLIY/+EclYE6hINred/ezleB0HFTdnNieVU4avp0Xn5ne2yt/acv72b/j1tP+Wcv/AD0f3/8A19sVcjVvMk/ey/6xP+Wcv/PVvf8Az9ayLeztv7QkUzPgW1of+QlKD9989/0/h6ircdjbeZL++k/1if8AMTmH/LVvfn69uvemmzeqo33fTouy8xmkq39l/wCtl6XH/LOX/nsff/PfmjXFb+xL397L/wAe8v8Ayzl/v/X/AD35qrplnbvpuTM+cTjjUZR/y2PbP6d+tGs2dumj3bLNISLeXg6jK38foTz9O/WlrymqUfb7v4uy7+py3iU4+OXh1Wlb/kG3mCQ+Scp2JzXa3qt/a1n+9m+9c/8ALOX+4Pf/AD3rxf4kxwt+0N4GtAWeMSZYi6kdjk/89PvdutevXlnbDU7VRM+Ga4/5iUp/gGMHP/6+9NtnFhGnOSu+vRfy+o/W9D03WkWPWLKC/jjTei3Nq0gU7O24nH1/pSWOlWf/AAk93qHkL9vjeK3S5+zyeYsZhB2Bs5Az2/HpUr2Ntub99L/qv+glL/c+v6fhUdnZ2x1S9BmfC3EWD/aco/5Yjqc/r26UO+h0KMeWWr27LuvMs6Hp1rp1rFb6dELSDzg/lwQOq7mUkthSBkn8T1rjPDcu34gC3LybpPD9m4OyTgC5lGOvv249Oa7CzsbYCLM0o/eJ11KVf4Prx9e3SvMtGjgk+M1jD5rhf+EXiZ/9NkXDfaugYHIGD93oOtDbujKqoqKs38Uei7S8z0/Ukb7DD+9m+/Z/8s5f+ew9/wDPbFW3RvNg/ezf61/+WcvH7we/8ufxrJv7O2SyhImfO60HOpS/89RnjP8A+z1FWnsbXzYP30n+tf8A5icv/PQe/H179aNbmrUeVavd9F2XmNlVv7TX97L/AMec/wDyzk/56r7/AOe9XpUbzroebKflb/lnLz93rz/P/CseWzt/7QVPOkwbSY/8hGXOfNX3/Tv1q5LY2pnuv30uCG/5icxz93vnn/PpTVxyUdNX9y7+pyXwqvGvovE5MkuU12/H3JPX2Oe3f8a7G6Rv7Pm/ey/6ub/lnJ/zz+v+e9eV/A4Q3UnjSKSVx5GuXYGL2SPht3cH5unU9a9JuLK2WxlImkyI5jzqUv8Ac9M//r6UtbHNg0uSOr+5d35lm3Vv7Oh/eS/6qP8A5Zyf88j7/wCfpS36N9s0/wDezf8AH7H/AMs5f+eLe/8A9f8ACqcNlbNYRHzpMmKM8ajL/wA8j2z/APq6U69s7ZbuxxM+DeRg51OXp5Td88fXt0od7HVaPO9Xs+i/zNKBW821/eyjKp0jl4+97/y/xrzH4KyGfWvH7qzpjWlXCxvzggZ+U+3fr2xXoUFjbebaZml4VP8AmJSj+978f59a8s+BNtC9949WSR1Ca8wX/THiJG/vtPzfU9OtDvdGTUeZ6v7l3XmewIrb5f3s3+sT/lnL/wA9W9/8/Wqemq32Kf8Aey/6y6/5Zy/89z7/AOe/NCWNtvl/fSf6xP8AmJzf89W9+fr+PeqlhZ272c5Mz/fuRxqUv/PY44zz/XrRrctKPK9Xuui7PzLOuqRol5mWX/j3l6xyf3+nX/Pfmn3OmWiapNqSwr/aDnyGufs7iRowAQpYnOM9q434qwRQeGLTyp5MvqNspBu5Jcj7Up7n5fXPeup1uK0s7G9unkndIDJMVTUpWJCx54yeenX8KE3cScbWbejfReRUg8O6TpOvw3Ol6fbWdxMblZJYLR42cbQcEg5PPPP41u7W83/Wy/6v/nnL/c+v+fpXJ+HNS0/xPpui6xZ/aYLe+W4kWOfUZPMQbcYPJ9PxroPsNt5v+ul/1f8A0Epf7n1/T8KE3qHuShFpu1uy7vzJNNRv7Svf3s3/AB8Q/wDLOX/ngPf/AD9Ks2itiL97KP3idI5T/B7H/P0rL0+ztjqF0DM4Czw/8xKUf8sR1Of17dKsWdjbARZmlH7xOupSr/B9ePr26UJuw6qjrq9l0Xb1E0JW/sWx/ey/6iL/AJZy/wB/6/57c0/Ukb7DD+9m+/Z/8s5f+ew9/wDPbFZEb6fpvhQalfXEqW1tZpPMUv5vlVWJbCj2HQdOop0L2Go+H9O1C0nlMF0ljLHv1GUHa0gPIzwcHp/D1FK75S3y+3au783Zd15nQOrb4v3s3+sb/lnL/wA9V9/8/WqMqt/aa/vZf+POf/lnL/z1X3/z3p72Ntvi/fSf6xv+YnN/z1X34+v49qpS2dv/AGgqedJg2kx/5CMuc+avv+nfrTdyaSj3fXovPzNeZW8y7/eyn5X6xy8/d68/z/wqrZq32vUv3s3/AB9S/wDLOX/nknv/AJ78U2extvNu/wB9Lyr/APMSlOfu+/P9fwrgfiNrB8PvYixnufOvNdFuUgvndpIjGu8cn3Hzde1Db0I5oQpttvbsvLzPQ7pG/s+b97L/AKub/lnJ/wA8/r/nvSW6t/Zkf72X/Uxf8s5P+ef1/wA/Sq13Y2qWc22eVgqTYJ1GUfwemf8A9dNgsrZtOQ+dJkxRHjUZf+efpn/9XSnrc0Sjybvfsv8AMt36N9s0/wDezf8AH7H/AMs5f+eLe/8A9f8ACrEKt5lp+9lHyp0jl4+905/l/jWbe2dst3Y4mfBvIwc6nL08pu+ePr26VNDY22+1/fSDCp11KYY+9154/wA+tJX1Jko8i1e3ZefmLaq39pTfvZf+Pa1/5Zy/89JPf/PbmriK2+X97N/rE/5Zy/8APVvf/P1rjNYY2nibw9bW9zKsV3PBDOBfyfMojuXwTnIG5FPt+Jrp0sbbfL++k/1if8xOb/nq3vz9fx70JsKnLd6vp0XZeYacCLCbM0vMt1jMcvP74+/+e/NU/FWmWl/pDyX0C3L2qSTwGa3djFIHwGUk/KfcdO9effEy3iE3gUpK53eJ2RsXsj8b5PU8fUcnrXoOs2dumj3bLNISIJeDqMrfx+hPP079aV3ylRade138XZdyTVvDukXeqHU7vTrafUY5PkupbRjKu1crhicjB6enWvPfifcsfi78PrAGQlbua4LlHGBjb3Oe3+Nek3ljbES4mlP7x+mpSt/B9efr36V5l47t7IfFrw4jSyeZuTYTdyPnMrZw55Xj0xmqbZxV4p01yt/cv8z1ja3m/wCtl/1f/POX+59f8/Sq1grf2xd/vZvvW/SOX/nm3v8A57cUz7Dbeb/rpf8AV/8AQSl/ufX9PwqvY2dsdWuVMz4VoOf7SlH/ACzPU5//AFdKTvodkVHllq9uy7rzNW0VsRfvZR+8TpHKf4PY/wCfpVPQFb+xbL97L/x7xf8ALOX++ff/AD25os7G2AizNKP3iddSlX+D68fXt0qrolnbvpFmzTOCbeLpqUq/xnsDx9O3Wh3uDUeWWr3XRefmc34yvGh+Ivw5si8pE0ssufLfjbA445z/AB9iPau7ZW3RfvZv9Y3/ACzl/wCeq+/+frXknxBjhtfi58Ltjsyv56MWvHfGVUfeJyh57dK9Pextt0X76T/WP/zE5f8Anqvvx9fx7U1e5yU1H2s9Xuui7eok6t/ao/ey/wDHpP8A8s5f+ey+/wDnvzVyZW8y7/eyn5X6xy8/d68/z/wrJns7f+0tvnSYNrOf+QjKT/rV9/079atT2Nt5t3++l5V/+YlKc/d9+f6/hSVzrko+7q/uXf1JLFG8/VP3s3/H3J/yzl/55J7/AOfpXEeJnP8Aws3w7D5kuf7L1F87H/uKPXP9PWuttLO2abUszPxdSAY1OX/nkvvz9T16VwXiKGJfizoMAlby/wCx7+TJvXJzgD73XHH3ehpa8plXSvHV7x6L/M9ItUb+z4f3sv8Aq4f+Wcn/ADz+v+e1MvFb7Rpv72Yf6ZH/AMs5f+eLe/8An6VXt7K2axiJmkyY4TxqUv8Ac9M//q6U25s7ZbjT8TPzdxg51KXp5Le/H17dKbvY2SjzPV9ei7epqQq3mWn72UfKnSOXj73Tn+X+Ncd4xU/bbPLuf9FXqjjHzN6n+XFdLBY23m2n76XhU/5iUox9734/p+Ncp4rgiiurNUkYj7MpO67eQ53N69PpU1L2OrL0vb6N/cvPzOh0rVNPj0iyR721V1t7YEG4cEEHkY9v07Ul/qmnvZwhb21JDWhx9oftKCfyHX07Vd0a6xotgPOn4trYY81Ox/zj070ajdYsYR50/D2Y4lTtMP8AI9O9Oz5Tn932z0fxd/NeQxtW07zYz9utfvt/y8P/AM9B/n9etU5NU0/+0Ff7bbbfsky5+0P181SB/wDW71tNdfvYz5s/Dsf9an/PQH/P+FZ73iNqoVbiRitpOrATIcEyqcHH8qbuRS5b7Pr19fI8/wDGGqWH/C6PBsou4WjFvfqzJMzBSY0xkntXcWOqaer3m69tRuuZ2H+kPyCBg/5615t8VdSz8a/ACo0jmKWXeSwJUSFFBJHHavVdOuvnvv303/H3cf8ALVO4FGtzDDOLVTR79/JeRWudV09rGZRfWpJjlAH2h+6UkGq6eNOiU31qGCICPtD5/wBV/n+XSr11cj+z5/3s3+rm/wCWif3KbbXP/EshHmzfcTjzE/544/z/AI07O50+7y7P7/8AgFS91TT2u7Ere2pC3iMT9pk4HlMM/wD1/wAK8/1PUrRPjz4VuUuofI/sh4JJDOwXLGZsZ6j7g4Fejz6lDc3FjLb3cksa6gELpPGwDLG6sMjjIII/SvNY3WX48xXklw4Fr9ltlJZQylrS4YgHpg5FTqcOMcfZU2k+nX18j0G31TTxqEjm9tQptrUA/aX6h3z+WR9O1Wo9W03fJ/p9r/rE/wCXl/8Anqf8/r1pba6xqUo86fi1tB/rU7SP/kenerkd188n72fmRD/rU/56sf8AP+FNJnXV5b7Pp18l5GLpmqaemnbXvbYNifg3D95SR+n59aNZ1Swk0e7RL22ZmglAAuHJJ3/5471c0m6H9mY82fpcD/WJ3mNGu3P/ABJb0GWf/j3lHMid3zS15Tb3fb7P4u/n6HiXjK5huv2oPCk0EySQxPCu5JCyjIcn5jz2r2O71TT21K0Zb21Kq1xki4c4ygx/nvXkvxAY/wDDQnh+7BZsXtqu5mBP+rk7jivZr26H9q2X72f71x/y0T+4KGmcGCivaTdn16/3X5ET6tp25v8ATrX/AFX/AD8P/c/zx+FR2eqaeup3jNe2oVriIg/aZMECEDr9e/4Vovc5LfvZv9Vj/WJ/cxUVjdD+1b8+dP8A8fMR/wBamf8AUgU2nodS5eWWj27+a8iG01bTQIs31r/rF63Dj+CvJvDN3CvxpN1LKggGjJaiQyHapVoXOT1/j/CvWfD/AIg07VrdZtK1RLyOKdUc29xG2xgnQ+h+vavJfD2rxTfFDRWSQ+Z5tzbMVYA/JBa8Z6Zypod7o5q0oyinFO3NHrfv5HqN/qmnvZwhb21JDWhx9oftKCfyHX07VafVtN8yD/TrX/WP/wAvD/8APQfl9fxp+o3WLGEedPw9mOJU7TD/ACPTvVt7rMkH76biVz/rU/56A/5/woSdzpfLyrR7vr5LyMWTVNP/ALQV/tttt+yTLn7Q/XzVIH/1u9XJNW03zrg/brXBDf8ALw5/u/n/AJ9KbPdqupAtPKFFnPkmVMcyrV+S6BmuCJpjuVsHzU5+7/h2pxuOfLpo/v8AP0PJvgs1rp9340lnmjjS51R5Ud5WVWDBzwe/9a9FudV09rGZRfWpJjlAH2h+6VxXwnvU/t7xUiXMj4lGSCFIP7zjJ4P1HWvQrq5H9nz/AL2b/Vzf8tE/uUlexzYOKjFKSd/XzfkUIdV09bCJTe2wYRRgj7Q//PI/5/SnXuqae13Ylb21IW8RiftMnA8phn/6/wCFW7e5zp0I82b/AFUf/LRP+eRFJqd6kdxZSSXEqot4jM7TRgAeUwyT0Hpn+tDTsdXu870ez6/8AZBq2neba/6da8Kn/Lw4/vfl/n1ry74IXlnban8QDLcwxo+vuULzMu4eYeRjr9e3avXYrsK1s3nTYVF5EqejdPz715H+zTfQTeHvE9yrMtxca60jskijcvyFevplsEevNDTujkqTjGqo2evn5p9j1BNW03fL/p9r/rF/5eH/AOerf5/XrVSw1TT0tJg17agl7k4+0P3mJH5j8+tbKXXzS/vZ+ZFP+tT/AJ6sf8+/tVLTbrNlP++n/wBZdf8ALVO85NFnc6Vy8r0e66+T8jhfi7e2dzoOlC3uYpWTVLdj5cjPgeeOTnp+HWun8XarpzeHdZCXtszGGfAW4dif3J9etc38arlW0XQVaSVmOrwbcupx++B7V2PjCdpfDetqkkzsYLggGRDn9yfShX5jNctndPd9fJeR5n8BtUtv+FdeHFuLi3jaBruNg0zKQMcZA6f1r0/+1tO8z/j+tf8AV/8APw/9z/PH4V598EwLLwvYW4eZdl3ecB1HWJD0P1r0/wC1DzP9bN/q8f6xP7lEbk0OX2FO6fw9/N+RlafqmnrqF2zXtqFaeIgm5cZAhA/n3/CrFpq2mgRZvrX/AFi9bhx/BUmnXWNRvT50/E8R4lT/AJ4AVatLraIv3swxIp4kQfwYoV7G1Xlu9Hsuvl6HnXj7V4IvhHqdvaTW8t5caelmkQlZmLSvs+6eM/N+HUVoeENQsV+HPhiJry2EiWOmhlNw+Rgrn8u/p2qXxFcIfAunK7yuhn04FTImCBdpx9KseFboD4d+Gh504xaaaOJU7Mv8u3p3qbOxm0vrz0e/fz9DbfVtN3xf6fa/6xv+Xl/+eq/5/XrVOXVNPOoK32222i0mXP2h+vmqQP8APWtp7r54v30/EjH/AFqf89VP+f8ACqMtz/xNFHmzf8ec4/1id5Vqnc0pcvZ9evr5CTatpvmXX+nWvKt0uHP938/8+lePfG2+tZdW8MCKWOUf2+0hKSsy7fKjGefx5r2+a6zJdHzZjlX6yJz93/DtXzp+0BdTS/EHQkSWRoYbl7na7K3zbolzx7UpX0ObEW9i7J9Ot+q8j3i71XTms51W+tSSkoH+kP3Tj/Pemwarp405FN7ahhFGMfaH6+XV++uR9iuB5s33Jv8Alon9ym29znTYh5s3MMX/AC0T/nnVWdzqXLybPfv/AMAp3uqae13Ylb21IW8RiftMnA8phn/6/wCFTQ6tpvmWv+nWvCr1uHH978v8+tTahdj7ZYHzp/8Aj9Q/61P+eTCrEN1iS1PmzDCp0kTj73+Pekk9SZKPItHt39fI4LW9Ss5fH3hGNbmB4zKJGYTMQuy3uuvp94dOldgmrabuk/0+1/1i/wDLy/8Az1b/AD+vWvO/GcsifG74aztK4gaK4QHehYMqN09B84616kl188v76fmRD/rU/wCerH/Pv7UK+pjzRlVno2vd6+S8jyT4m31m83gULdQsU8TtI22Vmwu+QgnPQe4616DrOqafJo92iXtszNBKABcPknf/AJ471wXxZ1GC2i8E3V1dGKCDxO8kks0i7UXfISSR0+pr0bV76OfQLqSG4kkje3lKssyFWBf1Halrym8OX6y1Z/F3/wCAOu9W00iXF9a/6xulw5/grxjxbqUVz8fLGRZozZ2slqnmiQlAW3t97qa9M/4WHol54om0K3vbhpyZCs7OghkkACmJX6NIOcgdge9cX4mCH4sC88x/MOtWMed43Y+zOc56dabvY5lOEkuW/Xrf7L8j07+1tO8z/j+tf9X/AM/D/wBz/PH4VXstU09dVuWN7ahWaDBNw4BxGc8/5xWt9qHmf62b/V4/1if3Kq2N0BrF2fNn4aD/AJaJ/wA8zQ09Dpjy8stHt3815DLTVtNAizfWv+sXrcOP4Kq6Jqmnx6TZo97aqywRgg3DjB3f547VsWl1tEX72YYkU8SIP4MVT0C6xo1l+9nGLeIcSp2Y0O9xvl5Ho9119fI8m+KWo2zfFP4Wy29zA6RSv5jCViqAlAcnqv4V6w+rabui/wBPtf8AWN/y8P8A89V/z+vWvL/i9N/xcj4Yy+bJ+7nA/wBauR+9hHGOg54zXrz3XzRfvp+JHP8ArU/56qf8+/tT1ucdPldWej3XXy9DGn1TTzqe8XtsV+yzrn7Q5581SP8APfrVqbVtN8y6/wBOteVbpcOf7v5/59KWe5B1YfvZubSf/loneVf8/wAquzXWZLo+bMcq/WROfu/4dqSTOyXL7uj+/wA/QyrPVNPWbUi17ajddSMv+kvyPKXkev8AkVwfiO7tT8W/D84uIDC2i36B/ObBPAxmvSLG7Hn6p++n5u5P+Wqf88kFea6zfed8dNPiMjjyNBvOQy5OVzgn8KWvKYYjlTjo949f+Ad/barp62MKm+tQRHECPtD9kpt1qmntPp5W9tSFu42P+kvwPKbn/P0q/a3I/s+D97N/q4f+Wif3Kbd3J+0acRLOcXkZOJE4/csM02nY6Fy8z0fXr5ehFDq2m+Za/wCnWvCr1uHH978v8+tcr4rvLWe7tGhuIZFFsoJWVjg7m456fSu4husSWp82YYVOkicfe/x71x3jGbde2f7yQ4tlHLqcfM3pU1L2OnAcvt9E/v8AXyOg0m9u10iyVbW6ZRbWwBF1AAQDxwTn6Z5Hekvr27NlCDa3agNZ4/0qDtKMDr+Xp34qxo3mf2LYY8j/AI9rb/nn68f/AF/1pNR8z7DD/qPv2fXy/wDnsMf/AF/1p293c5rx9s/dXxefdeZx+uaz401iS503Q9FuNJKkpJf315DlS0gOYQuVc4PUnAb6VgyQ2nwu1WO/03T9VXStQglh1BBOLlw4YbLg43YyflYkjJYEdK9Zbf5sf+p/1jf88/8AnoP8/wD1qoyhjqahhCVNlOCPk5Hmrn/P5VTRyQoxktbX7/f8jyDxXeJf/E6XXzhrK0XTHjnN1EV2vNktvB2kEL+Heu6sviBoyG5Y342S3MrKxu4QDuAA5PHPr37VzPwy8NTWeveNtF12wtJLO2uLeSzVkUw+UJJJY9ueDtL/AIYxXon2GDUbLU7C/gtbiyluJ0khfZtYYHHH0H9KmxOHv7OUuVa97/5lDxZ4nk0HRRLc6bqcz3DyW0MNvLDI8jsnQAHoByT0Arn77XvFfiDw69n4a0S903fGIZL3VZkhMf7lQTFGPmY4LYbgcDk1N4X8DzaFPd3d9qI1Fbe2lttMWRl/0aEqWYEHguScbuuBiu1tt/8AZkP+p+4n9z/nj/n/APXTtqaJOcbtJK+39M81l02++HR0ebQINWfw5bXpe8043UUxj3pkyQqoLkr+8YjJyD61g69rcKav/wAJJazH7I3iDSgZjcRhRF9lxuz0HDnr05zXtF+ZBeaeR5AIvU5/d/8APJq8m8AeBbHVD4t0jWLB00pfEH2m3hkkCq6Ip2DJ6p2x6UuXoc9ej7sVBK1r9fPz6nUxfEzw7HcmdtYgWKSC2RWOoQBTsd84OcHGfw71u6r4sj0jTTqN1BfPbTTRLD9nnhmedmlYqEVSS5IyRj3PSpBpVlcTSWk9jp8loLS1AhaKLaAXk6DHHU5/WsPwt4Cj0fWEvJ7tbiKwkdNMtAVWGzR53PAz8zYO3cei8dKaTN60pXtyx1trrpovMxR4v8XXGmPa6V4V1GD7eJUsbu5njIhUynzGuUH+rIJ4XPzY6iqGpDU/AqaVHc6vrl3p2oie2u0vJorgGYrkOrLlkBZR8vTnivT9J3/2Z/yx/wCXj+5/z2P+f5UutNKmj3bKYlYQSEFSgIO/qPf0/Slb3SlRtWV2nLm3fr5W+Z4z4o1aDXfidpGqaY32uJNZs4/MjuI3y3lSArkHAOR9BXrWqau9vq1kLpJYJGa42JLe26l8qBxz/ntXlXjrw75HjS5tdPlFimp67ZyPKkaHZJJBKGKdvf6muxn+Gvhdbiyt5tJtJ2Mc0LzSuGdgqDnJY4Oecjv0os7GGFlK8rQV9d79vU3PE/i2Hw5aC51aC9jV18uNEmikkkbZ91UXJb8O1cqnja+8VpNB4Ptdftri9vola9nhEKW0aRr5hLMMbyoZV+orW8I+CZND1B73UtVl1a6gge2sGuHQ/ZrcrkD3kPQt16CussjIdWvyTBn7RF18v/niKbRr71SEtFHT57rzZ5lo7r4F+IWnxR2VxbaRf6bDbG5muYgWniJCBn+7uIkA5wTXN6BYS6Z468Nyxhbh21/UxvhkUF+GXgngfcByfavbb3TLbWdMbT9TgtriyndBJE5QBsLkZ79QD9RXk/ibw9JZ2Hw60zw5KdOZ75R9ohIMqB1kMjbjkbiNxJahqzMqqdOLkkuVNaa9/X1PVL+7vPsUO+0u0G6zwTdQdpRgdfy9O/FVdZ8WW2kXVnFqbS28sjyOiPdwlsCQZbAPA9zxmuY1HwCukw2V94TvWsdQg+yIUuLjzYLrMoH75SSSc4JYYPFb/hXw/c6Zf3mq6pJYz65qdwWuJbcKI0RGVUiTcchQBnnqWY0Wd9zfnukuRbvvbZeZy2vXsvjzU00zSp74aPFZ3C6sYZ4kaVJD8kaOwIOSMtjkAe4rV8BazfW39seHdQa6ub7R3eMFp4g5tWCGFmJP7w4ypZe6jvXVTGQ6omTCf9Dn/uf89Vrn/Hngi38U3RuTeS6dfwRyR/abN0VpImCho29VOfw7UJdiJ03FqaSb177dt/mcL8GtSc+NPFwtUlnWUmYbJUQkF5MEluDn2r1e5vbs2E2bO7A2SjP2qDj5PrXjGm6Prdp8YfFOmeBrrS9HW2tImKXVv5kbR/3V7dya7RvCniS3W31pvEKXeuJ5gu4JnCWM0G3JiWNeV9Q3XNJLQIVOWVuRO39d0bVx4zsLBFs7udkuY4ot0Zu4SQDEcZAPGf61y3jHU5PiPGND0i0uLnR3kDXF7JdosMrm3fyo0I4kw2GJzgbR3rqfAfh9/D2gN500dxqN6wury43q3mOYzjGecBcAD29a370MlxpyKLdVW8jVVHlgAeS3AHTH6U2nbcuUfau0opLXv/n95yXgHxRePaW2h6ukw8RaZEIbiJZ4496IGCzJvA3Iy4ORkDJGc1wn7NElzptt4gsY4p5VLWF3hJkj2+YueQ+M9ByOPWvSfF3g9fEs2nXEOoz6VqUEJgS8s2jDGFw2+NgeCDgHnkfjXndjbarpPxGvPB/hp4rX7bpenmXUpNjSQQQgoXQdPMJZRzwOp6UNO5xVE4VINxTS/H8f8j2WO+vd8uLK8yZE6XUH/PVvf/PXpXMR+OtIs21KyudRhjurQ3TXEUmo26tGDMScgn359e3FZ9x4O8Sa481l4n8TRTaJ5pDQ2EaWs0w8zEe6Qe+4tjjhe2a3dD8OaTaaSbeHS9M8qJ7kKGiic/69u5ySfx+lFnc7FOUou0IrVb37PszzP4reP9J1mz0KDT7o3EMOqRST3KyxyQwr5m4bpF4UnHQ/XpXoHxN1m+h8A65cWsM6maNkila5hdD5iBAflPOQ3auP+PNhbpYeEbVLa0jtZ9aVZookRRICTwQvX8a6LSPhX4d0XafKe8eK5Lxm5uN6pj5kUJnGF4A47etFtTK05JxajZ376beZD8PZJrP7Rp8VvKZLLUbuJo47iPg+RGDyT9T/APXruDe3ok5srsHy/wDn6g/ufWvJ9D8Oyaz8S/Fkesqj6PHqU0sVvjZ5sxhXL7gRlQBwB3rpNS8EalY3bzeBtYi0YTR7Z7SfE9uQU5dQSSsmOnOKIoKVRxpRXs07J9X3fmOT4hwWXjS406a3vUt1cGe8MiGKOZYUAhDgFd/JzkjGAOtPT4lRJrOnWtrYajPYPPHDcXyyIsUMzriJAx4YnByc4XKjqa3fBWjw+HYptP03aIoriJi8jozyOYQWdiepJyT7mrWs6PB4i0SbStTCtaXTIr7JFRxhcghuoIIBz6ihLTcurGTve2yf4bb7ficr4q1Sa28I6JBLBcqbm80+KI/aIvnYXCvgD6ITz0xzWh4Wu7pvAHh0LaXQQWmm4IuYccMuAOc/TPTvVDwb4A0fTIYNUVJrzUXVJ0mvbkTGN2JU7ATgcE9u9Y3hnwVd3vhvT7rxtb2b3aQWFnbWccm1baBXwNxDDMjbiW9Bgdqm2g3dYvmcVdvu9NUemyXt6HhzZXmfMfGbqD/nqvv/AJPPSuEm+J+ir4oGnzPewy7LizWWZ40geQOGKrKfkOMYOD14ptz4G1vTdVvl8IavaaZpGpIsc0MzGaS2dZQrSQZJCkrtGDxnJrodM0Cy0u203SY7e1mtLKwlSMTrHISRKuWO7PzEknPuapplQm27RhFb9/PzMaH4r6Tdare2zJfwxMri3u5pYhDd8IT5b9Hxx07dOhrz/wCJFzaeI9Z1XUrZnmNlAhRywcZe4iBAZeM4Fe8Sx4ll+S2zEjhMCP5BhR8vpxxxXE/FByngXxVcTqkiW1x55VCoPy+Se3t+FDXcylG9GXNbTXS/kbmseJ7ayLWl7MLa5mWYJHLqFsrH93zxuz0/+tWXr/jKTTPD9sNPga81C7EMFnALuJxK20AkhMttUEknHA61jeAvClhc+BpdS1jTbS41DV0uLm5e7SN5NrZKKSeRtXGMYro/DXg7QdBiS80fSbC0uWgRTJHtLYZMkDJOM98UWd9zSMpTh8MUn63/ADMC48aeI/D8tnb+NdHvbm7SeOWO70QCaGdzGyiIDGVkycc8YHWrvgnxhrEl/c6b4pjgg1W08uZY4LuKPbbuhZc7yMld20kZGQa7G/8AMF5Yf6jP21P+ef8Azyas7XPC2j+JJLH+3NNsr3yowqGXaMKckjII4yBwfQUW3IcJRindPTZ/8D8Dy/xNrTat8afBc9pKJbXSDHbyBZ43KzzrKQocfL92MdTxmvU9T8TQ6NLEurM9k11OscHn31unmsJScDJ5PP4ZyeCK8f8AjrpcPhnwna3Hhy0s7EWlxYy4gVRnAuFXOOSct1P+FeheFvAGj2ugW0OpabY3l6bSK2uppW8zzSzASEbycbioJIweB2pJGMFKnUnFxi27PrZXOP8Ai7ei61TwFo17YSzC41+ecpNNE6sqysrIQPXzOp44OKu33hbxN4d02Sy8GalNZeHpFkFxZ3ssMxt4y/z/AGdgcgkYwpGOMjrWV4l8GaNofiTwjqlhCY7q519oDmbzFREMuFUZO0HAz64Fev65v/sW9/1P+ol/uf3/APP9KLe6dMacaldqpFfF3f8Amcvr/hcv4Mh0PRrO4tZNPnE+nzzXcL+VOg3CRjyTlsliOuSK5XUG1mbxFpGsavpstnPf67AVgFzGSWiheMnnBAPUFgOK9fu9+Jc+T/rG6bP7n+f/ANdcD8YjKIdCKGMONSlKlNmQRBJ6U2rLclxj8aSVk+/Z+Z02r+JYdGQzauxsoxFndcX9unGzHdufSuK1LV/EfizWJIPAmqPYW6xRyzX4MUn73yyIowW+UqRuLEZIGO/Xa8J+C/D8FnpmoLpNi981jHmaYrKx3RAn75I5JNdRYBxq10B5AANuAP3eAPKNDQ0nUhK6SVul+68ziNO+KMFt4dmk1CKeLXLBxBNp63EbSvcBCqhUA3lXYcMF+6c1V8CeJPFGlX2laR4pWK5i1eDztOmguI43XaVYwFT1xuJBODgc9DXex6NYT6tY6rLY2L6lbOFhuSsfmIDHg8/Tjms2bw/Y+JPCtnZatBFJF5EZR1dUkiYll3Iw5VsE8/nQ07i5Jcrbto499d9/69Dy/wCKE2o3Hxe8HO8MscNlHYsEeaMtukuwPlI+Ufc/i6YzXtT315vi/wBDu/8AWP8A8vUH/PVff/PXpXlmt+CtH8F6bY3tlcz5m1XTJJZL25E5wsxOBnoBkkj25retPFviPxM9vP4R0WxTSWlkC6hqriNZh5gw8aL8xXdxk9unGaLa7nPSlGnUlzRV2/Pz8yPxH421e28UXNtpOgXmoJp1s/8AaWLqLfGkkgb92oz5jhRkqPUdjW1ceO9Ofw/qWvW0zzaZHC7mY3cI/ugKy5yrEjG3Gc8YyDR4V0WXQLa3s5547m9a1nmvLlnVjPO0ib3yeeSBgdgABS6h4G8P3PiGTWJNLsxqEcpuWdCoWWRQApdQdrYzkcdefWhJnQ1NWlZarZ9Nelv1ucNa+MPFmgtaeI/E8t1caNqMsiXdpbLGwsmkjV4SMANgL8rs3r2rn11xdV+P0eqWE8dzZPpsltE8NxG+SYCT86nbn2Ne7WfmGbVQ3kENdSAg+Xz+6WvHvjoT4bPhq+0C2sbS/uL94t8cSYZjEEG5V64DGlb3THEQVJJxSsrPr/mesLqNxb6Wks1tcJAkURaR7uBVACdSSeK47Qr/AFPxJrtp4ia8vhpsGotb2Fpa3kaRyKsbIZJCceYWwCP4QB1JNXrH4baRb2Zj1yMazfl1ae5vJQxdsdNoIUKMDC47V1NyrJLpiotuqrdxgKBGAB5LcY9KbWm50pRrSvKKtq+vbrqOgvrwSWv+h3fCp0uoP9rpz/P/AArk/FlxPJd2ZkhnjItlADTRtxub0/kea7WHf5lr/qPurjPl/wC1XH+Md322zz5f/HsvTb/eb0qai0PQy9x9vpFfj5+Zv6Ta3p0iyZLqRVNtbED7ChwM8c55+vekvrW9FlCWupGG604+wJ3lGD1//X0q3o1vnRbA+Tcc2tschB3P1/L+lJqVtmxh/c3HL2Z4Re8w9/yp2XKc3tf3zV18XZd0BtL7zY/9Mk/1jf8ALhH/AM9R7/56VSltr3+0APtUm77JOd32FOB5q+/69q2Gt/30X7m4/wBYw+6P+eoHr/k1Rlt/+Jmv7qf/AI85z90dpV96bSJpVdenXovPyHy2t/504+2ScBv+XCP/AGPf/P41VsbW9L3m26kXFzOD/oKHJwMnr/8AqrVlt8T3A8m44DcbRx9z396p6fb/AD337mf/AI+7j+Eeg96GldChV9x7fciC5tb4WMpN3IR5cuR9hTn5PrSW9re/2dERduBsTA+wpx+59c/561curf8A4l837qf/AFc38I/ufWktoP8AiWQnyp/uR/wj/njn1osrle19zp9yK19a3ou7INdSEm8QD/QEGD5Tds/p+NT29rfmW1/0yQ/u1x/oEZ7N7807ULb/AEywHk3H/H6g+4v/ADxY+tWIIMzWoENwS0YIAUc8N70JLUiVX3Ftt2XmZdva3pv5ALqTd9mtDu+wJyDI+O/696tJaX2+T/TJP9Yn/LhH/wA9W9/89KLa2zqUp8m45tbQ8KveR/fv2q5Hb/PL+5uOJEH3R/z1Yev+TQkh1auvTp0XZGPptrenTSVupFGLjj7Ch/5anPOf/wBVGtW16uj3he6kZRBKSPsKDPz+ueP6VZ0m3/4lf+pn6XH8I7TH3o123xol7+5n/wCPeU/dHZ/rSsuU19r+/tp8XZdzi/ifDdprHg5JLl2Z9fjCk2aptPlnsDz9DXWXlrejU7UG6kLFrjB+woMfIM8Z/wD1VyvxWHleJvAkQilHma+PvKM8RdOvXmu0vbf/AImtn+5n+9c/wj+4Pem0rHLhqnvy269F/KNe1vvm/wBMk/1X/Pgn9z61HZ2t6dUvQLqQMLiME/YEOT5I7Z/T8avvb8t+6n/1Wfuj+59ahsbb/ibX48m4/wCPmIY2L/zwHvQ0tDVVfdltt2XdDLS1viIsXj/6xf8AlwjP8H1/z1rmP+EZvtSu/Ceqw3jRjTMSYNoMlZFePAAOG69W9K7K0t8iL9zOcyKOFH9zPrVPQrfOiWZ8m4/1MHIUd3Pv+VDSuKc1KDTtvHovMr31reizhLXUjDdacfYE7yjB6/8A6+lWntL/AMyD/TJP9a//AC4J/wA9B7/56UalbZsYf3Nxy9meEXvMPf8AKrb2+JYP3NxzK4+6P+egHrRZXG6vurVbvouyMeW2vf7QA+1Sbvsk53fYU4Hmr7/r2q5Pa33mXX+mScK//LhGP7vvx/n1pstv/wATNf3U/wDx5zn7o7Sr71dnt8SXX7mcYV+qjj7vXmhJDlV+Hb7l39DB0/Q0XVtQ1OEGPVJZJree5+xqzSooG0YJwAPQVcubW+FjKTdyEeXLkfYU5+T61Pp9v899+5n/AOPu4/hHoPepLq3/AOJfN+6n/wBXN/CP7n1oS90OdRnZW+5FOG1vfsERF24HlJx9hTj90ff/AD1p19a3ou7INdSEm8QD/QEGD5Tds/p+NWLeDGnQ/up/9VH1Uf8API+9LqFt/plgPJuP+P1B9xf+eLH1oaVh+1997bPohkFrfeZa/wCmScqn/LhGeze/P+fSsOw8MLD4tvNZSSU6nPZWkbTtZI2E3t8qjOADtH+8RXTw2+ZLUeTcHKr0Uc/e6c1VtrbOpSnybj/j1tD91e8j+/ftQ0rkc6d27aW6Lv6Alpf75f8ATJP9Yn/Lgn/PVvf/AD0qrY2t6bSYrdSKN91x9gT/AJ7HJ6//AKulayW3zy/ubjiRB9wf89WHr/k1S063xZT/ALm4/wBZddVHac+9Flcaq+69t10XZnlvx1t7lZPA/n3DSA61wGtlj5G706/SvUru0vgXzeSf649bCMfwj3/SvN/jvCFk8DZSRc6w33wBnAbpzXqd3b4L/upx++I5Uf3R70JakwqaX03fReRl3lte/wBp2ga7kJ3XGD9hQY+QZ4z/APqqx9lvvM/4/JP9X/z4J/c+tLe2/wDxNbP9zP8Aeuf4R/cHvVr7P+8/1M/+r/uj+59aElqXKr7sdtuy7szdPtr06hdgXUgIniBP2BDn9yO2f0/GrFpa3xEWLx/9Yv8Ay4Rn+D6/560unW//ABMr39zcf8fEP8K/88AfWrVpb7hF+6nOZE6KP7mfWhJWFVq6vbZdF2MnRbW9bSLMpdSKphhIH2FDj5/XPP8AWnX1reizhLXUjDdaYH2BO8owev8A+vpU+hW+dFsT5M/+ohPCju/1p+pW2bGH9zccvZnhF7zD3/KlZcpo6v75q6+Lsu4PaX26L/TJP9Y//LhH/wA9V9/89KpS217/AGiB9qk3fZJzu+wpwPNX3/XtWy9t88X7m45kcfdH/PVR6/5NUJbf/iaL+6n/AOPOc/dHaVfem0iKVX069F5jp7W+8y6/0yThX/5cIx/d9+P8+tYHiPw7c+IdC8RaQ906i7kkiJNoq87IyScHPQdPxrqp7fEl1+5nGFfqo4+715qrZW/+lakPJuOLqX+Ef88k96GldEc6nTlF21XZeRVewuoNMaKK6k8mOGRFU2KfdEeAM59KdBa3v9nIRduB5UfH2FOP3frmrd1b/wDEvm/dT/6ub+Ef3PrSW9vjTIz5U/8AqYv4R/zz+tOyuWqloWVvuRWvrW9F3ZBrqQk3iAf6AgwfKbtn9PxqaC1vvMtf9Mk5VP8AlwjP9735/wA+lP1C2/0ywHk3H/H6g+4v/PFj61Ygt8yWv7mc5VOijn73TmkktRSq+4ttuy8zifHHhG68XaBqeitdsklxb2RWZrIAJidjn5TzwGA9c89K6uOzvhvH2yTh0H/HhH/z1b3/AM9KLW2zqUx8m4/49rX+Ed5JPf8AKrqW3zy/ubjiRB9wf89WHr/k0JImpJKbkrXfL0XZHl3j+C5F74J3Tvz4hmC5tUTDZl568/Tt0rudatr1dIvC91IyiCUkfYUGfn9c8f0rkvG8GL7wUPLlXPiC5+8o5wZenJrttct8aJe/uZ/+PeXqo7P9aVvdLhU/2jp8XZDru1vgJc3j/wCsb/lwjH8H1/z1ryr9o+K/i8KacEuWM0mqCKMm2WLazAr1B9+lewXdvgS/uZxiRhyo/uZ9a81+O2nC9sfDlqd8Il1yNS8ijAxz2PtTklYydTmg1ps+i7M7ew0u/srS2tGvH3QW6xHFgn8MYHr7Ulla3p1a5AupA26DJ+woc/uzjjNajQZmP7mf7mcbR/c+tVbG3zrF2PJuPvW/G0f88m96GloaQqWhJafD2XdCWlrfERYvH/1i/wDLhGf4Pr/nrVXQ7a9bSbMpdSKpgiIH2FGx8x755/rWraW+RF+5nOZFHCj+5n1qnoFvnRrL9zOf9HiPCju596Glcbq+5LbddF5+R5p+0RbXkfwqupXuZH2NaMP9GWLB3kA7hz/j+Fd14b0e+0zw7otgtzIgtoFhC/Y0fG10GNxPP+R3rC+NWltqPw5nsY4JN91LYQqzKPlLTqMjn8Pzruvsu3yF8m4++w+4O0qj1/yaLK5xwqfv5PTp0XZmTNa3o1LBupN32W4O77CnA81eOv69qtz2t95l1/pknCv/AMuEY/u+/H+fWknt8at/qZ+LS4/hHaVferk9viS6/czjCv1Ucfd680JI7JVfh2+5d/QzbS1vTNqWLqRcXTg/6AnJ8peevH0/GvHv2mrW6Tw/4bnmuHkCapgZt1iwSo7j6V7XY237/VP3Nxxdyfwr/wA8k968u/aK0uW78JaL5UbqBq0akuAOq9ufalZcpjial1bT7PReR6VFbXzWqMbyTlYzzYof4PXNR3VreifT83UjE3aAf6AnB8lvfn6fjV2CD/Qoj5M/3Iv4R/c+tR3lv/pGnfubjm8jH3R/zxY+tNpWN41fee3XouwkFrfeZa/6ZJyqf8uEZ/ve/P8An0rk/FkNwl3aCWZpCbZSCbZU43N6dfrXbwW+ZLX9zOcqnRRz97pzXHeMYtt7Z/u5Rm1U8gc/M3vU1ErHVl9S+Itp9y8zb0nS9Ok0iyd7O0Z2t7Ykm3ckknk5/n69qS/0vTks4StpZglrQZ+zv3lAP6dfXtUel6vpcWlWcclxaiRLe3VgYJCQQeef5+vai+1fS5LOJVuLUsGtScwSdpQW/Tr69qPd5SbYj2r+K3N5+RdbSdN82P8A0Kz++3/Lu/8Az0H+f061Tl0vTxqCoLS02/ZJmx5D9RKoB/8Ar9qnbW9J82P/AEm1xvb/AJd5Onmf4fpVSTV9MOoLILi22i1mXPkSdTIpH6Cm+UmnHEX15uvfzNCXSNN864/0Kz6N/wAu7j+5+X+fWqtjpenM95us7Q7bmdR/o78AAYH+elSya1pPnT4ubXBzjEEmP4en6/rVay1fS0e73XFsN1zOw/cScggYofLdCjHEcj+L8Se50rTlsZmFnaAiOUg+Q/ZKSDStObTomNnaFiiEnyHz/qv8f8aZcaxpbWUqi4tixjlA/cSd04pINY0tdPjU3FsGCICPIk/55Y/n+tHu3KSxHL9r8SW+0vTlu7ILZ2YDXiKcW78jym4+me341Pb6Tpplts2Vn9wZzbuezfnVO91fS3urIrcWpVLtGb9xJwvlMPyyang1rSRLbk3NrgIM5glI6N19e36ULl1IlHEci+Lbz8yO30vTjqEiGzs9otrUgfZ36l3z/TPr2q0mkaaXk/0Kz/1if8u7/wDPVv8AP0461Rg1fSxfyO1xa7Tb2q5MEnUO+79CM+varKa3pIeTNza/fXH+jy9PMP8AT9OOtCcR1I4i+nN06Psivpml6e+nbntLQtifnyH7SkD9Pyo1nS9Pj0e7eO0tFdYJSCIHBB3/AOfpUenavpkWn7HuLYNifjyJO8pI/TpRq+r6ZLpN3HHcWxdoZAAIJBk7uKXu8ppav7b7Vubz7lbxN4L0nV9R0u6dY4Dpt6blUht2AlIUDa2edvPQc1fvNL05dTtVWztArNcZAt35wgx/ntUtxrWlFn23Nt99ukEg7L/9eq13q+ltqVq63FsURp8nyJOMoMU242MqNOvF3tLVPo+xbfSdNy3+hWn+q/54P/c/zzUdnpenNqd6rWdmVW4iAH2d8AGEHp9e1D61pWWxc23+rx/qJOuyo7TV9LXUrx2uLUI88ZU/Z5MECIA/hmh8ug1HEcsvi28+6LdrpOmkRZsrP/WL1t3P8FVNF0vT30e0d7S0ZjDCSTbvknec/wCe/aprXWtJAi3XNt99ScwSHjZ/jVXR9X0uLSbWOW4tg6xQggwSHB3HP/1/XtQ+W43HEcr+Ldd/Mmv9L05LOEraWYJa0Gfs795QD+nX17VafSNN8yD/AEKz/wBY/wDy7v8A89B+f0/DrVG+1fS5LOJVuLUsGtScwSdpQW/Tr69qsvrek+ZDi5tcCR8/6PJ08wdfw/Sj3LiccRyr4t337Iry6Xp41BUFpabfskzY8h+olUA//X7Vcm0nTfMusWVnwrYxbuP7vT0rPk1fTDqCyC4ttotZlz5EnUyKR+gq1NrWk+Zc4ubblWxiCT/Z6enf9aFyjlHEafF+PcjsdL05nvN1naHbczqP9HfgADA/z0p9zpWnLYzMLO0BEcpB8h+yVBZavpaPd7ri2G65nYfuJOQQMU+41jS2spVFxbFjHKB+4k7pxSXLYbWI5/tfiPh0rTjYRMbO0LGKMk+Q/Xyj/n9aW+0vTlu7ILZ2YDXiKcW78jym4+me341DDrGlrYxKbi3DCNAQIJOojIP60t7q+lvdWRW4tSqXaM37iThfKYflk0PlsHLiOd/F17luHSdN8y2zZWfKrnNu5/vdfWq9vpenHUJENnZ7RbWpA+zv1Lvn+mfXtT4da0nfbZubbAVc5gk/2uvr2/SoINX0sX8jtcWu029quTBJ1Dvu/QjPr2pvlJUcR73xdO/cvJpGmb5f9Cs/9Yv/AC7v/wA9W/z9OOtVLHS9Oe0mLWdoSHuQP9HftMQP06enepk1rSd0mbm1++uP9Hl/56H+n6cdaq2Or6XHazK1xahi9wRiCTvMSP06enei8bgo4jlfxbrv2ZyXxV8Mfbf+EZn0qwjKWV/JcXTRRMoSIBhls9RnAwPWu6u9J00b8WVn/rj0t3H8I/ziqGr6vpkuk3ccdxbF2hkAAgkGTu4q3da1pJL7bm2/1pPEEg42j9KE43FGnXSTXNdt9H5EV5penLqdqq2doFZrjIFu/OEGP89qs/2Tpvmf8eVn/q/+fd/7lUrvV9LbUrV1uLYojT5PkScZQYqx/bWlb/8Aj5tsbMf6iTrsoXLqVJYjlj8W3n3YzT9K05tQu1aztCqzxAA27kAGEH+f+NWLTSdNIizZWf8ArF627n+Cqdjq+lpf3TvcWoV5oiCYJDkCEA/rVi11rSQIt1zbffUnMEh42f40LlsKpHEa25tl37EGjaXp8mkWbvaWjM0MRJMDkn5/8/XtT7/S9OSzhK2lmCWtBn7O/eUA/p19e1QaPq+mRaVZxyXFsHWGIMDBIcHfz/8AXp99q+lyWcSrcWpYNak5gk7Sgt+nX17Uvd5TRrEe2fxW5vPuXn0jTd8X+hWf+sb/AJd3/wCeq/5+nHWqUul6f/aKoLS02m0mbHkP181cH/6/arD63pO+PFza/fbP+jy/89B/T9OKpyavph1BZBcW20Wsy58iTqZFI/QcU24kUo4jrzde/maE2k6b5l1iys+FbGLdx/d6elVrXS9Oa61ANZ2hC3Mir/o78Dyk4p82taT5lzi5tuVbGIJP9np6d/1qC11fS0ub8tcWoD3EjL+4k5HloB+oND5boUI4jlfxbefkTXOlactjMws7QERykHyH7JSQaVpx05GNnaFjFGc+Q+c+XTLjWNLaylUXFsWMcoH7iTunFJDrGlrp6Kbi2DCKMY8iTqE5/Wj3blWxHL9rfzJb7S9OW7sgtnZgNeIpxbvyPKbj6Z7fjU8Ok6b5lrmys+VXObdz/e6+tU73V9Le6sitxalUu0Zv3EnC+Uw/LJqaHWtJ8y2zc23CrnMEn+119e36ULl1JlHEci+Lbz8yO20vTjqEqmzs9ot7UgG3c8mR8/yGfXtVtNI0zfL/AKFZ/wCsX/l3f/nq3+fpx1qhb6vpYv5ZGuLXaYLZQTBJ1Ejk/oRn17VaTWtJ3SZubX764/0eX/nof6fpx1oXIFSOIvpzdO/ZHI+KdJjmPhn7NBax28etzPcPsMY2gyoqnd1yWCgDnnFdNrOl6fHpF26WloriCUgiBwQd/wDn6Uy01TSRZSLLNZlhLcOoNvIcZmJUj0OOnp3pNX1fTJdJu447i2LtDIABBIMndxS93lHClWjX5kpay8zQutJ00CXFlZ/6xulu4/grM1rw7pF5qemJPZWxWG4mnULDIoLony5HcDPQ/jV661rSSJdtzbffYjEEg42f41Wu9X0ttStXW4tiitPk+RJxlABTbjYmEK8laSlaz6PsXf7J03zP+PKz/wBX/wA+7/3Kr2Wl6c2rXKtZ2hVWgwDbuQMxnNP/ALa0rf8A8fNtjZj/AFEnXZVez1fS11S5dri2CO0OCYJDnEZB/Wh8mg1HEcsvi28+6L1rpOmkRZsrP/WL1t3P8FVNE0vT5NJs3ktLRmaCMkm3ckndU1rrWkgRbrm2++pOYJDxs/xqro2r6XFpdpHLcWyusEYIMEhwd3PSh8txuOI5X8W67+ZS8XWFlbaPYywW0EcgvtL+ZIH/AOftM7vUfTrxit19J03zIz9is/8AWN/y7v8A89V/z9OOtUL/AFbSpbOFRPaMQ9qxBt5P4ZQT+IHX17VafWtJ3R4ubX77Z/0eX/noP6fpx1ovG5iqGIjJ1Peu/J9F/wAEhudNsH1Zt1randbTuf3D8nzV5/z0q1NpOm+ZdYsrPhWxi3cf3enpVCbV9LOo+YLi22C2mXIgk6mVSP06frVmbWtJ8y5xc23KtjEEn+z09O/60LlNXHELlS5vufcS00vTmm1INZ2ZC3Tqv+jvwPKU4FZniXwpp2qafbldlo9nM12rQQNliiHCnOeOavWmr6Wk2oFri1Ae5dl/cScjy1H4ciluNY0trKVRcWxYxygfuJO6cUly2FOnWm1GSk1p0ZJb6VpzWMTGztMmOIn9w/8Acpt1penLPYBbS0Aa7jU/6O/I8pjj8/8AGm2+saWtlEpuLYMI4gf3EnZOabc6vpbz2JW4tSEukZswScDymH8z+dD5bFqOI5n8XXv2LsOk6b5lrmys+VXObdz/AHuvrXKeKrO1gu7RYIII1NspIWJhzubrnqfeulh1rSfMts3Ntwq5zBJ/tdfXt+lcz4nvLS5urV7aSF1FuqsVjYc7m6570qnLbQ6MCqyr+/zW87+Z/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing the two major findings of mitral stenosis: right ventricular hypertrophy and marked&nbsp;left atrial abnormality (enlargement). The presence of right ventricular hypertrophy is indicated by the tall R in V1 (as part of a qR complex) with right axis deviation. Incomplete right bundle branch block is also seen as evidenced by the rsR' in lead V2, and the prominent S waves in leads V5 and V6 with normal QRS duration. The large negative component of the P wave in lead VI (an anterior-posterior lead) indicates left atrial enlargement; the tall (&gt;2.5 mm) P wave in lead II suggests concurrent right atrial enlargement due, in this case, to secondary pulmonary hypertension. The ST and T wave abnormalities are nonspecific.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18713=[""].join("\n");
var outline_f18_17_18713=null;
var title_f18_17_18714="Initial treatment of advanced stage (III/IV) follicular lymphoma";
var content_f18_17_18714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of advanced stage (III/IV) follicular lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/17/18714/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/17/18714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19673870\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of FL depends upon the stage of disease at presentation as evaluated by the Ann Arbor Staging system (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). Patients with localized (stage I) disease are candidates for radiation therapy, which is curative in a percentage of patients. In contrast, the treatment of advanced (stage",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    disease is not curative and focuses largely on symptom control with chemoimmunotherapy with or without radiation therapy. The management of patients with stage II FL is more variable, with some clinicians offering treatment similar to that used for stage I disease and others offering treatment similar to that used for advanced stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H87719265#H87719265\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Bulky stage II FL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of advanced stage",
"    <span class=\"nowrap\">",
"     (III/IV)",
"    </span>",
"    FL is discussed here. The initial treatment of limited stage",
"    <span class=\"nowrap\">",
"     (I/II)",
"    </span>",
"    FL and the management of relapsed or refractory FL are presented separately, as are the epidemiology, clinical presentation, pathologic features, diagnosis, and pathobiology of follicular lymphoma. Of importance, the recommendations presented here pertain to patients with histologic grade I, II, or IIIa FL; patients with grade IIIb FL are treated as aggressive lymphomas (eg, diffuse large B cell lymphoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19674049\">",
"    <span class=\"h1\">",
"     PRE-TREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with NHL must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. These investigations are important for determining the treatment strategy and for predicting outcome with the Follicular Lymphoma International Prognostic Index (FLIPI) or one of its variants. General approaches to the diagnostic work-up and staging of NHL are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). The pre-treatment evaluation for patients with advanced stage FL is the same as that of patients with limited stage FL. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Pre-treatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675515\">",
"    <span class=\"h1\">",
"     ADVANCED STAGE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced stage disease includes disease on both sides of the diaphragm (stage III) or diffuse involvement of one or more extralymphatic tissues (stage IV) (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). Seventy to 85 percent of patients present with advanced stage disease. Survival rates vary and can be estimated for the population using the FLIPI score with five- and 10-year overall survival rates ranging from approximately 50 to 90 and 35 to 70 percent, respectively in the pre-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with advanced stage disease are usually not cured with conventional treatment. While remissions can be attained, repeated relapses are common. Treatment focuses on the alleviation of symptoms and improvement of quality of life.",
"   </p>",
"   <p>",
"    The treatment of patients with advanced stage FL varies widely [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/1\">",
"     1",
"    </a>",
"    ]. Whenever available, patients should be encouraged to participate in clinical trials. Asymptomatic patients can be observed initially. Once therapy is indicated, immunotherapy-based treatment (eg, chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) is preferred because it results in superior response rates, progression-free survival, and overall survival. Off-label use of radioimmunoconjugates may be considered for patients with comorbid conditions that make them poor candidates for chemotherapy. Alternatively, oral chemotherapy without rituximab (eg, low dose single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) may be used for the uncommon patient who cannot tolerate rituximab or who is not a candidate for more intensive intravenous chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/2\">",
"     2",
"    </a>",
"    ]. Local radiation can be administered for the palliation of locally symptomatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675522\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with asymptomatic, stable FL do not require immediate treatment, but should be followed closely. The disease course is variable with some patients demonstrating stable disease for years and others progressing more rapidly. Rarely, patients may have spontaneous remissions lasting longer than one year.",
"   </p>",
"   <p>",
"    Clinicians differ in the criteria that they use to initiate treatment. The two most commonly used systems are those proposed by the Groupe d-Etude des Lymphomes Folliculaires (GELF) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/3\">",
"     3",
"    </a>",
"    ] and the British National Lymphoma Investigation (BNLI) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/4\">",
"     4",
"    </a>",
"    ]. Our approach, described below, incorporates factors of each.",
"   </p>",
"   <p>",
"    The following findings are clear indications for treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local symptoms due to progressive or bulky nodal disease",
"     </li>",
"     <li>",
"      Compromise of normal organ function due to progressive or bulky disease",
"     </li>",
"     <li>",
"      Presence of systemic B symptoms (ie, fevers, weight loss, night sweats) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H13#H13\">",
"       \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for B symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Presence of symptomatic extranodal disease, such as effusions",
"     </li>",
"     <li>",
"      Cytopenias due to extensive bone marrow infiltration, autoimmune hemolytic anemia or thrombocytopenia, or hypersplenism",
"     </li>",
"     <li>",
"      An increase in disease tempo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are used as general indications for therapy because treatment of these factors is thought to improve quality of life. These are similar to the indications for therapy used in the trials comparing observation with initial therapy described in the previous section and most of the trials of chemotherapy for advanced stage disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675529\">",
"    <span class=\"h3\">",
"     Observation of asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from several retrospective studies and three randomized trials support the use of an initial period of observation for asymptomatic patients with low volume disease. The randomized trials compared chemotherapy regimens of different intensities with initial observation followed by chemotherapy at the time of progression.",
"   </p>",
"   <p>",
"    The largest prospective trial of observation in FL included 309 patients with asymptomatic stage III or IV indolent NHL (66 percent FL) randomly assigned to immediate treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    or initial observation followed by treatment with chlorambucil upon the development of progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/4\">",
"     4",
"    </a>",
"    ]. Progressive disease was defined as an increase in disease tempo or the development of signs or symptoms related to bulky disease (eg, cytopenias, B symptoms, effusions). Radiation therapy was allowed in either group for control of local symptoms. Median follow-up was 16 years. Patients who underwent initial observation demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar overall survival (approximately six years) and cause-specific survival (approximately nine years) when compared with those who received immediate therapy.",
"     </li>",
"     <li>",
"      Nineteen percent had not yet required chemotherapy 10 years after enrollment. In an exploratory analysis, 40 and 16 percent of those older or younger than 70 years, respectively, had required chemotherapy at 10 years. The median length of time until chemotherapy was 31 months.",
"     </li>",
"     <li>",
"      Seven patients had spontaneous clinical remissions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar outcomes have been noted in other prospective trials of initial treatment versus observation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/3,5-9\">",
"     3,5-9",
"    </a>",
"    ]. The prolonged treatment-free period potentially gained with initial observation may also decrease the potential for drug resistance by avoiding exposure of the tumor to chemotherapy.",
"   </p>",
"   <p>",
"    For asymptomatic, stable patients with advanced stage FL, we suggest initial observation rather than chemotherapy at the time of diagnosis. Immunotherapy-based treatment (eg, chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) is reserved for disease progression. This preference is largely based upon the prospective trials that have demonstrated no difference in overall survival with deferred therapy and the theoretical avoidance of drug resistance. Alternatively, patients seeking immediate treatment should be encouraged to participate in clinical trials. As an example, an international study, recently closed to accrual, is comparing initial observation to initial treatment with rituximab monotherapy in asymptomatic patients.",
"   </p>",
"   <p>",
"    We follow asymptomatic patients in clinic every three months for the first year and then every three to six months thereafter until progressive disease is noted. At these appointments we perform a history, physical examination, and laboratory studies including a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), and beta-2-microglobulin. Imaging studies are repeated only if clinically indicated. Progressive disease is defined by an enlarging liver, spleen, or lymph node mass or by the development of new lesions, signs, or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progression of FL to the more aggressive variant diffuse large B cell lymphoma (DLBCL) occurs regardless of whether FL is treated aggressively or conservatively, at a rate of approximately 3 percent per year, depending upon the magnitude of the large cell component. Histologic transformation should be suspected if there is a rapid progression of lymphadenopathy, infiltration of extranodal sites, the development of systemic symptoms, or an elevated serum LDH. Biopsy of a suspicious area is indicated in such circumstances. In addition, we have a low threshold for obtaining a biopsy for all patients with FL at the time of progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675536\">",
"    <span class=\"h2\">",
"     Immunotherapy-based treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185285840\">",
"    <span class=\"h3\">",
"     Overview of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy with monoclonal antibodies is a key component of the treatment of patients with FL; its chemo-immunotherapy results in superior response rates, progression-free survival, and overall survival. The anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was the first monoclonal antibody to be used successfully in FL. While a clear benefit from immunotherapy is recognized, the ideal timing of administration (eg, before, with, or following chemotherapy) and preferred agent are yet unknown.",
"   </p>",
"   <p>",
"    Retrospective analyses have demonstrated improvements in survival of patients with FL over time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This improvement appears to correspond with the addition of immunotherapy with either monoclonal antibodies or interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The use of interferon in front line therapy has been largely abandoned since monoclonal antibodies offer a similar benefit in survival with a more favorable toxicity profile.",
"   </p>",
"   <p>",
"    The benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to combination chemotherapy has been demonstrated in several randomized trials of chemotherapy with or without rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. All of these trials have demonstrated improved response rates and time to progression when rituximab was added; many also showed an improvement in overall survival with rituximab. Progression-free survival rates at three years were increased approximately 15 to 30 percent.",
"   </p>",
"   <p>",
"    A meta-analysis of seven randomized trials involving 1943 patients with previously untreated or previously treated indolent NHL demonstrated that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing regimens, as compared with those treated with the same regimens not containing rituximab, had the following significant outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher overall response rate (relative risk of obtaining a tumor response 1.21; 95% CI 1.16-1.27)",
"     </li>",
"     <li>",
"      Improved disease control (hazard ratio of developing a disease-associated event 0.62; 95% CI 0.55-0.71)",
"     </li>",
"     <li>",
"      Better overall survival (HR for mortality 0.65; 95% CI 0.54-0.78)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there has been heterogeneity in the outcomes of individual trials, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to chemotherapy appears to prolong survival in patients with previously untreated FL. The major toxicities of rituximab include infusion reactions (ie, fevers, rigors, and hypotension) and infections related to immunosuppression. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective trials have also investigated the use of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and the use of radioimmunotherapy as consolidation therapy after initial combination chemotherapy. These approaches appear promising, but have short follow-up at this time. (See",
"    <a class=\"local\" href=\"#H19675550\">",
"     'Immunotherapy alone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19675564\">",
"     'Radioimmunoconjugates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with previously untreated FL who require therapy, we recommend treatment with an immunotherapy-based regimen rather than chemotherapy alone. We typically administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy; we prefer this to rituximab alone, chemotherapy followed by rituximab, or chemotherapy followed by a radioimmunoconjugate, principally due to the greater clinical experience with this approach. The use of chemoimmunotherapy followed by a radioimmunoconjugate is under investigation. (See",
"    <a class=\"local\" href=\"#H19675564\">",
"     'Radioimmunoconjugates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675543\">",
"    <span class=\"h3\">",
"     Chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, immunotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a key component to the treatment of patients with FL. Rituximab can be administered either alone or in combination with chemotherapy. Chemotherapy regimens that have been combined with rituximab in prospective trials include those listed below. A choice among these various regimens depends upon patient characteristics and physician comfort. In general, we prefer BR given the fewer side effects associated with this regimen and trials that suggest increased efficacy when compared with R-CHOP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (BR) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/22\">",
"       22",
"      </a>",
"      ] &mdash; Bendamustine (90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 2) plus rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1) every 28 days for six cycles was compared with standard R-CHOP for six cycles in a randomized, phase III trial of 514 patients with advanced follicular, indolent, and mantle cell lymphoma, and showed superior median PFS (69.5 versus 31.2 months, hazard ratio 0.58, 95% CI 0.44-0.74) for all histologic subtypes except marginal zone lymphoma with less toxicity, including lower rates of grade 3 and 4 neutropenia (29 versus 69 percent) and leukocytopenia (37 versus 72 percent), fewer infectious episodes (37 versus 50 percent), less paresthesia (7 versus 29 percent), less stomatitis (6 versus 19 percent), and no alopecia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/22\">",
"       22",
"      </a>",
"      ]. There was no difference in OS at a median follow-up of 45 months. The number of second malignancies was similar between the two treatment arms (20 versus 23 cases). The long-term toxicity profile and impact on future treatments, including hematopoietic stem cell collection, are unknown.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-CVP) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/17,18\">",
"       17,18",
"      </a>",
"      ] &mdash; Side effects are generally mild with gastrointestinal toxicities and peripheral neuropathy being most common. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia occurs in approximately 24 percent. No treatment-related deaths occurred in this trial, but five patients experienced life-threatening events. Overall response rate (ORR) was 81 percent. Median time to progression (TTP) was 2.8 years and the three-year overall survival (OS) rate was 89 percent. In a phase II trial, the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      to R-CVP was well tolerated, but did not appear to improve response rates over those seen with R-CVP alone [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-CHOP) (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/21,24\">",
"       21,24",
"      </a>",
"      ] &mdash; The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effect is granulocytopenia (63 percent). Other common side effects are generally mild to moderate alopecia, nausea, vomiting, and infusion related reactions. There is a 1 percent treatment-related mortality rate. ORR was 96 percent. Median TTP was 6.8 years and the four-year OS rate was 83 percent. The administration of R-CHOP over 14 days (R-CHOP-14) does not improve ORRs, progression-free survival (PFS), or OS when compared with the standard administration of R-CHOP over 21 days (R-CHOP-21), but requires the addition of prophylactic growth factor support for all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (FR) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/26\">",
"       26",
"      </a>",
"      ] &mdash; The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity is neutropenia, occurring in 70 to 80 percent of patients. Other common, mild or moderate toxicities include opportunistic infections (eg, herpes) and infusion reactions. ORR was 90 percent. Median TTP had not been reached after a median follow-up of 3.7 years. Three-year OS was approximately 90 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"       \"Overview of infectious complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-FMD) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/27\">",
"       27",
"      </a>",
"      ] &mdash; The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity is neutropenia (27 percent). Other common side effects include opportunistic infections including Pneumocystis jirovecii. Prophylactic use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      is recommended with this regimen, and corticosteroids should be omitted in patients who develop opportunistic infections. ORR was 95 to 100 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"       \"Overview of infectious complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients with newly diagnosed symptomatic advanced stage FL we suggest BR rather than other regimens. This preference is based upon our experience with the regimen and the improved progression-free survival rates and less toxicity when compared with R-CHOP. R-CVP would be an acceptable alternative in patients who are not candidates for anthracyclines (eg, those with underlying cardiac disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675550\">",
"    <span class=\"h3\">",
"     Immunotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    appears promising given its low toxicity profile and good response rates. However, long-term follow-up of such an approach is limited. The following describes the largest phase II trials evaluating rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV per week for a minimum of four consecutive weeks) as initial therapy in patients with indolent lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective trial of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 62 chemotherapy-naive patients, most of whom had stage III or IV disease, overall response rates at six weeks and at maximum response were 47 and 73 percent, with 7 and 37 percent complete remissions, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. At a median follow-up of 30 months, median progression-free survival was 34 months. Toxicity was mostly infusion related and of brief duration.",
"     </li>",
"     <li>",
"      A second trial evaluated 50 patients with stage II to IV FL and low tumor burden (no nodal or extranodal mass &gt;7 cm, B symptoms, splenomegaly, pleural effusion, ascites, organ compression, elevated serum lactate dehydrogenase, or beta-2-microglobulin) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/28\">",
"       28",
"      </a>",
"      ]. The overall response rate at 50 days was 73 percent. Median time to progression was approximately 13 months. Toxicity was minimal; the number and severity of adverse events decreased with subsequent infusions.",
"     </li>",
"     <li>",
"      An international trial of 202 patients with previously untreated or",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      FL administered four weekly doses of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/30,35\">",
"       30,35",
"      </a>",
"      ]. The 151 patients with responding or stable disease at week 12 were randomized to no further treatment or prolonged rituximab maintenance every two months for four doses. At a median follow-up of 35 months, patients who received the prolonged rituximab maintenance had a significantly longer median event-free-survival (23 versus 12 months) when compared with those randomized to observation with no apparent increase in toxicity. This benefit appears to be maintained with long-term follow-up demonstrating 35 percent of responders still in remission at eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/35\">",
"       35",
"      </a>",
"      ]. Of note, 45 percent of newly diagnosed patients in this study were in remission at eight years with extended schedule rituximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longer term follow-up of these results is awaited before this treatment can be recommended as initial therapy. In particular, it is not known if single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    prolongs overall survival when given to previously untreated patients with this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675557\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of radiation therapy in advanced stage FL is limited to the use of local palliative radiation for the treatment of locally symptomatic disease. Consolidation radiation therapy given after chemotherapy does not appear to improve outcomes and may result in secondary disorders.",
"   </p>",
"   <p>",
"    Studies from the National Cancer Institute and Stanford have failed to demonstrate improvements in relapse-free survival or overall survival when radiation therapy is added to conventional chemotherapy. Although myelodysplasia (MDS) and acute leukemia are uncommonly seen in patients with indolent lymphomas treated with chemotherapy alone, a 15-year cumulative incidence of MDS and secondary acute leukemia of 17 percent has been reported for the combination of low dose total lymphoid irradiation and cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/36\">",
"     36",
"    </a>",
"    ]. This suggests that combined modality therapy increases the incidence of hematopoietic stem cell disorders. As such, we do not use combined modality therapy in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675564\">",
"    <span class=\"h2\">",
"     Radioimmunoconjugates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-CD20 radioimmunoconjugates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    tiuxetan,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    ) have demonstrated efficacy in relapsed or refractory FL. In addition, several prospective trials have investigated the use of these agents in patients with previously untreated FL receiving chemotherapy without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which is also directed against CD20. Based largely upon these trials, the US Food and Drug Administration approved the use of ibritumomab tiuxetan for the treatment of FL patients who have achieved a partial or complete response to first line chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III, placebo-controlled, randomized trial evaluated the use of a single treatment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      tiuxetan following complete or partial response to induction therapy in 414 patients with CD20-positive advanced stage FL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/37\">",
"       37",
"      </a>",
"      ]. The majority of patients did not receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as part of their initial therapy. At a median follow-up of 3.5 years, patients treated with ibritumomab tiuxetan had a significantly longer median progression-free survival (37 versus 13 months), and many patients were able to convert from partial to complete responses.",
"     </li>",
"     <li>",
"      In another phase III trial, 554 patients with newly diagnosed FL were randomly assigned to chemoimmunotherapy alone (RCHOP for six cycles) or to chemotherapy plus a radioimmunoconjugate (CHOP for six cycles followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/38\">",
"       38",
"      </a>",
"      ]. When compared with R-CHOP, CHOP plus tositumomab resulted in similar rates of overall (84 percent each) and complete (45 versus 40 percent) remissions. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia was greater (18 versus 2 percent) among those who received a radioimmunoconjugate. At a median follow-up of 4.9 years, chemoimmunotherapy alone resulted in similar rates of progression-free (76 versus 80 percent) and overall (97 versus 93 percent) survival at two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials suggest that consolidation with a radioimmunoconjugate may be able to improve the quality of remission by converting partial responses into complete responses. However, there is no clear benefit from the use of chemotherapy followed by an anti-CD20 radioimmunoconjugate rather than initial chemoimmunotherapy alone. It is not known whether the addition of an anti-CD20 radioimmunoconjugate improves outcomes of patients already receiving chemoimmunotherapy. The role in this setting is under investigation. Until more definitive data are available, we do",
"    <strong>",
"     not",
"    </strong>",
"    use radioimmunoconjugates as part of first-line therapy, but would use them in relapsed or refractory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Radioimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonrandomized trials have also evaluated the off-label use of radioimmunoconjugates as single-agent therapy for the management of previously untreated disease. While initial reports suggest good response rates and tolerability, long-term follow-up of such an approach is limited. The following describes the largest phase II trials evaluating radioimmunotherapy for initial management of advanced stage FL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II trial of 59 patients with previously untreated stage II to IV FL requiring therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      tiuxetan resulted in an overall response rate of 87 percent at six months with 56 percent of patients achieving a complete remission or an unconfirmed complete remission [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/39\">",
"       39",
"      </a>",
"      ]. After a median follow-up of 31 months, the median progression-free survival was 26 months and the median overall survival had not been reached. Rates of progression-free survival at one and two years were 77 and 54 percent, respectively. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia, leukopenia, neutropenia, and lymphopenia were seen in approximately 48, 34, 32, and 20 percent. Non-hematologic toxicities were mostly mild to moderate and included infections (20 percent) and gastrointestinal toxicities (10 percent).",
"     </li>",
"     <li>",
"      In another phase II trial evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      in 76 patients with stage III or IV FL requiring therapy, the overall response rate was 95 percent with 75 percent complete remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/40\">",
"       40",
"      </a>",
"      ]. The median progression-free survival was six years and the 10-year progression-free survival rate was 40 percent. One patient developed myelodysplastic syndrome eight years after treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radioimmunoconjugates may be considered as single agent therapy for patients with comorbid conditions that make them poor candidates for chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19675571\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185285990\">",
"    <span class=\"h3\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective randomized trials have examined the use of high dose chemotherapy followed by hematopoietic cell transplantation (HCT) in the treatment of newly diagnosed FL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. While some have demonstrated improvements in progression-free survival, none has shown an overall survival benefit. As an example, a prospective, multicenter phase III study of 136 patients with newly diagnosed high-risk FL randomly assigned therapy to six courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or rituximab-supplemented high-dose sequential chemotherapy with autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients were eligible if they had Ann Arbor stage III or IV FL and an age-adjusted IPI score &ge;2. When compared with those who received R-CHOP alone, patients assigned to receive HCT had significantly higher rates of complete remission (85 versus 62 percent). At a median follow-up of 51 months, four-year overall survival rates were approximately 80 percent for both groups.",
"   </p>",
"   <p>",
"    A 2012 Cochrane systematic review and meta-analysis of these trials found that high dose chemotherapy followed by autologous HCT resulted in significantly improved progression-free survival (hazard ratio [HR] 0.42; 95% confidence interval (CI) 0.33-0.54) but similar overall survival (HR 0.97; 95% CI 0.76-1.24) when compared with combination chemotherapy or immunochemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/47\">",
"     47",
"    </a>",
"    ]. There was also no significant difference in the rates of treatment-related mortality and rates of secondary hematologic and solid cancers. Similar results were found in a second systemic review and meta-analysis performed by another group of investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with previously untreated advanced stage FL who require therapy, we recommend treatment with an immunotherapy-based regimen rather than chemotherapy alone or hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185285997\">",
"    <span class=\"h3\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) may cure a percentage of patients with advanced stage disease, but is associated with a treatment-related mortality rate of approximately 30 percent. Given this high mortality rate, allogeneic HCT is reserved for young, highly motivated patients with relapsed or resistant FL. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677043\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677051\">",
"    <span class=\"h2\">",
"     Grade IIIb FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL tumors are graded on a scale from I to III according to the number of centroblasts per high powered field. FL grade IIIb (not IIIa) is synonymous with what is often referred to as follicular large cell lymphoma. In contrast to lower grade FLs, this histologic variant has a lesser tendency to involve the bone marrow or peripheral blood and often presents with larger lymphoid masses. Although the follicular architecture is preserved, the clinical presentation, behavior, and outcome with treatment more closely approximates that of the aggressive NHL variant diffuse large B cell lymphoma (DLBCL). Grade IIIb FL is treated according to protocols used for DLBCL. The treatment of DLBCL is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677058\">",
"    <span class=\"h2\">",
"     Patients with hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports, primarily from Europe, have indicated that treatment of a coexisting hepatitis C virus infection (HCV) with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has resulted in complete clinical remissions in some patients with indolent lymphoma, including FL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the effect of treatment with interferon alpha, alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , in 18 patients with splenic MZL, coexisting hepatitis C virus (HCV) infection, and mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/49\">",
"     49",
"    </a>",
"    ]. Hematologic and virologic responses were correlated, in that all 14 patients (78 percent) who cleared HCV RNA had a sustained hematologic response. Monoclonal immunoglobulin gene rearrangement persisted after treatment regardless of response. Interferon was without effect in six patients with splenic MZL who were not infected with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar treatment results were noted in a series of 13 patients with HCV infection and various forms of indolent lymphoma, including follicular [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial trial of treatment directed at the hepatitis C virus infection may be indicated for patients with HCV who are asymptomatic from their lymphoma and would otherwise not require the initiation of chemotherapy directed at their lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H5#H5\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677226\">",
"    <span class=\"h1\">",
"     EVALUATION OF RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of initially planned treatment of FL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse. The response evaluation of patients with advanced stage FL is the same as that of patients with limited stage FL. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Evaluation of response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677725\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677456\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy refers to the prolonged administration of agents with low toxicity profiles in an attempt to prevent progression of disease. Several trials have investigated the use of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    after chemoimmunotherapy, after immunotherapy alone, and after chemotherapy alone. While the goal of treatment is a complete remission (CR), many patients only obtain a partial remission (PR) with induction chemotherapy. There has been an increasing interest in using maintenance therapy after induction therapy in order to convert some of the PRs into CRs. This is principally because patients who attain a CR demonstrate longer remissions and a trend towards increased overall survival. Even though maintenance therapy is designed to have a low toxicity profile, a decision regarding the use of maintenance therapy in an individual patient must take into consideration both the potential benefit from attaining a deeper response and the likelihood that this patient will tolerate the prolonged therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677463\">",
"    <span class=\"h3\">",
"     After chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with newly diagnosed FL who have had at least a partial response to initial therapy, we suggest maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    rather than observation. When administering maintenance rituximab, it is important to use one of the established regimens, such as that used in the PRIMA study (rituximab every two months for a total of two years) described below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. There are no published data regarding the safety or efficacy of therapy extending beyond this; as such rituximab maintenance should NOT exceed two years. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    after chemoimmunotherapy in patients with FL has been examined in a meta-analysis of nine trials enrolling 2586 patients with FL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/55\">",
"     55",
"    </a>",
"    ]. While maintenance rituximab appeared to improve progression-free survival rates, toxicities were increased and the effect on overall survival was not clear. The meta-analysis demonstrated improved survival rates for patients with relapsed disease, but not for patients with previously untreated FL. This meta-analysis did not include results from the PRIMA trial:",
"   </p>",
"   <p>",
"    The Primary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    and Maintenance (PRIMA) phase III intergroup trial in 1019 patients with previously untreated FL who had demonstrated an initial response to chemoimmunotherapy randomly assigned maintenance with rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every eight weeks for 24 months) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. At a median follow-up of 36 months from randomization, patients assigned to rituximab maintenance demonstrated the following significant findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of progression-free survival at 36 months (75 versus 58 percent)",
"     </li>",
"     <li>",
"      Higher percentage of patients in complete response (CR) or unconfirmed CR at 24 months (72 versus 52 percent)",
"     </li>",
"     <li>",
"      Higher overall rate of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events (24 versus 17 percent)",
"     </li>",
"     <li>",
"      Higher rate of infections (39 versus 24 percent), the majority of which could be treated in the ambulatory setting (grade 2)",
"     </li>",
"     <li>",
"      Similar survival and quality of life ratings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further follow-up is needed to measure long-term toxicities and determine if the improvement in progression-free survival translates into an overall survival benefit. It is unclear whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    maintenance will change the efficacy of second line therapies and thereby eliminate a survival benefit. In addition, it is unknown how maintenance rituximab may compare with other maintenance options, such as radioimmunotherapy. Despite these caveats, we suggest the use of a short course of maintenance rituximab because it appears to improve progression-free survival without impairing quality of life. Radioimmunotherapy is an acceptable alternative for patients with a partial response following chemoimmunotherapy. (See",
"    <a class=\"local\" href=\"#H19675564\">",
"     'Radioimmunoconjugates'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677470\">",
"    <span class=\"h3\">",
"     After immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy alone, we suggest a prolonged (extended) rituximab schedule rather than a four-week administration schedule. We administer four weekly doses of single agent rituximab followed by four additional doses administered every two months. This preference places a high value on the prolonged event-free survival rates and the low toxicity profile seen with maintenance rituximab in this population. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach is supported by a randomized trial, described above, which evaluated the use of a prolonged",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    schedule after initial treatment with single agent rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. After demonstrating response or disease stabilization at week 12 after four weekly doses of single agent rituximab, patients randomly assigned to continue with rituximab maintenance (every two months for four doses) had a significantly longer median event-free survival (24 versus 13 months) when compared with those randomized to observation. There was no apparent increase in toxicity, and those patients who had not received chemotherapy before had an even more pronounced improvement in median event-free survival with prolonged rituximab therapy (36 versus 19 months) when compared with observation. (See",
"    <a class=\"local\" href=\"#H19675550\">",
"     'Immunotherapy alone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In comparison, it is not clear whether the use of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    until progression improves outcomes in patients with FL after an initial prolonged immunotherapy schedule. In another multicenter trial, 384 patients with low tumor burden previously untreated FL received four weekly doses of rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients achieving a complete or partial response were randomly assigned to rituximab maintenance (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three months until progression) or to observation and retreatment with four weekly doses of rituximab at the time of progression. Rituximab therapy was well tolerated with the maintenance arm receiving approximately three times as much rituximab than the observation arm. When compared with observation and retreatment, maintenance rituximab resulted in a similar median time to treatment failure (3.9 versus 3.6 years) and similar health related quality of life and anxiety ratings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677477\">",
"    <span class=\"h3\">",
"     After chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be of benefit for the uncommon patient who does not receive immunotherapy as part of initial treatment. A randomized trial of maintenance rituximab versus observation after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CVP) in 311 patients with indolent non-Hodgkin lymphoma (91 percent FL) reported that patients who received maintenance rituximab had improved rates of three-year progression-free survival (68 versus 33 percent). Survival rates were similar between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/17/18714/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who receive chemotherapy alone for the initial treatment of FL, we recommend a subsequent course of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    rather than observation alone. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677745\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete or partial remission, patients are seen at periodic intervals to monitor for treatment complications and assess for progression. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677836\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better strategy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677843\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FL generally have an excellent prognosis; however, there are groups of patients who have more as well as less favorable survival. The Follicular Lymphoma International Prognostic Index (FLIPI) (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 2",
"    </a>",
"    ) was developed specifically for patients with FL, since the International Prognostic Index, which was developed in patients with aggressive NHL, resulted in conflicting results, due in large part to a low number of patients with indolent lymphoma (approximately 10 percent) belonging to the higher risk groups.",
"   </p>",
"   <p>",
"    This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H75814042#H75814042\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Follicular lymphoma IPI (FLIPI)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677850\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TRANSFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An integral part of the natural history of FL is progression to a higher grade histologic subtype, such as diffuse large B cell lymphoma. As is detailed separately, a subgroup of patients with FL who transform to a more aggressive histology may attain complete remission following treatment with CHOP-like chemotherapy and some may be cured by high dose chemotherapy followed by autologous hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"       \"Patient information: Follicular lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19677976\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma. Treatment of FL depends upon the stage of disease at presentation as evaluated by the Ann Arbor Staging system (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. Enrollment in clinical trials should be encouraged. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Pre-treatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced stage disease includes disease on both sides of the diaphragm (stage III) or diffuse involvement of one or more extralymphatic tissues (stage IV). Advanced stage FL and is not curable with conventional treatment. Thus, in contrast to patients with curable aggressive lymphomas, the major indication for treatment is alleviation of symptoms and most patients with asymptomatic disease may defer therapy. (See",
"      <a class=\"local\" href=\"#H19675522\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with previously untreated advanced stage FL who require therapy, we recommend treatment with an immunotherapy-based regimen rather than chemotherapy alone or hematopoietic cell transplantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A choice among the various regimens depends upon patient characteristics and physician comfort. We suggest BR rather than other regimens (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This preference is based upon our experience with the regimen and the improved progression-free survival rates and less toxicity when compared with R-CHOP. R-CVP would be an acceptable alternative in patients who are not candidates for anthracyclines (eg, those with underlying cardiac disease). (See",
"      <a class=\"local\" href=\"#H19675536\">",
"       'Immunotherapy-based treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are evaluated after treatment with laboratory studies and a computed tomography, in addition to a history and physical examination, to determine response to therapy. Patients attaining a complete or partial remission are followed at periodic intervals for disease progression. Patients who fail to achieve a partial remission are treated as refractory disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H19#H19\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Evaluation of response to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      maintenance (versus no maintenance) in patients with advanced FL after initial induction of response may be dependent upon the choice of initial therapy. (See",
"      <a class=\"local\" href=\"#H19677456\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with newly diagnosed FL who have had at least a partial response to initial therapy, we suggest maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When administering maintenance rituximab, it is important to use one of the established regimens, such as that used in the PRIMA study (rituximab every two months for a total of two years). There are no published data regarding the safety or efficacy of therapy extending beyond this; as such rituximab maintenance should",
"      <strong>",
"       not",
"      </strong>",
"      exceed two years.",
"     </li>",
"     <li>",
"      For patients initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy alone, we suggest a prolonged (extended) rituximab schedule rather than a four-week administration schedule (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We administer four weekly doses of single agent rituximab followed by four additional doses administered every two months.",
"     </li>",
"     <li>",
"      For patients who receive chemotherapy alone for the initial treatment of FL, we recommend a subsequent course of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than observation alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of patients treated for FL will have an initial response with approximately half demonstrating a complete response. Unfortunately, therapy for FL is not curative and virtually all of these patients will ultimately develop progressive disease. The treatment of relapsed or refractory disease is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/1\">",
"      Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/2\">",
"      Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/3\">",
"      Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/4\">",
"      Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/5\">",
"      Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/6\">",
"      O'Brien ME, Easterbrook P, Powell J, et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med 1991; 80:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/7\">",
"      Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin's lymphoma. Cancer 1980; 45:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/8\">",
"      Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/9\">",
"      Solal-C&eacute;ligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012; 30:3848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/10\">",
"      Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/11\">",
"      Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/12\">",
"      Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/13\">",
"      Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/14\">",
"      Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/15\">",
"      Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007; :CD003805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/16\">",
"      Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/17\">",
"      Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/18\">",
"      Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/19\">",
"      Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/20\">",
"      Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/21\">",
"      Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/22\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/23\">",
"      Sehn LH, MacDonald D, Rubin S, et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2011; 29:3396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/24\">",
"      Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22:4711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/25\">",
"      Watanabe T, Tobinai K, Shibata T, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 2011; 29:3990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/26\">",
"      Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/27\">",
"      McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/28\">",
"      Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/29\">",
"      Conconi A, Martinelli G, Thi&eacute;blemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/30\">",
"      Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/31\">",
"      Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/32\">",
"      Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/33\">",
"      Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/34\">",
"      Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/35\">",
"      Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/36\">",
"      Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/37\">",
"      Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/38\">",
"      Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013; 31:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/39\">",
"      Scholz CW, Pinto A, Linkesch W, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013; 31:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/40\">",
"      Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/41\">",
"      Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/42\">",
"      Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22:4926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/43\">",
"      Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/44\">",
"      Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009; 113:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/45\">",
"      Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/46\">",
"      Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111:4004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/47\">",
"      Schaaf M, Reiser M, Borchmann P, et al. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev 2012; 1:CD007678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/48\">",
"      Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/49\">",
"      Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005; 105:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/50\">",
"      Hermine O, Lefr&egrave;re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/51\">",
"      Gisbert JP, Garc&iacute;a-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/52\">",
"      Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/53\">",
"      Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/54\">",
"      Zhou H, Zhang B, Zhang J, et al. Rituximab maintenance therapy for follicular lymphoma. Lancet 2011; 377:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/55\">",
"      Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/56\">",
"      Kahl BS, Hong F, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma (abstract LBA 6). Blood 2011; 118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/17/18714/abstract/57\">",
"      Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27:1607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83847 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18714=[""].join("\n");
var outline_f18_17_18714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19677976\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19673870\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19674049\">",
"      PRE-TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19675515\">",
"      ADVANCED STAGE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19675522\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19675529\">",
"      - Observation of asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19675536\">",
"      Immunotherapy-based treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H185285840\">",
"      - Overview of benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19675543\">",
"      - Chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19675550\">",
"      - Immunotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19675557\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19675564\">",
"      Radioimmunoconjugates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19675571\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H185285990\">",
"      - Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H185285997\">",
"      - Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677043\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19677051\">",
"      Grade IIIb FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19677058\">",
"      Patients with hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677226\">",
"      EVALUATION OF RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677725\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19677456\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19677463\">",
"      - After chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19677470\">",
"      - After immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19677477\">",
"      - After chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19677745\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677836\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677843\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677850\">",
"      HISTOLOGIC TRANSFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19677976\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/83847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/23/37243\" title=\"table 2\">",
"      Follic lymphoma int prog index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 3\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=related_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_17_18715="Occupational asthma vs RADS";
var content_f18_17_18715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of occupational asthma with a latency period and reactive airways dysfunction syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Occupational asthma with a latency period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reactive airways dysfunction syndrome and irritant-induced asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latency period",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diagnosis",
"       </td>",
"       <td>",
"        Various - eg, peak expiratory flow monitoring, specific inhalation challenges; IgE-mediated allergy if suspected agent is of a high-molecular-weight nature",
"       </td>",
"       <td>",
"        History; pulmonary function testing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Pathology",
"       </td>",
"       <td rowspan=\"2\">",
"        Similar to asthma",
"       </td>",
"       <td>",
"        Acute: epithelial shedding and hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic: regeneration of epithelial cells; few lymphocytes and neutrophils; increased collagen deposition and thickness of basement membrane",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pulmonary function testing",
"       </td>",
"       <td>",
"        Better reversibility to bronchodilator",
"       </td>",
"       <td>",
"        Less reversibility to bronchodilator",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18715=[""].join("\n");
var outline_f18_17_18715=null;
var title_f18_17_18716="Side effects TCAs";
var content_f18_17_18716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Side effects of tricyclic antidepressants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anticholinergic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dry mouth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary retention",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blurred vision",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paralytic ileus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Palpitations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arrhythmias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypotension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart block",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nausea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dyspepsia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anorexia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Altered taste",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tremors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paresthesias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mental clouding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sedation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18716=[""].join("\n");
var outline_f18_17_18716=null;
var title_f18_17_18717="Crystalloids and colloids for plasma expansion in adults";
var content_f18_17_18717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Crystalloids and colloids for plasma expansion in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Solution (US trade name)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sodium (mEq/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potassium (mEq/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chloride (mEq/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osmolarity (mOsm/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean molecular weight (Daltons)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Molar substitution*",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Volume effect (percent of bolus remaining intravascular)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma volume expansion duration (hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium chloride 0.9 percent",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        310",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactated Ringer's injection",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        275",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin (human) 5 percent",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        68,000",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        2-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gelatin 4 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        284",
"       </td>",
"       <td>",
"        30,000",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        70-80",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetrastarch 6 percent 130/0.4 (Voluven&reg;)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        130,000",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentastarch 10 percent 200/0.5 (Pentaspan&reg; Canadian trade name)",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        326",
"       </td>",
"       <td>",
"        200,000 to 300,000",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        6-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyethyl starch (hetastarch) 6 percent 450/0.6",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        450,000",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        24-36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyethyl starch (hetastarch) 6 percent 600/0.75 (Hespan&reg;)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        600,000",
"       </td>",
"       <td>",
"        0.75",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        24-36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyethylstarch (hetastarch) 6 percent 600/0.75 (Hextend&reg;)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        670,000",
"       </td>",
"       <td>",
"        0.75",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        24-36",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Molar substitution is the average hydroxyethyl groups per one glucose unit.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Not available in US.",
"      <br>",
"       &Delta; In sodium chloride 0.9 percent.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        In Lactated Ringer's injection.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18717=[""].join("\n");
var outline_f18_17_18717=null;
var title_f18_17_18718="Platelet count and survival";
var content_f18_17_18718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Platelet count and platelet survival in megakaryocyte disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Platelet kinetic studies were performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The median platelet counts were greater than normal only in inflammatory conditions and ET. Right panel: Platelet survival was significantly different from normal only in ITP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18718=[""].join("\n");
var outline_f18_17_18718=null;
var title_f18_17_18719="Structure sulfasalazine 5 ASA";
var content_f18_17_18719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structures of sulfasalazine, mesalamine, and olsalazine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sulfasalazine is a composite molecule composed of 5-aminosalicylic acid (5-ASA) linked by an azo bond to sulfapyridine. Mesalamine is the 5-ASA moiety alone, while olsalazine consists of two 5-ASA molecules joined by an azo bond.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_17_18719=[""].join("\n");
var outline_f18_17_18719=null;
